Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AADAT KAT2, KATII ENSG00000109576 Aminoadipate aminotransferase 4 170060222-170091699 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037502 Supported Approved Vesicles
Plasma membrane Colorectal cancer:5.59e-4 (favourable) Expressed in all Tissue enhanced liver: 34.6 prostate: 23.3 AASS LKRSDH, LORSDH ENSG00000008311 Aminoadipate-semialdehyde synthase 7 122075647-122144280 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020637, HPA020728, HPA020734 Supported Validated Vesicles
Mitochondria Liver cancer:9.81e-4 (favourable) Expressed in all Mixed ovary: 30.6 ABCA1 ABC1, HDLDT1, TGD ENSG00000165029 ATP-binding cassette, sub-family A (ABC1), member 1 9 104781002-104928237 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057283, CAB069889 Approved Approved Nucleoplasm
Vesicles Expressed in all Mixed adrenal gland: 38.1 ABCG1 ABC8 ENSG00000160179 ATP-binding cassette, sub-family G (WHITE), member 1 21 42199689-42297244 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA031470, HPA031471 Approved Supported Golgi apparatus
Vesicles Renal cancer:7.16e-6 (favourable) Expressed in all Expressed in all spleen: 43.7 ABHD6 ENSG00000163686 Abhydrolase domain containing 6 3 58237506-58295693 Enzymes, Predicted membrane proteins Evidence at protein level HPA017283, HPA073225 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable) Expressed in all Mixed small intestine: 52.0 ACBD4 FLJ13322 ENSG00000181513 Acyl-CoA binding domain containing 4 17 45132600-45144181 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051772 Approved Approved Nucleus
Vesicles Pancreatic cancer:4.64e-4 (favourable), Liver cancer:4.76e-4 (favourable), Urothelial cancer:6.53e-4 (favourable) Expressed in all Expressed in all duodenum: 31.2 ACBD7 bA455B2.2, FLJ38219 ENSG00000176244 Acyl-CoA binding domain containing 7 10 15077523-15088776 Predicted intracellular proteins Evidence at protein level HPA043326, HPA062478 Uncertain Approved Vesicles
Cytosol Mixed Tissue enriched 5 cerebral cortex: 40.8 testis: 7.9 ACHE YT ENSG00000087085 Acetylcholinesterase (Yt blood group) 7 100889994-100896974 Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019704, HPA027098 Approved Golgi apparatus
Vesicles Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable) Mixed Tissue enhanced skeletal muscle: 58.5 cerebral cortex: 14.1 ACKR3 CMKOR1, CXCR7, GPR159, RDC1 ENSG00000144476 Atypical chemokine receptor 3 2 236567787-236582358 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA032003, HPA049718 Approved Supported Vesicles
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all placenta: 175.2 ACOT8 hACTE-III, hTE, NAP1, PTE-2, PTE1 ENSG00000101473 Acyl-CoA thioesterase 8 20 45841721-45857406 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010261 Approved Supported Vesicles
Mitochondria Renal cancer:3.18e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 30.1 ACOX1 PALMCOX ENSG00000161533 Acyl-CoA oxidase 1, palmitoyl 17 75941507-75979363 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB021094, HPA021192, HPA021195, HPA028759 Approved Validated Nucleus
Vesicles Renal cancer:5.25e-7 (favourable) Expressed in all Expressed in all liver: 98.4 ACOX2 BRCACOX, BRCOX, THCCox ENSG00000168306 Acyl-CoA oxidase 2, branched chain 3 58505136-58537319 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038280, HPA064845 Approved Supported Vesicles
Mitochondria Tissue enhanced Tissue enhanced liver: 87.8 kidney: 42.3 ACRBP CT23, OY-TES-1, SP32 ENSG00000111644 Acrosin binding protein 12 6638075-6647460 Predicted secreted proteins Evidence at protein level HPA039081, HPA039082 Supported Approved Nucleoplasm
Vesicles Mixed Tissue enriched 19 testis: 432.6 thyroid gland: 22.6 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM32 ENSG00000197140 ADAM metallopeptidase domain 32 8 39106990-39284911 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044156, HPA062151 Approved Approved Nucleus
Vesicles Not detected Tissue enriched 31 testis: 28.7 epididymis: 0.9 ADAM9 CORD9, KIAA0021, MCMP, MDC9, Mltng ENSG00000168615 ADAM metallopeptidase domain 9 8 38996869-39105144 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004000 Approved Endoplasmic reticulum
Vesicles Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 116.7 ADAMTS19 ENSG00000145808 ADAM metallopeptidase with thrombospondin type 1 motif, 19 5 129460265-129738683 Enzymes, Predicted secreted proteins Evidence at transcript level HPA056171, HPA058438 Uncertain Approved Vesicles
Midbody Tissue enhanced Group enriched 13 cervix, uterine: 16.4;endometrium: 16.4;placenta: 5.2;smooth muscle: 8.9 adrenal gland: 0.9 ADAMTS2 ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif, 2 5 179110851-179345430 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA028444 Uncertain Approved Vesicles
Plasma membrane Renal cancer:1.71e-8 (unfavourable) Expressed in all Mixed placenta: 27.2 ADAMTS9 KIAA1312 ENSG00000163638 ADAM metallopeptidase with thrombospondin type 1 motif, 9 3 64515654-64688000 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028567, HPA028577, HPA028601 Approved Supported Endoplasmic reticulum
Vesicles Expressed in all Tissue enhanced placenta: 45.0 adipose tissue: 31.9 ADAMTSL2 KIAA0605 ENSG00000197859 ADAMTS-like 2 9 133532164-133575519 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045634, HPA053812 Approved Approved Nucleoplasm
Vesicles Colorectal cancer:5.01e-4 (unfavourable), Pancreatic cancer:6.70e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 29.2 kidney: 11.1 AGK FLJ10842, MULK ENSG00000006530 Acylglycerol kinase 7 141551189-141655244 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA020959, HPA053471 Supported Supported Vesicles
Mitochondria Expressed in all Expressed in all parathyroid gland: 24.8 AGTPBP1 CCP1, KIAA1035, Nna1 ENSG00000135049 ATP/GTP binding protein 1 9 85546539-85742029 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA057208 Approved Approved Nucleoli
Vesicles Expressed in all Expressed in all bone marrow: 39.3 AMACR RACE ENSG00000242110 Alpha-methylacyl-CoA racemase 5 33986178-34008108 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB001809, HPA019527, HPA020912 Supported Supported Vesicles
Plasma membrane Colorectal cancer:7.11e-4 (favourable) Expressed in all Expressed in all kidney: 134.0 AMBRA1 DCAF3, FLJ20294, KIAA1736, WDR94 ENSG00000110497 Autophagy/beclin-1 regulator 1 11 46396414-46594125 Predicted intracellular proteins Evidence at protein level CAB017825, HPA038535 Approved Approved Vesicles
Mitochondria Renal cancer:1.61e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.6 ANAPC15 APC15, C11orf51, DKFZP564M082, HSPC020 ENSG00000110200 Anaphase promoting complex subunit 15 11 72106378-72112780 Predicted intracellular proteins Evidence at protein level HPA036596 Approved Approved Nucleoplasm
Vesicles Ovarian cancer:2.55e-4 (favourable), Liver cancer:4.37e-4 (unfavourable) Expressed in all Expressed in all testis: 78.0 ANGPTL4 ARP4, FIAF, HFARP, NL2, PGAR, pp1158 ENSG00000167772 Angiopoietin-like 4 19 8363289-8374373 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007879, CAB033770 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 78.2 liver: 43.3 ANKRD26 KIAA1074, THC2 ENSG00000107890 Ankyrin repeat domain 26 10 26991914-27100498 Predicted intracellular proteins Evidence at protein level HPA040654, HPA041460 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed testis: 10.8 ANKRD39 MGC41816 ENSG00000213337 Ankyrin repeat domain 39 2 96836611-96858095 Predicted intracellular proteins Evidence at protein level HPA042678 Approved Approved Nucleoplasm
Vesicles Renal cancer:6.78e-9 (unfavourable), Pancreatic cancer:6.12e-5 (favourable), Colorectal cancer:2.26e-4 (unfavourable), Urothelial cancer:5.21e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 17.2 AP1B1 ADTB1, AP105A, BAM22, CLAPB2 ENSG00000100280 Adaptor-related protein complex 1, beta 1 subunit 22 29327680-29423179 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA065226, HPA068520 Approved Supported Golgi apparatus
Vesicles Renal cancer:7.24e-6 (favourable), Liver cancer:5.55e-5 (unfavourable), Cervical cancer:4.81e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 102.2 AP1G1 ADTG, CLAPG1 ENSG00000166747 Adaptor-related protein complex 1, gamma 1 subunit 16 71729000-71809201 Predicted intracellular proteins Evidence at protein level CAB009049, HPA041224 Approved Validated Vesicles
Cytosol Renal cancer:2.96e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 87.2 AP1S1 AP19, CLAPS1, EKV3, SIGMA1A, WUGSC:H_DJ0747G18.2 ENSG00000106367 Adaptor-related protein complex 1, sigma 1 subunit 7 101154397-101161596 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA060945 Supported Supported Golgi apparatus
Vesicles Expressed in all Expressed in all cerebral cortex: 107.3 AP1S2 MRX59, MRXS5, PGS, SIGMA1B ENSG00000182287 Adaptor-related protein complex 1, sigma 2 subunit X 15825806-15855014 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049894, HPA060945 Uncertain Supported Golgi apparatus
Vesicles Ovarian cancer:5.53e-6 (favourable), Breast cancer:9.86e-4 (favourable) Expressed in all Tissue enriched 7 epididymis: 906.3 smooth muscle: 125.6 AP2A2 ADTAB, CLAPA2, DKFZP564D1864, HIP9, HYPJ, KIAA0899 ENSG00000183020 Adaptor-related protein complex 2, alpha 2 subunit 11 924894-1012245 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017514, HPA043040 Supported Validated Nucleoplasm
Vesicles Liver cancer:9.27e-5 (unfavourable), Pancreatic cancer:4.57e-4 (favourable) Expressed in all Mixed spleen: 16.6 APOA1 ENSG00000118137 Apolipoprotein A-I 11 116835751-116837950 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016778, HPA046715 Supported Approved Vesicles
Cytosol Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable) Tissue enriched Tissue enhanced liver: 8446.1;small intestine: 4222.2 duodenum: 1654.8 APOB ENSG00000084674 Apolipoprotein B 2 21001429-21044073 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016070, HPA049793 Supported Supported Vesicles
Cytosol Tissue enriched Group enriched 122 duodenum: 187.7;liver: 619.0;small intestine: 340.0 adipose tissue: 3.1 APP AD1 ENSG00000142192 Amyloid beta (A4) precursor protein 21 25880550-26171128 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000157, HPA001462 Supported Approved Golgi apparatus
Vesicles Renal cancer:2.79e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 1206.8 AQP11 ENSG00000178301 Aquaporin 11 11 77589391-77610355 Predicted membrane proteins, Transporters Evidence at protein level HPA042879 Approved Approved Nucleoplasm
Vesicles Ovarian cancer:9.89e-4 (favourable) Mixed Tissue enhanced duodenum: 24.8;small intestine: 23.6 adrenal gland: 10.1 ARC Arg3.1, KIAA0278 ENSG00000198576 Activity-regulated cytoskeleton-associated protein 8 142611044-142614472 Predicted intracellular proteins Evidence at protein level HPA056430 Approved Vesicles
Microtubules Tissue enriched Group enriched 7 adipose tissue: 14.1;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5 placenta: 1.4 ARCN1 COPD ENSG00000095139 Archain 1 11 118572390-118603033 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA037573, HPA044874 Approved Validated Golgi apparatus
Vesicles Liver cancer:2.97e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 142.0 ARHGAP19 FLJ00194, MGC14258 ENSG00000213390 Rho GTPase activating protein 19 10 97222173-97292673 Predicted intracellular proteins Evidence at protein level HPA035777, HPA043231 Uncertain Approved Vesicles
Plasma membrane Renal cancer:7.47e-5 (unfavourable) Expressed in all Mixed testis: 34.1 ARHGAP25 KIAA0053 ENSG00000163219 Rho GTPase activating protein 25 2 68679601-68826833 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035346, HPA061395 Supported Approved Nucleoplasm
Vesicles Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced spleen: 90.9 lymph node: 82.3 ARID4B BCAA, BRCAA1, RBP1L1, SAP180 ENSG00000054267 AT rich interactive domain 4B (RBP1-like) 1 235131634-235328219 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA027333, HPA053692 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.23e-4 (unfavourable) Expressed in all Expressed in all testis: 30.3 ARL4D ARF4L ENSG00000175906 ADP-ribosylation factor-like 4D 17 43398959-43401137 Predicted intracellular proteins Evidence at protein level HPA060379 Uncertain Approved Golgi apparatus
Vesicles Endometrial cancer:1.16e-5 (favourable), Head and neck cancer:6.66e-4 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable) Expressed in all Mixed thyroid gland: 62.4 ARL6 BBS3, RP55 ENSG00000113966 ADP-ribosylation factor-like 6 3 97764521-97801242 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019361 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.53e-7 (favourable) Expressed in all Mixed parathyroid gland: 19.2 ARMCX4 CXorf35, GASP4, MGC40053 ENSG00000196440 Armadillo repeat containing, X-linked 4 X 101418287-101533459 Predicted intracellular proteins Evidence at protein level HPA000429, HPA051930 Uncertain Approved Nucleoplasm
Vesicles Pancreatic cancer:8.20e-5 (favourable) Mixed Mixed parathyroid gland: 14.1 ARNTL bHLHe5, BMAL1, JAP3, MOP3, PASD3 ENSG00000133794 Aryl hydrocarbon receptor nuclear translocator-like 11 13276652-13387266 Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level CAB045962, HPA050938 Supported Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 27.5 ARPC1B ARC41, p40-ARC, p41-ARC ENSG00000130429 Actin related protein 2/3 complex, subunit 1B, 41kDa 7 99374249-99394801 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004832 Approved Supported Vesicles
Cytosol Renal cancer:1.62e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable) Expressed in all Expressed in all spleen: 259.0 ARSD ENSG00000006756 Arylsulfatase D X 2903970-2929351 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004694, HPA063835 Supported Approved Vesicles
Lipid droplets Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable) Expressed in all Mixed fallopian tube: 44.7 ARSK DKFZp313G1735, TSULF ENSG00000164291 Arylsulfatase family, member K 5 95555074-95605064 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042384 Approved Approved Nucleus
Vesicles Liver cancer:2.59e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 22.5 ASAP3 CENTB6, DDEFL1, FLJ20199, UPLC1 ENSG00000088280 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 1 23428563-23484568 Predicted intracellular proteins Evidence at protein level HPA020537, HPA020546 Approved Supported Nucleoplasm
Vesicles Renal cancer:5.12e-5 (favourable), Lung cancer:2.80e-4 (favourable), Endometrial cancer:5.56e-4 (unfavourable), Ovarian cancer:8.30e-4 (unfavourable) Expressed in all Mixed skin: 32.6 ASGR1 CLEC4H1 ENSG00000141505 Asialoglycoprotein receptor 1 17 7173431-7179564 Predicted intracellular proteins Evidence at protein level HPA011954, HPA012852 Supported Supported Vesicles
Cell Junctions Tissue enriched Tissue enriched 13 liver: 236.1 testis: 17.7 ASPN FLJ20129, PLAP1, SLRR1C ENSG00000106819 Asporin 9 92456205-92482506 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA008435, HPA024230 Approved Supported Nucleoplasm
Vesicles Renal cancer:1.64e-7 (unfavourable) Expressed in all Tissue enhanced endometrium: 114.7;smooth muscle: 159.0 gallbladder: 104.4 ASTN1 ASTN ENSG00000152092 Astrotactin 1 1 176857302-177164973 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074112 Approved Golgi apparatus
Vesicles Tissue enriched Group enriched 6 adrenal gland: 19.7;cerebral cortex: 67.0 ovary: 7.4 ATP7A MNK ENSG00000165240 ATPase, Cu++ transporting, alpha polypeptide X 77910656-78050395 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA012887, HPA048107 Approved Supported Golgi apparatus
Vesicles Renal cancer:8.38e-4 (favourable) Expressed in all Mixed parathyroid gland: 15.0 ATP8B4 ATPIM, KIAA1939 ENSG00000104043 ATPase, class I, type 8B, member 4 15 49858238-50182817 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040254 Approved Approved Nucleoplasm
Vesicles Mixed Tissue enhanced bone marrow: 23.1 endometrium: 9.2 AUP1 ENSG00000115307 Ancient ubiquitous protein 1 2 74526645-74529939 Predicted membrane proteins Evidence at protein level HPA007674 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 57.1 AXIN1 PPP1R49 ENSG00000103126 Axin 1 16 287440-352673 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012987 Approved Supported Nucleoli
Vesicles Liver cancer:3.38e-5 (unfavourable) Expressed in all Expressed in all spleen: 15.8 B4GALNT3 B4GalNac-T3, FLJ16224, FLJ40362 ENSG00000139044 Beta-1,4-N-acetyl-galactosaminyl transferase 3 12 460364-563509 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011404 Approved Supported Golgi apparatus
Vesicles Endometrial cancer:1.69e-10 (favourable) Mixed Tissue enhanced stomach: 69.0 colon: 22.0 B4GALT2 beta4Gal-T2 ENSG00000117411 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 1 43978943-43991170 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007620, HPA047739 Supported Supported Golgi apparatus
Vesicles Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 49.6 BARX1 ENSG00000131668 BARX homeobox 1 9 93951622-93955372 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055858 Approved Nucleoplasm
Vesicles Endometrial cancer:8.16e-6 (unfavourable), Head and neck cancer:1.02e-4 (unfavourable) Tissue enhanced Tissue enriched 7 stomach: 11.2 testis: 1.5 BCL7A BCL7 ENSG00000110987 B-cell CLL/lymphoma 7A 12 122019422-122062044 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019762 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 13.8 BIRC6 BRUCE ENSG00000115760 Baculoviral IAP repeat containing 6 2 32357028-32618899 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA074409, HPA074738 Supported Golgi apparatus
Vesicles Expressed in all Mixed parathyroid gland: 30.8 BLOC1S4 BCAS4L, CNO, FLJ11230 ENSG00000186222 Biogenesis of lysosomal organelles complex-1, subunit 4, cappuccino 4 6716055-6717671 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043840 Approved Approved Vesicles
Cytosol Liver cancer:1.06e-4 (unfavourable) Expressed in all Expressed in all ovary: 12.7 BORCS8 MEF2BNB ENSG00000254901 BLOC-1 related complex subunit 8 19 19176903-19192591 Predicted intracellular proteins Evidence at protein level HPA045700 Approved Approved Nucleoplasm
Vesicles Pancreatic cancer:4.05e-5 (favourable) Expressed in all Mixed cerebral cortex: 17.4 BRAF BRAF1 ENSG00000157764 B-Raf proto-oncogene, serine/threonine kinase 7 140719327-140924764 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001328, CAB004552, HPA071048 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 41.6 BRINP2 DBCCR1L2, FAM5B ENSG00000198797 Bone morphogenetic protein/retinoic acid inducible neural-specific 2 1 177171497-177282422 Predicted secreted proteins Evidence at transcript level HPA050681, HPA061920 Uncertain Approved Nucleoli
Vesicles Tissue enriched Group enriched 9 adrenal gland: 11.5;cerebral cortex: 35.5 testis: 2.4 BTAF1 MOT1, TAF(II)170, TAF-172, TAF172, TAFII170 ENSG00000095564 BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa 10 91923769-92030325 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA070682 Approved Nucleoplasm
Vesicles Renal cancer:4.04e-5 (unfavourable), Head and neck cancer:5.07e-4 (favourable) Expressed in all Expressed in all skin: 59.9 BTG2 MGC126063, MGC126064, PC3, TIS21 ENSG00000159388 BTG family, member 2 1 203305491-203309602 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA002355 Uncertain Approved Nucleoplasm
Vesicles Breast cancer:8.53e-4 (favourable) Expressed in all Expressed in all ovary: 662.9 BTNL9 BTN8, FLJ32535 ENSG00000165810 Butyrophilin-like 9 5 181040225-181061523 Predicted membrane proteins Evidence at protein level HPA043429 Approved Nuclear membrane
Vesicles Liver cancer:1.55e-9 (favourable), Endometrial cancer:7.51e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 166.7 lung: 56.0 C10orf10 DEPP, FIG, Fseg ENSG00000165507 Chromosome 10 open reading frame 10 10 44970981-44978810 Predicted secreted proteins Evidence at protein level CAB013687, HPA037819 Uncertain Approved Nucleus
Vesicles Renal cancer:2.29e-6 (unfavourable) Expressed in all Expressed in all adipose tissue: 236.8 C11orf24 DM4E3 ENSG00000171067 Chromosome 11 open reading frame 24 11 68261335-68272001 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012748 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable) Expressed in all Expressed in all small intestine: 67.2 C15orf57 CCDC32, MGC20481 ENSG00000128891 Chromosome 15 open reading frame 57 15 40528683-40565057 Predicted intracellular proteins Evidence at protein level HPA041688 Uncertain Approved Nuclear speckles
Vesicles Expressed in all Expressed in all thyroid gland: 35.3 C16orf72 FLJ41272, PRO0149 ENSG00000182831 Chromosome 16 open reading frame 72 16 9091648-9121640 Predicted intracellular proteins Evidence at protein level HPA041568, HPA067492 Uncertain Approved Nucleoplasm
Vesicles Head and neck cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 67.7 C17orf64 ENSG00000141371 Chromosome 17 open reading frame 64 17 60392429-60431421 Predicted intracellular proteins Evidence at protein level HPA044415 Supported Approved Nucleoplasm
Vesicles Not detected Tissue enriched 227 testis: 184.8 spleen: 0.8 C17orf80 FLJ20721, HLC-8, MIG3, SPEP1 ENSG00000141219 Chromosome 17 open reading frame 80 17 73232233-73248947 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012896 Uncertain Approved Nucleoplasm
Vesicles Liver cancer:9.02e-6 (unfavourable), Colorectal cancer:1.43e-4 (favourable) Expressed in all Expressed in all testis: 71.6 C18orf32 FLJ23458 ENSG00000177576 Chromosome 18 open reading frame 32 18 49477250-49487252 Predicted membrane proteins Evidence at protein level HPA040921 Approved Approved Nucleoplasm
Vesicles Renal cancer:8.89e-9 (favourable) Expressed in all Expressed in all cerebral cortex: 120.0 C19orf81 ENSG00000235034 Chromosome 19 open reading frame 81 19 50649445-50659310 Predicted intracellular proteins Evidence at protein level HPA060238 Supported Approved Vesicles
Aggresome Tissue enhanced Tissue enriched 11 testis: 5.3 cerebral cortex,epididymis: 0.4 C1orf53 ENSG00000203724 Chromosome 1 open reading frame 53 1 197902647-197907367 Predicted intracellular proteins Evidence at transcript level HPA065352 Approved Vesicles
Aggresome Breast cancer:1.63e-4 (favourable), Endometrial cancer:3.78e-4 (unfavourable) Expressed in all Mixed adrenal gland: 6.3 C5orf38 CEI, IRX2NB ENSG00000186493 Chromosome 5 open reading frame 38 5 2752131-2755397 Predicted intracellular proteins Evidence at protein level HPA073667 Validated Golgi apparatus
Vesicles Mixed Tissue enhanced lung: 13.8;salivary gland: 13.0 skin: 8.5 C9orf84 FLJ32779 ENSG00000165181 Chromosome 9 open reading frame 84 9 111686173-111795008 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA032108 Approved Vesicles
Cytosol Mixed Tissue enriched 10 testis: 30.9 adrenal gland: 3.1 CA11 CARP2, CARPX1 ENSG00000063180 Carbonic anhydrase XI 19 48637942-48646312 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041778 Approved Vesicles
Microtubules Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 244.8 ovary: 49.6 CA12 HsT18816 ENSG00000074410 Carbonic anhydrase XII 15 63321378-63382161 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA008773, CAB025181, CAB062549, CAB068179, HPA073203 Supported Approved Nucleus
Vesicles Pancreatic cancer:3.80e-6 (unfavourable) Expressed in all Tissue enhanced kidney: 307.3;skin: 168.7 rectum: 105.5 CACNA1H Cav3.2 ENSG00000196557 Calcium channel, voltage-dependent, T type, alpha 1H subunit 16 1153241-1221771 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039125 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable) Expressed in all Tissue enhanced ovary: 50.6 seminal vesicle: 46.9 CACNB3 CACNLB3 ENSG00000167535 Calcium channel, voltage-dependent, beta 3 subunit 12 48813794-48828941 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA059515 Approved Golgi apparatus
Vesicles Mixed Mixed endometrium: 39.8 CADPS2 ENSG00000081803 Ca++-dependent secretion activator 2 7 122318425-122886759 Predicted intracellular proteins Evidence at protein level HPA056398 Approved Nucleoplasm
Vesicles Renal cancer:1.01e-7 (favourable) Expressed in all Mixed cervix, uterine,parathyroid gland: 44.9 CALCOCO2 MGC17318, NDP52 ENSG00000136436 Calcium binding and coiled-coil domain 2 17 48830988-48866522 Predicted intracellular proteins Evidence at protein level HPA022989, HPA023019, HPA023195 Supported Supported Vesicles
Cytosol Expressed in all Expressed in all testis: 247.8 CALN1 ENSG00000183166 Calneuron 1 7 71779491-72447151 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036278, HPA036708 Approved Uncertain Vesicles
Plasma membrane Mixed Group enriched 5 adrenal gland: 14.8;cerebral cortex: 46.5 testis: 6.0 CASP10 MCH4 ENSG00000003400 Caspase 10, apoptosis-related cysteine peptidase 2 201182881-201229406 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003780, HPA017059 Approved Uncertain Golgi apparatus
Vesicles Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable) Expressed in all Mixed spleen: 24.6 CAT ENSG00000121691 Catalase 11 34438925-34472062 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001515, HPA051282, HPA055838 Supported Supported Vesicles
Cytosol Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable) Expressed in all Expressed in all liver: 624.4 CAV3 LGMD1C, LQT9, VIP-21, VIP21 ENSG00000182533 Caveolin 3 3 8733800-8841808 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB017518, CAB018557, HPA054488 Supported Supported Vesicles
Plasma membrane Tissue enhanced Group enriched 6 heart muscle: 13.0;skeletal muscle: 63.3 esophagus: 6.0 CBS HIP4 ENSG00000160200 Cystathionine-beta-synthase 21 43053191-43076943 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001223 Supported Approved Nucleoli
Vesicles Mixed Tissue enhanced liver: 56.7;ovary: 31.1 cerebral cortex: 19.9 CBSL ENSG00000274276 Cystathionine-beta-synthase like 21 6444869-6468040 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001223 Supported Approved Nucleoli
Vesicles Mixed Tissue enhanced cerebral cortex: 46.0;liver: 27.4 thyroid gland: 22.1 CC2D1B KIAA1836 ENSG00000154222 Coiled-coil and C2 domain containing 1B 1 52345723-52366193 Predicted intracellular proteins Evidence at protein level HPA027500, HPA031426 Uncertain Supported Nucleoplasm
Vesicles Liver cancer:1.45e-5 (unfavourable) Expressed in all Expressed in all lung: 18.8 CCDC115 ccp1, FLJ30131, MGC12981 ENSG00000136710 Coiled-coil domain containing 115 2 130338241-130342349 Predicted intracellular proteins Evidence at protein level HPA034598 Approved Supported Vesicles
Plasma membrane Breast cancer:7.59e-4 (favourable) Expressed in all Expressed in all ovary: 55.3 CCDC122 FLJ31846 ENSG00000151773 Coiled-coil domain containing 122 13 43823909-43879727 Predicted intracellular proteins Evidence at protein level CAB034233, HPA054995, HPA061456 Approved Approved Nucleus
Vesicles Mixed Mixed thyroid gland: 7.8 CCDC144A FLJ43983, KIAA0565 ENSG00000170160 Coiled-coil domain containing 144A 17 16689537-16777881 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022996, HPA047220, HPA047851 Approved Approved Nucleoplasm
Vesicles Not detected Tissue enhanced testis: 16.7 endometrium: 6.3 CCDC146 KIAA1505 ENSG00000135205 Coiled-coil domain containing 146 7 77122434-77329533 Predicted intracellular proteins Evidence at protein level HPA020082, HPA020105 Uncertain Approved Golgi apparatus
Vesicles Head and neck cancer:7.37e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 57.0;testis: 39.7 thyroid gland: 13.7 CCDC65 CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28 ENSG00000139537 Coiled-coil domain containing 65 12 48904110-48931840 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038520, HPA057573 Uncertain Approved Vesicles
Microtubule organizing center Mixed Group enriched 11 fallopian tube: 42.4;testis: 67.5 lung: 4.8 CCDC93 FLJ10996 ENSG00000125633 Coiled-coil domain containing 93 2 117915478-118014133 Predicted intracellular proteins Evidence at protein level HPA054183 Approved Supported Vesicles
Plasma membrane Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 24.5 CCL15 HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3 ENSG00000275718 Chemokine (C-C motif) ligand 15 17 35996440-36002038 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058608 Approved Golgi apparatus
Vesicles Urothelial cancer:3.02e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 22.1;rectum: 31.0;small intestine: 27.2 colon: 19.3 CCL2 GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF ENSG00000108691 Chemokine (C-C motif) ligand 2 17 34255218-34257203 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013676, HPA019163 Approved Approved Golgi apparatus
Vesicles Renal cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 412.4 CD55 CR, CROM, DAF, TC ENSG00000196352 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1 207321508-207386804 Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002190, CAB010454, HPA024386 Supported Uncertain Vesicles
Midbody ring Renal cancer:9.36e-4 (unfavourable) Expressed in all Expressed in all lung: 324.6 CD59 16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20 ENSG00000085063 CD59 molecule, complement regulatory protein 11 33698261-33736445 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001448, HPA026494 Supported Approved Golgi apparatus
Vesicles Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all epididymis: 907.3 CD68 DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1 ENSG00000129226 CD68 molecule 17 7579467-7582113 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000051, CAB000066, HPA048982, CAB072861, CAB072862 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.14e-5 (unfavourable) Mixed Expressed in all lung: 534.2 CD93 C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4 ENSG00000125810 CD93 molecule 20 23079349-23086340 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA009300, HPA012368 Supported Approved Vesicles
Plasma membrane Renal cancer:2.74e-4 (unfavourable) Expressed in all Expressed in all placenta: 195.4 CDK19 bA346C16.3, CDC2L6, CDK11, KIAA1028 ENSG00000155111 Cyclin-dependent kinase 19 6 110609978-110815958 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007053 Approved Approved Nucleoplasm
Vesicles Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable) Expressed in all Mixed prostate: 43.5 CDK5R1 Nck5a, p35nck5a ENSG00000176749 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 17 32486619-32491256 Predicted intracellular proteins Evidence at protein level HPA000252 Supported Nucleoplasm
Vesicles Mixed Tissue enriched 7 cerebral cortex: 98.7 lymph node: 14.9 CDKL1 KKIALRE ENSG00000100490 Cyclin-dependent kinase-like 1 (CDC2-related kinase) 14 50329404-50416461 Enzymes, Predicted intracellular proteins Evidence at protein level HPA059605, HPA065919 Uncertain Validated Nucleoplasm
Vesicles Mixed Mixed fallopian tube: 33.1 CDKL3 NKIAMRE ENSG00000006837 Cyclin-dependent kinase-like 3 5 134286350-134371047 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027751 Uncertain Nucleoplasm
Vesicles Mixed Tissue enriched 9 testis: 28.7 cerebral cortex: 3.2 CDKN1B KIP1, P27KIP1 ENSG00000111276 Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 12 12715058-12722371 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB003691, CAB021888, HPA059086 Approved Supported Nucleus
Vesicles Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable) Expressed in all Expressed in all ovary: 72.9 CEBPA C/EBP-alpha, CEBP ENSG00000245848 CCAAT/enhancer binding protein (C/EBP), alpha 19 33299934-33302564 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052734, HPA065037, HPA067937 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all adipose tissue: 107.9 CEBPZ CBF2, CTF2 ENSG00000115816 CCAAT/enhancer binding protein (C/EBP), zeta 2 37201612-37231713 Predicted intracellular proteins Evidence at protein level HPA052065 Uncertain Approved Nucleus
Vesicles Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:5.07e-4 (unfavourable), Pancreatic cancer:8.13e-4 (unfavourable) Expressed in all Expressed in all testis: 68.2 CENPBD1 MGC16385 ENSG00000177946 CENPB DNA-binding domains containing 1 16 89969791-89972534 Predicted intracellular proteins Evidence at transcript level HPA052759, HPA060522 Uncertain Approved Nucleoli
Vesicles Renal cancer:5.27e-11 (favourable) Expressed in all Mixed parathyroid gland: 11.0 CERS4 FLJ12089, LASS4, Trh1 ENSG00000090661 Ceramide synthase 4 19 8206736-8262421 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033734, HPA054729 Uncertain Approved Nucleus
Vesicles Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable) Expressed in all Mixed thyroid gland: 80.7 CFB BF, BFD, H2-Bf ENSG00000243649 Complement factor B 6 31945650-31952084 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000951, HPA001817, HPA001832, CAB016381 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable) Expressed in all Tissue enriched 20 liver: 283.0 stomach: 13.9 CGRRF1 CGR19, RNF197 ENSG00000100532 Cell growth regulator with ring finger domain 1 14 54509812-54539309 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002930 Uncertain Supported Nucleoplasm
Vesicles Renal cancer:2.57e-8 (favourable), Liver cancer:6.84e-4 (unfavourable) Expressed in all Expressed in all testis: 33.6 CHEK1 CHK1 ENSG00000149554 Checkpoint kinase 1 11 125625136-125676255 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044364 Approved Nucleoplasm
Vesicles Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 61.6;seminal vesicle: 52.5 testis: 21.8 CIC KIAA0306 ENSG00000079432 Capicua transcriptional repressor 19 42268537-42295797 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026388, HPA044341, HPA064725 Approved Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 55.0 CLCF1 BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6 ENSG00000175505 Cardiotrophin-like cytokine factor 1 11 67364168-67374177 Disease related genes, Predicted secreted proteins Evidence at protein level HPA042444 Uncertain Approved Nuclear bodies
Vesicles Expressed in all Tissue enhanced gallbladder: 26.4 endometrium: 21.4 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDN9 ENSG00000213937 Claudin 9 16 3012456-3014505 Predicted membrane proteins Evidence at protein level HPA076613 Supported Vesicles
Cell Junctions Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 3.1 bone marrow: 1.7 CLEC16A Gop-1, KIAA0350 ENSG00000038532 C-type lectin domain family 16, member A 16 10944488-11182189 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035814, HPA035815, HPA061385 Approved Approved Nucleus
Vesicles Renal cancer:2.92e-6 (favourable) Expressed in all Expressed in all testis: 60.2 CLEC7A CD369, CLECSF12, dectin-1, hDectin-1 ENSG00000172243 C-type lectin domain family 7, member A 12 10116777-10130258 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043244, HPA050229 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.31e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 67.3 bone marrow: 53.5 CLINT1 CLINT, ENTH, EPNR, KIAA0171 ENSG00000113282 Clathrin interactor 1 5 157785743-157859175 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043280, HPA056947 Supported Supported Nucleoplasm
Vesicles Renal cancer:8.88e-5 (favourable), Colorectal cancer:2.95e-4 (favourable), Thyroid cancer:6.77e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 167.9 CLUAP1 CFAP22, FAP22, FLJ13297, IFT38, KIAA0643 ENSG00000103351 Clusterin associated protein 1 16 3500924-3539048 Predicted intracellular proteins Evidence at protein level HPA036976, HPA044191 Uncertain Supported Nucleoplasm
Vesicles Endometrial cancer:3.01e-4 (favourable) Expressed in all Expressed in all testis: 71.7 CLUH CLU1, KIAA0664 ENSG00000132361 Clustered mitochondria (cluA/CLU1) homolog 17 2689386-2712663 Predicted intracellular proteins Evidence at protein level HPA031505, HPA044346 Uncertain Supported Nuclear bodies
Vesicles Renal cancer:1.92e-5 (favourable) Expressed in all Expressed in all esophagus: 50.9 CNGA1 CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49 ENSG00000198515 Cyclic nucleotide gated channel alpha 1 4 47935977-48016672 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA076168 Approved Vesicles
Plasma membrane Mixed Mixed liver: 14.2 CNGB1 CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45 ENSG00000070729 Cyclic nucleotide gated channel beta 1 16 57882340-57971116 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039159, HPA060355 Uncertain Approved Vesicles
Cytosol Tissue enriched Mixed adrenal gland,appendix: 1.6 COG4 COD1, DKFZP586E1519 ENSG00000103051 Component of oligomeric golgi complex 4 16 70480568-70523565 Predicted intracellular proteins Evidence at protein level HPA040924, HPA042539 Approved Approved Golgi apparatus
Vesicles Liver cancer:1.64e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 47.6 COL1A1 OI4 ENSG00000108821 Collagen, type I, alpha 1 17 50183289-50201632 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008405, HPA011795 Uncertain Approved Vesicles
Cytosol Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 1863.2 COL22A1 ENSG00000169436 Collagen, type XXII, alpha 1 8 138588235-138914006 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024830 Approved Supported Endoplasmic reticulum
Vesicles Lung cancer:2.13e-6 (unfavourable), Glioma:3.62e-4 (unfavourable) Mixed Tissue enhanced adrenal gland: 9.8 prostate: 4.8 COL4A3 ENSG00000169031 Collagen, type IV, alpha 3 (Goodpasture antigen) 2 227164565-227314792 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042064 Approved Approved Endoplasmic reticulum
Vesicles Renal cancer:2.51e-7 (favourable) Group enriched Tissue enhanced thyroid gland: 26.7 lung: 22.4 COL9A2 EDM2, MED ENSG00000049089 Collagen, type IX, alpha 2 1 40300487-40317816 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA056316 Uncertain Approved Nucleus
Vesicles Endometrial cancer:5.13e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 52.3 seminal vesicle: 32.1 COLGALT2 C1orf17, GLT25D2, KIAA0584 ENSG00000198756 Collagen beta(1-O)galactosyltransferase 2 1 183929854-184037729 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031749, HPA031750 Approved Approved Nucleus
Vesicles Tissue enhanced Tissue enriched 5 cerebral cortex: 46.5 adrenal gland: 8.5 COMT ENSG00000093010 Catechol-O-methyltransferase 22 19941607-19969975 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001169, CAB011233 Supported Approved Endoplasmic reticulum
Vesicles Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable) Expressed in all Expressed in all placenta: 172.0 COPS2 ALIEN, CSN2, TRIP15 ENSG00000166200 COP9 signalosome subunit 2 15 49106068-49155661 Predicted intracellular proteins Evidence at protein level HPA016867, HPA018271, HPA061071 Approved Validated Vesicles
Cytokinetic bridge Expressed in all Expressed in all thyroid gland: 103.1 CPEB1 CPEB, FLJ13203 ENSG00000214575 Cytoplasmic polyadenylation element binding protein 1 15 82543201-82648861 Predicted intracellular proteins Evidence at protein level HPA040396 Approved Nucleoplasm
Vesicles Tissue enriched Tissue enhanced testis: 61.1 cerebral cortex: 22.4 CPQ LDP, PGCP ENSG00000104324 Carboxypeptidase Q 8 96645227-97149654 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023235, HPA024490 Supported Approved Golgi apparatus
Vesicles Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 380.7 CPSF2 KIAA1367 ENSG00000165934 Cleavage and polyadenylation specific factor 2, 100kDa 14 92121937-92172145 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA024238 Supported Approved Nucleoplasm
Vesicles Liver cancer:4.35e-7 (unfavourable) Expressed in all Expressed in all testis: 47.6 CREG1 CREG ENSG00000143162 Cellular repressor of E1A-stimulated genes 1 1 167529677-167553767 Predicted secreted proteins Evidence at protein level HPA056390 Approved Vesicles
Microtubules Expressed in all Expressed in all thyroid gland: 208.5 CREM hCREM-2 ENSG00000095794 CAMP responsive element modulator 10 35126791-35212958 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001818, CAB018352 Supported Supported Nucleus
Vesicles Renal cancer:1.23e-5 (unfavourable) Expressed in all Expressed in all testis: 337.8 CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 150.2 CSK ENSG00000103653 C-src tyrosine kinase 15 74782057-74803198 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011203, HPA026488, HPA028425 Approved Approved Vesicles
Cytosol Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all lymph node: 197.7 CSRNP1 AXUD1, DKFZp566F164, FAM130B, TAIP-3, URAX1 ENSG00000144655 Cysteine-serine-rich nuclear protein 1 3 39141855-39154562 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA045207, HPA058463 Validated Nucleoplasm
Vesicles Renal cancer:1.07e-4 (favourable), Stomach cancer:6.47e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 123.7 CST3 ENSG00000101439 Cystatin C 20 23626706-23638473 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000118, HPA013143 Supported Supported Golgi apparatus
Vesicles Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1269.6 CTDSPL C3orf8, HYA22, PSR1, RBSP3, SCP3 ENSG00000144677 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like 3 37861960-37984469 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048325 Approved Approved Nucleoplasm
Vesicles Renal cancer:6.22e-14 (favourable) Expressed in all Expressed in all skin: 65.8 CTGF CCN2, IGFBP8 ENSG00000118523 Connective tissue growth factor 6 131948176-131951373 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB005123, HPA031074, HPA031075 Approved Validated Golgi apparatus
Vesicles Stomach cancer:5.04e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 841.0 CTNS CTNS-LSB, PQLC4 ENSG00000040531 Cystinosin, lysosomal cystine transporter 17 3636468-3661542 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA046947 Supported Vesicles
Intermediate filaments Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable) Expressed in all Expressed in all testis: 43.3 CTSB ENSG00000164733 Cathepsin B 8 11842524-11869448 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000457, HPA018156 Uncertain Supported Nucleoli
Vesicles Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 2885.5 CUZD1 ERG-1, UO-44 ENSG00000138161 CUB and zona pellucida-like domains 1 10 122832149-122850793 Predicted membrane proteins Evidence at protein level HPA068479, HPA068660, HPA074117 Supported Approved Nucleoli
Vesicles Tissue enriched Tissue enriched 170 pancreas: 380.4 testis: 2.2 CXCL16 CXCLG16, SR-PSOX, SRPSOX ENSG00000161921 Chemokine (C-X-C motif) ligand 16 17 4733526-4739922 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA053253, HPA066315 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed lung: 106.3 CYB5A CYB5 ENSG00000166347 Cytochrome b5 type A (microsomal) 18 74250847-74292016 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006333, HPA047548, HPA058547 Supported Approved Vesicles
Cytosol Liver cancer:4.15e-4 (favourable), Colorectal cancer:5.23e-4 (favourable) Expressed in all Expressed in all liver: 1254.1 DACH1 DACH ENSG00000276644 Dachshund family transcription factor 1 13 71437966-71867192 Predicted intracellular proteins Evidence at protein level HPA012672 Approved Supported Nucleoplasm
Vesicles Mixed Mixed cervix, uterine: 15.0 DACT3 DAPPER3, MGC15476, RRR1 ENSG00000197380 Dishevelled-binding antagonist of beta-catenin 3 19 46647612-46661138 Predicted intracellular proteins Evidence at protein level HPA043053 Approved Approved Nucleoplasm
Vesicles Renal cancer:7.97e-8 (unfavourable), Urothelial cancer:6.66e-4 (unfavourable) Mixed Mixed smooth muscle: 46.2 DAPK2 DRP-1, MGC119312 ENSG00000035664 Death-associated protein kinase 2 15 63907036-64072033 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071581 Supported Golgi apparatus
Vesicles Lung cancer:5.63e-4 (favourable) Tissue enriched Tissue enhanced thyroid gland: 48.9 lung: 29.9 DCAF15 C19orf72, MGC99481 ENSG00000132017 DDB1 and CUL4 associated factor 15 19 13952492-13961449 Predicted intracellular proteins Evidence at protein level HPA068351 Approved Vesicles
Mitochondria Renal cancer:1.34e-5 (unfavourable), Pancreatic cancer:7.97e-4 (favourable) Expressed in all Expressed in all testis: 59.9 DCHS2 CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ ENSG00000197410 Dachsous cadherin-related 2 4 154232037-154491716 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064159 Uncertain Approved Vesicles
Plasma membrane Not detected Mixed endometrium: 4.0 DCP1B FLJ31638 ENSG00000151065 Decapping mRNA 1B 12 1946054-2004535 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039709, HPA058778 Approved Supported Vesicles
Cytosol Expressed in all Expressed in all testis: 36.6 DCUN1D4 KIAA0276 ENSG00000109184 DCN1, defective in cullin neddylation 1, domain containing 4 4 51843000-51916837 Predicted intracellular proteins Evidence at protein level HPA036483, HPA036484 Uncertain Approved Nucleus
Vesicles Expressed in all Expressed in all testis: 28.7 DENND3 KIAA0870 ENSG00000105339 DENN/MADD domain containing 3 8 141117278-141195808 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024491 Approved Vesicles
Cytosol Expressed in all Mixed bone marrow: 68.7 DENND5A FLJ22354, FLJ33829, FLJ43455, KIAA1091, RAB6IP1 ENSG00000184014 DENN/MADD domain containing 5A 11 9138825-9265390 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052923, HPA055009 Uncertain Approved Golgi apparatus
Vesicles Renal cancer:1.14e-6 (unfavourable), Liver cancer:5.05e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 127.2 DGKG DAGK3 ENSG00000058866 Diacylglycerol kinase, gamma 90kDa 3 186105668-186362237 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036577 Approved Approved Vesicles
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 21.3 placenta: 11.1 DHRS4 FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2 ENSG00000157326 Dehydrogenase/reductase (SDR family) member 4 14 23953586-23969279 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023972 Uncertain Approved Nuclear membrane
Vesicles Renal cancer:4.55e-6 (favourable) Expressed in all Expressed in all kidney: 149.2 DHRS4L2 SDR25C3 ENSG00000187630 Dehydrogenase/reductase (SDR family) member 4 like 2 14 23969874-24006408 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023972 Uncertain Uncertain Nuclear membrane
Vesicles Ovarian cancer:3.21e-4 (favourable) Expressed in all Expressed in all kidney: 121.8 DIDO1 BYE1, C20orf158, DATF1, DIO-1, DIO1, dJ885L7.8, FLJ11265, KIAA0333 ENSG00000101191 Death inducer-obliterator 1 20 62877738-62937952 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004374, HPA049904 Supported Approved Nucleoplasm
Vesicles Pancreatic cancer:3.88e-4 (favourable), Head and neck cancer:5.13e-4 (favourable) Expressed in all Expressed in all fallopian tube: 47.7 DISP2 DISPB, HsT16908, KIAA1742 ENSG00000140323 Dispatched homolog 2 (Drosophila) 15 40358235-40378639 Predicted membrane proteins Evidence at protein level HPA059903 Uncertain Approved Nucleoplasm
Vesicles Mixed Tissue enhanced cerebral cortex: 7.5 thyroid gland: 1.9 DLG1 dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97 ENSG00000075711 Discs, large homolog 1 (Drosophila) 3 197042560-197299300 Predicted intracellular proteins Evidence at protein level CAB016307, HPA069593 Supported Uncertain Vesicles
Plasma membrane Expressed in all Expressed in all thyroid gland: 94.5 DLG2 chapsyn-110, PPP1R58, PSD-93, PSD93 ENSG00000150672 Discs, large homolog 2 (Drosophila) 11 83455012-85627922 Predicted intracellular proteins Evidence at protein level HPA021307, HPA023896, CAB072341 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 73.0 thyroid gland: 25.9 DMPK DM, DM1, DM1PK, DMK, MDPK, MT-PK ENSG00000104936 Dystrophia myotonica-protein kinase 19 45769717-45782552 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007164, HPA008905 Supported Approved Vesicles
Cytosol Pancreatic cancer:9.39e-5 (favourable) Expressed in all Expressed in all smooth muscle: 96.5 DNAJC13 KIAA0678, RME8 ENSG00000138246 DnaJ (Hsp40) homolog, subfamily C, member 13 3 132417526-132539032 Disease related genes, Predicted membrane proteins Evidence at protein level HPA036923, HPA036924 Approved Supported Vesicles
Cytosol Liver cancer:7.49e-4 (unfavourable), Pancreatic cancer:8.36e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 28.8 DNM1L DRP1, DVLP, DYMPLE, HDYNIV, VPS1 ENSG00000087470 Dynamin 1-like 12 32679200-32745650 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB009952, HPA039324 Supported Validated Vesicles
Cytosol Liver cancer:6.27e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 88.3 DNMT3B ENSG00000088305 DNA (cytosine-5-)-methyltransferase 3 beta 20 32762385-32809356 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001595, CAB069896 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable) Tissue enriched Tissue enhanced testis: 9.2 skin: 4.5 DOLPP1 LSFR2 ENSG00000167130 Dolichyldiphosphatase 1 9 129081100-129090438 Enzymes, Predicted membrane proteins Evidence at protein level HPA019179 Approved Approved Vesicles
Intermediate filaments Expressed in all Expressed in all duodenum: 26.5 DPP7 DPPII ENSG00000176978 Dipeptidyl-peptidase 7 9 137110542-137115177 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021282, CAB025541, HPA059381 Supported Validated Golgi apparatus
Vesicles Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable) Expressed in all Expressed in all adrenal gland: 71.0 DPYSL4 DRP-4, ULIP4 ENSG00000151640 Dihydropyrimidinase-like 4 10 132186900-132205776 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049066 Approved Approved Vesicles
Mitochondria Urothelial cancer:3.11e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 30.1 testis: 6.8 DRAM2 MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154 ENSG00000156171 DNA-damage regulated autophagy modulator 2 1 111117333-111140216 Predicted membrane proteins Evidence at protein level HPA018036, HPA061701 Supported Validated Golgi apparatus
Vesicles Liver cancer:3.45e-5 (unfavourable), Melanoma:6.43e-4 (unfavourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Mixed spleen: 19.8 DUSP22 JKAP, JSP1, MKPX, VHX ENSG00000112679 Dual specificity phosphatase 22 6 291630-351355 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031394 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 85.1 EBF1 EBF, OLF1 ENSG00000164330 Early B-cell factor 1 5 158695916-159099761 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA061169 Approved Nucleoplasm
Vesicles Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 41.6 placenta: 16.6 EBF3 COE3, DKFZp667B0210 ENSG00000108001 Early B-cell factor 3 10 129835283-129963841 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA061169 Approved Nucleoplasm
Vesicles Mixed Tissue enhanced adipose tissue: 20.1 lymph node: 12.9 EDA ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED ENSG00000158813 Ectodysplasin A X 69616067-70039469 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037972, HPA037973 Supported Vesicles
Lipid droplets Renal cancer:1.04e-9 (favourable) Mixed Tissue enhanced parathyroid gland: 19.0 thyroid gland: 10.0 EFNA4 EPLG4, LERK4 ENSG00000243364 Ephrin-A4 1 155063731-155069553 Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB021350, HPA064952 Approved Uncertain Nucleus
Vesicles Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable) Expressed in all Mixed skin: 24.5 EFNA5 AF1, EPLG7, LERK7 ENSG00000184349 Ephrin-A5 5 107376889-107670895 Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB013282, HPA054047 Approved Approved Vesicles
Cytosol Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable) Mixed Mixed cervix, uterine: 17.1 EGFL8 C6orf8, NG3 ENSG00000241404 EGF-like-domain, multiple 8 6 32164583-32168281 Predicted secreted proteins Evidence at protein level HPA061173 Uncertain Uncertain Nuclear speckles
Vesicles Mixed Mixed skin: 2.7 EGR3 PILOT ENSG00000179388 Early growth response 3 8 22687659-22693302 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA006206, CAB009373 Uncertain Uncertain Nucleus
Vesicles Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable) Mixed Mixed gallbladder: 49.7 EIF1AD haponin, MGC11102 ENSG00000175376 Eukaryotic translation initiation factor 1A domain containing 11 65996545-66002176 Predicted intracellular proteins Evidence at protein level HPA054991, HPA058735 Uncertain Supported Nucleoplasm
Vesicles Endometrial cancer:3.59e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 34.3 EIF2B3 EIF-2B, EIF2Bgamma ENSG00000070785 Eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa 1 44850522-44986722 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024213, HPA024218, HPA024219 Supported Supported Vesicles
Cytosol Liver cancer:1.73e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 48.6 ELFN2 dJ63G5.3, KIAA1904, LRRC62, PPP1R29 ENSG00000166897 Extracellular leucine-rich repeat and fibronectin type III domain containing 2 22 37367960-37427470 Predicted membrane proteins Evidence at protein level HPA000781 Approved Approved Nucleoplasm
Vesicles Renal cancer:7.21e-4 (unfavourable) Mixed Tissue enriched 7 cerebral cortex: 24.3 testis: 3.7 ELOVL3 CIG-30 ENSG00000119915 ELOVL fatty acid elongase 3 10 102226328-102229589 Enzymes, Predicted membrane proteins Evidence at protein level HPA036236 Supported Approved Vesicles
Cytosol Endometrial cancer:6.25e-5 (unfavourable) Tissue enhanced Tissue enhanced adipose tissue: 3.6;breast: 4.4;skin: 3.4 testis: 2.3 EML6 FLJ42562 ENSG00000214595 Echinoderm microtubule associated protein like 6 2 54723499-54972025 Predicted intracellular proteins Evidence at protein level HPA062808, HPA068759 Uncertain Approved Vesicles
Mitochondria Mixed Tissue enhanced lymph node: 7.6;tonsil: 8.7 appendix: 4.6 EPN3 FLJ20778, MGC129899 ENSG00000049283 Epsin 3 17 50532543-50543750 Predicted intracellular proteins Evidence at protein level HPA055546, HPA063224 Approved Supported Nucleoplasm
Vesicles Renal cancer:1.53e-5 (favourable) Mixed Mixed stomach: 27.4 EPS15 AF-1P, MLLT5 ENSG00000085832 Epidermal growth factor receptor pathway substrate 15 1 51354263-51519328 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA008451, CAB010164 Approved Validated Vesicles
Cytosol Cervical cancer:6.44e-4 (unfavourable) Expressed in all Expressed in all testis: 84.3 ERGIC1 ERGIC-32, ERGIC32, KIAA1181, NET24 ENSG00000113719 Endoplasmic reticulum-golgi intermediate compartment 1 5 172834275-172952685 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018666, HPA018900 Supported Validated Nucleoplasm
Vesicles Expressed in all Expressed in all prostate: 238.4 ERGIC2 Erv41, PTX1 ENSG00000087502 ERGIC and golgi 2 12 29337352-29381189 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049695 Approved Supported Nucleoli
Vesicles Renal cancer:3.76e-6 (unfavourable), Pancreatic cancer:7.02e-6 (unfavourable), Liver cancer:8.06e-6 (unfavourable), Ovarian cancer:8.18e-4 (favourable) Expressed in all Expressed in all testis: 105.6 ERI1 3'HEXO, THEX1 ENSG00000104626 Exoribonuclease 1 8 9002147-9116746 Predicted intracellular proteins Evidence at protein level CAB033838, HPA055548, HPA056074 Uncertain Approved Vesicles
Microtubules Colorectal cancer:8.05e-5 (favourable), Renal cancer:1.42e-4 (unfavourable) Expressed in all Mixed testis: 16.7 ERICH2 ENSG00000204334 Glutamate-rich 2 2 170783786-170798971 Predicted intracellular proteins Evidence at protein level HPA061010 Approved Nucleoli fibrillar center
Vesicles Renal cancer:8.98e-7 (unfavourable), Endometrial cancer:9.49e-4 (favourable) Expressed in all Tissue enriched 8 testis: 232.3 thyroid gland: 30.5 ESPL1 ESP1, KIAA0165, SEPA ENSG00000135476 Extra spindle pole bodies like 1, separase 12 53268299-53293643 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB012185 Uncertain Supported Nucleoplasm
Vesicles Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable) Mixed Tissue enhanced esophagus: 11.4;testis: 10.6 lymph node: 4.9 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 ESYT1 FAM62A, KIAA0747, MBC2 ENSG00000139641 Extended synaptotagmin-like protein 1 12 56118250-56144671 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016858, HPA076926 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:3.86e-4 (favourable) Expressed in all Expressed in all adipose tissue: 114.2 EVA1A FAM176A, FLJ13391, TMEM166 ENSG00000115363 Eva-1 homolog A (C. elegans) 2 75469302-75569722 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008055 Approved Supported Vesicles
Plasma membrane Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable) Mixed Tissue enhanced liver: 98.5 lung: 31.1 EVI5 NB4S ENSG00000067208 Ecotropic viral integration site 5 1 92508696-92792404 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027339, HPA053724 Approved Supported Golgi apparatus
Vesicles Expressed in all Mixed parathyroid gland: 15.2 EVL RNB6 ENSG00000196405 Enah/Vasp-like 14 99971449-100144236 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018849, HPA019536, CAB033987 Supported Approved Vesicles
Cytosol Pancreatic cancer:4.07e-6 (favourable), Renal cancer:4.14e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 208.7 EXOC3L1 EXOC3L, FLJ35539, FLJ35587 ENSG00000179044 Exocyst complex component 3-like 1 16 67184366-67190204 Predicted intracellular proteins Evidence at transcript level HPA029574 Uncertain Approved Vesicles
Plasma membrane Expressed in all Tissue enhanced spleen: 30.6 placenta: 8.4 EXOC3L2 FLJ36147, XTP7 ENSG00000130201 Exocyst complex component 3-like 2 19 45212621-45234211 Predicted intracellular proteins Evidence at protein level HPA041595, HPA061110 Approved Approved Nucleus
Vesicles Liver cancer:4.01e-5 (favourable), Head and neck cancer:1.27e-4 (favourable), Pancreatic cancer:2.10e-4 (favourable) Expressed in all Mixed spleen: 13.5 EXOC6 DKFZp761I2124, EXOC6A, FLJ1125, MGC33397, SEC15L, SEC15L1, Sec15p ENSG00000138190 Exocyst complex component 6 10 92834713-93059493 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036285, HPA059111 Approved Supported Nucleoplasm
Vesicles Renal cancer:4.66e-4 (favourable) Expressed in all Expressed in all placenta: 49.2 FAAP24 C19orf40, FLJ46828, MGC32020 ENSG00000131944 Fanconi anemia core complex associated protein 24 19 32972209-32978222 Predicted intracellular proteins Evidence at protein level HPA041168 Uncertain Supported Nucleoplasm
Vesicles Renal cancer:4.00e-7 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable) Expressed in all Mixed testis: 12.3 FAM173B ENSG00000150756 Family with sequence similarity 173, member B 5 10226330-10249897 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA074513 Approved Nucleus
Vesicles Breast cancer:1.32e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.7 FAM177A1 C14orf24 ENSG00000151327 Family with sequence similarity 177, member A1 14 35044907-35113130 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA053222, HPA055440 Uncertain Approved Nucleoplasm
Vesicles Ovarian cancer:8.51e-5 (favourable), Head and neck cancer:9.70e-4 (unfavourable) Expressed in all Expressed in all prostate: 102.4 FAM188B C7orf67, FLJ22374 ENSG00000106125 Family with sequence similarity 188, member B 7 30771417-30892387 Predicted intracellular proteins Evidence at protein level HPA019475, HPA030129, HPA030130 Approved Supported Vesicles
Cytosol Mixed Mixed fallopian tube: 18.4 FAM192A C16orf94, NIP30 ENSG00000172775 Family with sequence similarity 192, member A 16 57152466-57186116 Predicted intracellular proteins Evidence at protein level HPA054382, HPA059652 Uncertain Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 175.6 FAM207A C21orf70, PRED56 ENSG00000160256 Family with sequence similarity 207, member A 21 44940010-44976989 Predicted intracellular proteins Evidence at protein level CAB034178, HPA036354 Approved Approved Golgi apparatus
Vesicles Liver cancer:7.04e-4 (unfavourable), Renal cancer:7.80e-4 (unfavourable) Expressed in all Expressed in all testis: 20.8 FAM212A C3orf54 ENSG00000185614 Family with sequence similarity 212, member A 3 49803254-49805030 Predicted intracellular proteins Evidence at protein level HPA041879 Uncertain Approved Nucleoplasm
Vesicles Head and neck cancer:1.96e-4 (favourable) Expressed in all Tissue enhanced skin: 24.5 lung: 7.0 FAM78A C9orf59, FLJ00024 ENSG00000126882 Family with sequence similarity 78, member A 9 131258076-131276547 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021472, HPA023914 Uncertain Uncertain Nucleus
Vesicles Head and neck cancer:2.00e-4 (favourable), Cervical cancer:3.67e-4 (favourable) Expressed in all Mixed lymph node: 27.8 FAM78B ENSG00000188859 Family with sequence similarity 78, member B 1 166057426-166166969 Predicted intracellular proteins Evidence at transcript level HPA052789, HPA073246 Uncertain Approved Golgi apparatus
Vesicles Mixed Not detected adipose tissue,cerebral cortex,duodenum,stomach,testis: 0.2 FAM98B FLJ38426 ENSG00000171262 Family with sequence similarity 98, member B 15 38454127-38487710 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008320, HPA008502 Approved Supported Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 31.6 FANCL FAAP43, FLJ10335, PHF9, Pog ENSG00000115392 Fanconi anemia, complementation group L 2 58159243-58241372 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB033842, HPA036685, HPA036686 Supported Approved Nuclear bodies
Vesicles Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable) Expressed in all Expressed in all adrenal gland: 44.8 FBXW11 BTRC2, BTRCP2, Fbw11, Fbw1b, FBXW1B, Hos, KIAA0696 ENSG00000072803 F-box and WD repeat domain containing 11 5 171861549-172006873 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062578, HPA072204 Approved Approved Nucleoli
Vesicles Expressed in all Expressed in all parathyroid gland: 71.3 FBXW7 AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10 ENSG00000109670 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 4 152321259-152536101 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB013793, CAB029987 Supported Supported Nucleoplasm
Vesicles Renal cancer:1.52e-4 (unfavourable) Expressed in all Expressed in all skin: 87.7 FIG4 ALS11, CMT4J, dJ249I4.1, hSac3, KIAA0274, SAC3 ENSG00000112367 FIG4 phosphoinositide 5-phosphatase 6 109691312-109825428 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017823, HPA068859 Approved Approved Vesicles
Lipid droplets Liver cancer:4.73e-4 (unfavourable), Breast cancer:5.91e-4 (unfavourable), Renal cancer:8.19e-4 (favourable), Colorectal cancer:8.42e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 32.6 FOSB AP-1, DKFZp686C0818, G0S3, GOS3, GOSB, MGC42291 ENSG00000125740 FBJ murine osteosarcoma viral oncogene homolog B 19 45467995-45475179 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB010267, HPA054663 Approved Supported Nucleoplasm
Vesicles Expressed in all Mixed gallbladder: 560.0 FOXI1 FKHL10, FREAC6 ENSG00000168269 Forkhead box I1 5 170105897-170109725 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA071469 Supported Uncertain Nucleoli
Vesicles Group enriched Tissue enhanced breast: 10.4;kidney: 19.9;prostate: 6.5 salivary gland: 6.3 FOXK2 ILF, ILF1 ENSG00000141568 Forkhead box K2 17 82519713-82644662 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA027523 Approved Supported Nucleoplasm
Vesicles Liver cancer:1.24e-6 (unfavourable) Expressed in all Expressed in all testis: 64.8 FOXN2 HTLF ENSG00000170802 Forkhead box N2 2 48314637-48379294 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003485 Supported Supported Nucleus
Vesicles Renal cancer:2.81e-5 (unfavourable), Glioma:5.14e-4 (favourable) Expressed in all Expressed in all bone marrow: 36.5 FRAT1 ENSG00000165879 Frequently rearranged in advanced T-cell lymphomas 1 10 97319267-97321915 Predicted intracellular proteins Evidence at protein level CAB046472, HPA055258 Approved Approved Vesicles
Cytosol Renal cancer:6.36e-5 (favourable), Head and neck cancer:2.75e-4 (favourable), Cervical cancer:5.92e-4 (favourable) Expressed in all Mixed spleen: 9.4 FSTL1 FRP, FSL1 ENSG00000163430 Follistatin-like 1 3 120392293-120451253 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035251 Approved Approved Vesicles
Cytosol Renal cancer:1.33e-4 (unfavourable) Expressed in all Expressed in all placenta: 651.3 FTO ALKBH9, KIAA1752, MGC5149 ENSG00000140718 Fat mass and obesity associated 16 53703963-54121941 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB017123, HPA041086 Supported Approved Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 75.4 FZD3 ENSG00000104290 Frizzled class receptor 3 8 28494205-28574268 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB024995, HPA042320 Approved Approved Nucleoplasm
Vesicles Colorectal cancer:1.17e-4 (favourable), Ovarian cancer:3.71e-4 (favourable) Mixed Mixed cerebral cortex: 16.5 GABRD ENSG00000187730 Gamma-aminobutyric acid (GABA) A receptor, delta 1 2019324-2030751 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA044371 Supported Uncertain Golgi apparatus
Vesicles Renal cancer:4.12e-8 (unfavourable) Expressed in all Tissue enriched 10 cerebral cortex: 47.4 testis: 4.5 GAK DNAJC26 ENSG00000178950 Cyclin G associated kinase 4 849276-932373 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027405, HPA027459, HPA027463 Approved Validated Golgi apparatus
Vesicles Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable) Expressed in all Expressed in all duodenum: 52.9 GAL GAL-GMAP, GALN, GLNN, GMAP ENSG00000069482 Galanin/GMAP prepropeptide 11 68683779-68691175 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA049864 Supported Approved Golgi apparatus
Vesicles Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable) Mixed Tissue enhanced appendix: 18.7;smooth muscle: 11.9 colon: 5.3 GALNT15 GALNT7, GALNTL2, pp-GalNAc-T15 ENSG00000131386 Polypeptide N-acetylgalactosaminyltransferase 15 3 16174649-16231992 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017076, HPA051551 Uncertain Approved Vesicles
Plasma membrane Tissue enriched Tissue enhanced adipose tissue: 36.2;cerebral cortex: 41.4;placenta: 42.6 breast: 18.3 GCG GLP1, GLP2, GRPP ENSG00000115263 Glucagon 2 162142873-162152404 Predicted secreted proteins Evidence at protein level CAB000040, HPA036760, HPA036761 Supported Uncertain Golgi apparatus
Vesicles Tissue enriched Tissue enhanced pancreas: 346.2;rectum: 139.2;small intestine: 126.0 colon: 70.8 GCNT3 C2/4GnT, C2GnT-M, C2GnT2 ENSG00000140297 Glucosaminyl (N-acetyl) transferase 3, mucin type 15 59594875-59640239 Enzymes, Predicted membrane proteins Evidence at protein level HPA011154 Approved Approved Golgi apparatus
Vesicles Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable) Tissue enhanced Tissue enhanced colon: 144.6;gallbladder: 118.5;rectum: 136.6;small intestine: 141.0 duodenum: 100.5 GDNF ATF1, ATF2, HFB1-GDNF ENSG00000168621 Glial cell derived neurotrophic factor 5 37812677-37839686 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB005210, HPA070283 Supported Approved Nucleoplasm
Vesicles Mixed Mixed placenta: 6.9 GGA1 ENSG00000100083 Golgi-associated, gamma adaptin ear containing, ARF binding protein 1 22 37608475-37633564 Predicted intracellular proteins Evidence at protein level HPA048280, HPA051016 Supported Supported Nucleoplasm
Vesicles Pancreatic cancer:4.86e-4 (favourable), Liver cancer:6.29e-4 (unfavourable) Expressed in all Expressed in all testis: 199.1 GGT7 D20S101, dJ18C9.2, GGTL3, GGTL5 ENSG00000131067 Gamma-glutamyltransferase 7 20 34844720-34872860 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013204, HPA013339 Approved Approved Nucleus
Vesicles Endometrial cancer:1.26e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 50.1 GIGYF1 GYF1, PERQ1 ENSG00000146830 GRB10 interacting GYF protein 1 7 100679507-100689448 Predicted intracellular proteins Evidence at protein level HPA020999, HPA023995 Approved Approved Vesicles
Microtubules Pancreatic cancer:1.35e-5 (favourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:7.42e-4 (favourable) Expressed in all Expressed in all endometrium: 35.7 GIMAP7 IAN7, MGC27027 ENSG00000179144 GTPase, IMAP family member 7 7 150514830-150521073 Predicted intracellular proteins Evidence at protein level HPA020266, HPA020268 Supported Approved Vesicles
Cytosol Liver cancer:8.98e-5 (favourable), Head and neck cancer:7.43e-4 (favourable) Expressed in all Expressed in all lymph node: 184.0 GJB3 CX31, DFNA2, EKV ENSG00000188910 Gap junction protein, beta 3, 31kDa 1 34781189-34786369 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074472 Supported Vesicles
Cell Junctions Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable) Mixed Tissue enhanced esophagus: 33.7;skin: 77.4 tonsil: 12.1 GLB1 EBP, ELNR1 ENSG00000170266 Galactosidase, beta 1 3 32996608-33097230 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008382, HPA040610, HPA069503 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.14e-5 (favourable) Expressed in all Expressed in all epididymis: 120.4 GLIPR2 C9orf19, GAPR-1 ENSG00000122694 GLI pathogenesis-related 2 9 36136536-36163913 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029478 Approved Uncertain Vesicles
Microtubules Renal cancer:6.54e-7 (unfavourable) Expressed in all Expressed in all lung: 93.8 GNG2 ENSG00000186469 Guanine nucleotide binding protein (G protein), gamma 2 14 51826195-51979342 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003534, CAB018380 Uncertain Supported Approved Golgi apparatus
Vesicles Renal cancer:3.90e-6 (unfavourable), Pancreatic cancer:1.64e-4 (favourable) Expressed in all Expressed in all testis: 184.7 GNPDA1 GNPDA, GNPI, GPI, HLN, KIAA0060 ENSG00000113552 Glucosamine-6-phosphate deaminase 1 5 141991749-142013041 Enzymes, Predicted intracellular proteins Evidence at protein level HPA000499, HPA046891 Uncertain Approved Golgi apparatus
Vesicles Liver cancer:2.60e-6 (unfavourable) Expressed in all Expressed in all kidney: 77.1 GNPDA2 SB52 ENSG00000163281 Glucosamine-6-phosphate deaminase 2 4 44682200-44726595 Enzymes, Predicted intracellular proteins Evidence at protein level HPA000499, HPA046891 Uncertain Approved Golgi apparatus
Vesicles Expressed in all Expressed in all thyroid gland: 32.5 GOLPH3 GOPP1, GPP34, MIDAS, Vps74 ENSG00000113384 Golgi phosphoprotein 3 (coat-protein) 5 32124704-32174350 Predicted intracellular proteins Evidence at protein level HPA044564, HPA055841 Approved Supported Golgi apparatus
Vesicles Expressed in all Expressed in all gallbladder: 120.9 GPC6 ENSG00000183098 Glypican 6 13 93226842-94407401 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017671 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed gallbladder: 27.4 GPR1 ENSG00000183671 G protein-coupled receptor 1 2 206175316-206218047 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010525 Uncertain Supported Vesicles
Plasma membrane Mixed Tissue enhanced placenta: 11.2 esophagus: 5.5 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 GPR183 EBI2 ENSG00000169508 G protein-coupled receptor 183 13 99294530-99307405 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028847, CAB033690 Uncertain Approved Nuclear membrane
Vesicles Cervical cancer:9.77e-4 (favourable) Expressed in all Mixed appendix: 117.8 GPRC5A PEIG-1, RAI3, RAIG1, TIG1 ENSG00000013588 G protein-coupled receptor, class C, group 5, member A 12 12890782-12917937 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007928, HPA046526 Approved Validated Vesicles
Plasma membrane Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable) Mixed Tissue enhanced lung: 302.3 thyroid gland: 90.7 GPRIN1 GRIN1, KIAA1893 ENSG00000169258 G protein regulated inducer of neurite outgrowth 1 5 176595802-176610133 Predicted intracellular proteins Evidence at protein level HPA036478, HPA070892 Supported Supported Vesicles
Plasma membrane Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 27.9 duodenum: 3.9 GRASP Tamalin ENSG00000161835 GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein 12 52006940-52015889 Predicted intracellular proteins Evidence at protein level HPA040664, HPA062028 Approved Approved Nuclear bodies
Vesicles Expressed in all Mixed adipose tissue: 21.5 GRB10 ENSG00000106070 Growth factor receptor-bound protein 10 7 50590063-50793462 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB019423, HPA027502, HPA031818 Approved Approved Nuclear membrane
Vesicles Expressed in all Expressed in all thyroid gland: 44.8 GRIPAP1 DKFZp434P0630, GRASP-1, GRASP1, KIAA1167, MPMGp800B12492Q3 ENSG00000068400 GRIP1 associated protein 1 X 48973720-49002264 Predicted intracellular proteins Evidence at protein level HPA000282, HPA000615 Approved Approved Vesicles
Cytosol Renal cancer:3.92e-7 (unfavourable), Urothelial cancer:4.63e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 68.7 GSPT1 eRF3a, ETF3A, GST1 ENSG00000103342 G1 to S phase transition 1 16 11868128-11916082 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA052488 Approved Approved Vesicles
Cytosol Colorectal cancer:2.10e-5 (favourable), Renal cancer:3.06e-5 (favourable), Liver cancer:7.94e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 130.4 GYPC CD236, CD236R, Ge, GPC, GYPD ENSG00000136732 Glycophorin C (Gerbich blood group) 2 126655933-126696675 Blood group antigen proteins, CD markers, Predicted membrane proteins Evidence at protein level HPA008965, CAB009445 Supported Approved Vesicles
Cytosol Expressed in all Expressed in all bone marrow: 230.3 HAND2 bHLHa26, dHand, Hed, Thing2 ENSG00000164107 Heart and neural crest derivatives expressed 2 4 173524969-173530229 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA019591, CAB025576 Approved Supported Nucleoplasm
Vesicles Tissue enhanced Tissue enhanced endometrium: 83.7 smooth muscle: 77.6 HEBP1 HBP, HEBP ENSG00000013583 Heme binding protein 1 12 12974864-13000273 Predicted intracellular proteins Evidence at protein level HPA056417, HPA075277 Approved Approved Nucleus
Vesicles Expressed in all Expressed in all duodenum: 241.2 HECTD4 C12orf51, FLJ34154, KIAA0614 ENSG00000173064 HECT domain containing E3 ubiquitin protein ligase 4 12 112160188-112382439 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041062, HPA045473 Uncertain Approved Nucleoplasm
Vesicles Head and neck cancer:2.97e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 19.4 HEXIM1 CLP-1, EDG1, HIS1, MAQ1 ENSG00000186834 Hexamethylene bis-acetamide inducible 1 17 45148502-45152101 Predicted intracellular proteins Evidence at protein level HPA008926, CAB011625 Supported Validated Nucleoplasm
Vesicles Expressed in all Expressed in all placenta: 36.5 HFM1 FLJ36760, FLJ39011, MER3, SEC63D1 ENSG00000162669 HFM1, ATP-dependent DNA helicase homolog 1 91260766-91404869 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035036, HPA035557 Uncertain Golgi apparatus
Vesicles Tissue enhanced Tissue enriched 5 testis: 24.9 ovary: 4.7 HHLA3 ENSG00000197568 HERV-H LTR-associating 3 1 70354805-70385339 Predicted intracellular proteins Evidence at protein level HPA031323 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.03e-4 (unfavourable) Expressed in all Mixed epididymis: 21.9 HMOX2 HO-2 ENSG00000103415 Heme oxygenase 2 16 4474690-4510347 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025464, HPA040611 Supported Approved Vesicles
Cytosol Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable) Expressed in all Expressed in all testis: 97.3 HOOK2 HK2 ENSG00000095066 Hook microtubule-tethering protein 2 19 12763003-12872740 Predicted intracellular proteins Evidence at protein level HPA043519, HPA050351 Approved Supported Vesicles
Cytosol Prostate cancer:7.59e-5 (unfavourable), Renal cancer:3.28e-4 (favourable) Expressed in all Expressed in all thyroid gland: 95.9 HOXA2 HOX1K ENSG00000105996 Homeobox A2 7 27100354-27102811 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA078220 Approved Nucleus
Vesicles Mixed Tissue enhanced parathyroid gland: 8.1 epididymis: 6.1 HPSE HPA, HPSE1, HSE1 ENSG00000173083 Heparanase 4 83292461-83335153 Enzymes, Predicted secreted proteins Evidence at protein level HPA055344 Supported Nucleoplasm
Vesicles Mixed Tissue enhanced parathyroid gland: 19.6 testis: 10.1 HSD17B13 SCDR9, SDR16C3 ENSG00000170509 Hydroxysteroid (17-beta) dehydrogenase 13 4 87303789-87322906 Predicted intracellular proteins Evidence at protein level HPA029125 Uncertain Approved Golgi apparatus
Vesicles Liver cancer:2.94e-4 (favourable), Lung cancer:7.80e-4 (favourable) Tissue enriched Tissue enriched 29 liver: 293.7 adipose tissue: 10.2 HSD17B6 HSE, RODH, SDR9C6 ENSG00000025423 Hydroxysteroid (17-beta) dehydrogenase 6 12 56752161-56787790 Enzymes, Predicted intracellular proteins Evidence at protein level HPA059141 Supported Approved Nucleus
Vesicles Liver cancer:6.32e-4 (favourable) Tissue enriched Tissue enriched 10 liver: 929.1 seminal vesicle: 94.8 HSPA1A HSP70-1, HSPA1 ENSG00000204389 Heat shock 70kDa protein 1A 6 31815464-31817946 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB017451, CAB032815, HPA052504 Supported Uncertain Nucleoplasm
Vesicles Colorectal cancer:1.54e-5 (unfavourable) Expressed in all Mixed adrenal gland: 49.9 HSPA1B HSP70-2 ENSG00000204388 Heat shock 70kDa protein 1B 6 31827735-31830255 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB008640, HPA052504 Approved Uncertain Nucleoplasm
Vesicles Expressed in all Tissue enhanced adrenal gland: 34.3 urinary bladder: 15.0 HSPA1L HSP70-HOM, hum70t ENSG00000204390 Heat shock 70kDa protein 1-like 6 31809619-31815065 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043285, HPA052504 Supported Uncertain Nucleoplasm
Vesicles Ovarian cancer:1.02e-4 (favourable), Renal cancer:4.63e-4 (favourable) Expressed in all Tissue enriched 8 testis: 9.7 epididymis: 1.1 HSPA2 ENSG00000126803 Heat shock 70kDa protein 2 14 64535905-64546173 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000798, HPA052504 Approved Approved Uncertain Nucleoplasm
Vesicles Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable) Expressed in all Tissue enhanced testis: 188.7 cerebral cortex: 96.7 HSPA6 ENSG00000173110 Heat shock 70kDa protein 6 (HSP70B') 1 161524540-161526910 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017452, HPA028549, HPA052504 Approved Uncertain Nucleoplasm
Vesicles Renal cancer:1.98e-5 (unfavourable), Liver cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 27.7 spleen: 15.3 HSPA8 HSC70, HSC71, HSP73, HSPA10 ENSG00000109971 Heat shock 70kDa protein 8 11 123057489-123063230 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002056, HPA052504 Uncertain Uncertain Nucleoplasm
Vesicles Colorectal cancer:6.14e-6 (favourable), Liver cancer:1.93e-4 (unfavourable), Renal cancer:3.81e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1122.1 HSPBP1 FES1, HspBP1 ENSG00000133265 HSPA (heat shock 70kDa) binding protein, cytoplasmic cochaperone 1 19 55262231-55280381 Predicted intracellular proteins Evidence at protein level CAB005865, HPA071444 Supported Approved Vesicles
Cytosol Expressed in all Expressed in all fallopian tube: 39.6 HYKK AGPHD1, LOC123688 ENSG00000188266 Hydroxylysine kinase 15 78507564-78537372 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040706 Approved Approved Vesicles
Aggresome Mixed Mixed kidney: 12.3 ICA1 ICAp69 ENSG00000003147 Islet cell autoantigen 1, 69kDa 7 8113184-8262687 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017646, HPA061452 Approved Supported Vesicles
Cytosol Renal cancer:4.23e-8 (favourable) Expressed in all Mixed testis: 42.6 IFI30 GILT, IFI-30, IP-30, IP30, MGC32056 ENSG00000216490 Interferon, gamma-inducible protein 30 19 18173162-18178117 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026650 Approved Supported Vesicles
Cytosol Mixed Expressed in all appendix: 848.1 IFIT5 RI58 ENSG00000152778 Interferon-induced protein with tetratricopeptide repeats 5 10 89414586-89421001 Predicted intracellular proteins Evidence at protein level HPA037957, HPA062180 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed parathyroid gland: 35.6 IGF2 C11orf43, FLJ44734, IGF-II ENSG00000167244 Insulin-like growth factor 2 11 2129112-2141238 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007556, HPA007993 Supported Approved Nucleoplasm
Vesicles Liver cancer:7.12e-4 (favourable) Group enriched Tissue enriched 18 placenta: 3974.6 fallopian tube: 220.1 IGF2R CD222, CIMPR, M6P-R, MPR1, MPRI ENSG00000197081 Insulin-like growth factor 2 receptor 6 159969099-160113507 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009661, HPA011332 Supported Validated Golgi apparatus
Vesicles Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 49.5 IGFBPL1 bA113O24.1 ENSG00000137142 Insulin-like growth factor binding protein-like 1 9 38408994-38424447 Predicted secreted proteins Evidence at protein level HPA051354 Uncertain Approved Nucleoplasm
Vesicles Mixed Tissue enriched 8 thyroid gland: 31.3 cerebral cortex: 3.9 IL1RAP C3orf13, IL-1RAcP, IL1R3 ENSG00000196083 Interleukin 1 receptor accessory protein 3 190514051-190659750 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035293 Uncertain Approved Vesicles
Cytosol Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable) Expressed in all Tissue enhanced liver: 112.5;placenta: 53.2 gallbladder: 19.9 IL27RA CRL1, IL-27R, TCCR, WSX-1, WSX1, zcytor1 ENSG00000104998 Interleukin 27 receptor, alpha 19 14031748-14053216 Predicted membrane proteins Evidence at protein level HPA047188 Approved Vesicles
Cytosol Renal cancer:2.58e-10 (unfavourable), Breast cancer:1.74e-6 (favourable) Expressed in all Mixed tonsil: 31.5 IL31RA CRL, CRL3, GLM-R, Glmr, IL-31RA ENSG00000164509 Interleukin 31 receptor A 5 55851379-55922853 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051532 Approved Nucleoplasm
Vesicles Mixed Tissue enhanced testis: 3.7 bone marrow: 1.2 IL37 FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H4, IL-1RP1, IL1F7 ENSG00000125571 Interleukin 37 2 112912971-112918882 Predicted intracellular proteins Evidence at protein level HPA054371, HPA057950 Approved Supported Nucleoplasm
Vesicles Tissue enriched Tissue enriched 7 skin: 162.6 breast: 22.0 ILVBL 209L8, AHAS, FLJ39061, ILV2H, MGC1269, MGC19535 ENSG00000105135 IlvB (bacterial acetolactate synthase)-like 19 15114984-15125785 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067682 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 80.0 INMT ENSG00000241644 Indolethylamine N-methyltransferase 7 30697985-30757602 Enzymes, Predicted intracellular proteins Evidence at protein level HPA061343 Approved Golgi apparatus
Vesicles Liver cancer:5.72e-4 (favourable) Tissue enhanced Tissue enhanced lung: 144.9 seminal vesicle: 65.5 INPP1 ENSG00000151689 Inositol polyphosphate-1-phosphatase 2 190343470-190371665 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036698, HPA036699 Supported Uncertain Vesicles
Microtubule organizing center Thyroid cancer:1.12e-5 (favourable), Urothelial cancer:5.70e-4 (favourable) Expressed in all Expressed in all testis: 73.2 IPO9 FLJ10402, Imp9 ENSG00000198700 Importin 9 1 201829141-201884294 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA059540 Approved Vesicles
Cytosol Liver cancer:4.11e-5 (unfavourable), Renal cancer:2.86e-4 (unfavourable), Urothelial cancer:5.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.0 IQGAP2 ENSG00000145703 IQ motif containing GTPase activating protein 2 5 76403249-76708132 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004241, HPA037403, HPA037404 Approved Approved Vesicles
Plasma membrane Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 124.6 testis: 91.6 IQSEC1 ARF-GEP100, BRAG2, GEP100, KIAA0763 ENSG00000144711 IQ motif and Sec7 domain 1 3 12897220-13073117 Predicted intracellular proteins Evidence at protein level HPA038143, HPA038144 Uncertain Approved Nucleoli
Vesicles Renal cancer:3.58e-6 (favourable), Breast cancer:3.03e-5 (unfavourable), Pancreatic cancer:9.07e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 83.6 IRX4 ENSG00000113430 Iroquois homeobox 4 5 1877413-1887236 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA064094 Uncertain Nucleus
Vesicles Mixed Tissue enhanced prostate: 5.0;skin: 6.9 esophagus: 1.4 ISOC1 CGI-111 ENSG00000066583 Isochorismatase domain containing 1 5 129094751-129114028 Predicted intracellular proteins Evidence at protein level HPA070307 Approved Endoplasmic reticulum
Vesicles Expressed in all Expressed in all endometrium: 174.3 ITGA4 CD49D ENSG00000115232 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 2 181457202-181536187 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064041 Approved Golgi apparatus
Vesicles Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Mixed Tissue enhanced spleen: 68.6 appendix: 51.2 ITGA9 ALPHA-RLC, ITGA4L, RLC ENSG00000144668 Integrin, alpha 9 3 37452115-37823514 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030609 Approved Approved Nucleus
Vesicles Expressed in all Mixed thyroid gland: 34.5 ITIH5 MGC10848 ENSG00000123243 Inter-alpha-trypsin inhibitor heavy chain family, member 5 10 7559270-7666998 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038305 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed placenta: 122.7 ITM2B BRI, BRI2, BRICD2B, E25B, E3-16 ENSG00000136156 Integral membrane protein 2B 13 48233158-48270357 Disease related genes, Predicted membrane proteins Evidence at protein level HPA029292, HPA071992 Approved Validated Golgi apparatus
Vesicles Renal cancer:3.73e-5 (favourable) Expressed in all Expressed in all epididymis: 1826.9 ITSN2 KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP ENSG00000198399 Intersectin 2 2 24202864-24360714 Predicted intracellular proteins Evidence at protein level HPA036475 Approved Approved Vesicles
Plasma membrane Head and neck cancer:2.98e-4 (favourable) Expressed in all Expressed in all thyroid gland: 84.6 IZUMO4 C19orf36 ENSG00000099840 IZUMO family member 4 19 2096429-2099593 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA045099, HPA048496 Approved Uncertain Nucleoplasm
Vesicles Pancreatic cancer:1.69e-4 (favourable), Endometrial cancer:7.08e-4 (favourable) Mixed Tissue enriched 52 testis: 341.4 ovary: 6.5 JKAMP C14orf100, CDA06, HSPC213, HSPC327, JAMP ENSG00000050130 JNK1/MAPK8-associated membrane protein 14 59484443-59505410 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031172, HPA071650 Supported Approved Nucleoplasm
Vesicles Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 74.7 JMJD4 FLJ12517 ENSG00000081692 Jumonji domain containing 4 1 227730425-227735411 Predicted intracellular proteins Evidence at protein level HPA027260, HPA052861 Uncertain Approved Vesicles
Plasma membrane Renal cancer:3.16e-4 (unfavourable) Expressed in all Expressed in all testis: 12.9 JTB hJT ENSG00000143543 Jumping translocation breakpoint 1 153974269-153977688 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006514 Approved Approved Vesicles
Actin filaments Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable) Expressed in all Expressed in all epididymis: 114.3 KDELC2 MGC33424 ENSG00000178202 KDEL (Lys-Asp-Glu-Leu) containing 2 11 108472105-108498432 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039315, HPA039817, HPA066134 Uncertain Supported Nucleoplasm
Vesicles Urothelial cancer:6.27e-5 (unfavourable), Liver cancer:1.45e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 61.1 KDELR1 ERD2, ERD2.1, HDEL ENSG00000105438 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 19 48382570-48391553 Predicted membrane proteins, Transporters Evidence at protein level CAB017455 Approved Supported Golgi apparatus
Vesicles Liver cancer:1.61e-4 (unfavourable), Head and neck cancer:3.49e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 259.3 KIAA0430 LKAP, Marf1, PPP1R34 ENSG00000166783 KIAA0430 16 15594386-15643166 Predicted intracellular proteins Evidence at protein level HPA017992 Approved Supported Golgi apparatus
Vesicles Expressed in all Expressed in all parathyroid gland: 20.2 KIAA0895L LOC653319 ENSG00000196123 KIAA0895-like 16 67175602-67184040 Predicted intracellular proteins Evidence at transcript level HPA065996 Approved Approved Nucleoplasm
Vesicles Pancreatic cancer:3.16e-4 (favourable) Expressed in all Mixed cerebral cortex: 25.4 KIAA0922 DKFZp586H1322, TMEM131L ENSG00000121210 KIAA0922 4 153466346-153636711 Predicted membrane proteins Evidence at protein level HPA043472, HPA048443 Uncertain Approved Nucleoli fibrillar center
Vesicles Cervical cancer:6.69e-6 (favourable) Expressed in all Expressed in all lymph node: 57.0 KIAA1462 JCAD ENSG00000165757 KIAA1462 10 30012800-30115494 Predicted intracellular proteins Evidence at protein level HPA017956 Approved Supported Vesicles
Cell Junctions Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable) Expressed in all Mixed placenta: 48.3 KIAA1614 ENSG00000135835 KIAA1614 1 180913154-180951614 Predicted intracellular proteins Evidence at protein level HPA028227, HPA061684 Approved Approved Nuclear membrane
Vesicles Mixed Mixed thyroid gland: 3.0 KIAA1644 ENSG00000138944 KIAA1644 22 44243667-44312851 Predicted membrane proteins Evidence at transcript level HPA051178 Uncertain Approved Vesicles
Cytosol Mixed Tissue enhanced cerebral cortex: 27.6;endometrium: 42.5;smooth muscle: 44.0 cervix, uterine: 19.1 KISS1R AXOR12, GPR54, HOT7T175 ENSG00000116014 KISS1 receptor 19 917287-921015 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071913 Supported Vesicles
Plasma membrane Renal cancer:3.33e-6 (unfavourable) Tissue enhanced Tissue enriched 5 cerebral cortex: 1.2 appendix,lymph node,placenta: 0.2 KLHL12 C3IP1 ENSG00000117153 Kelch-like family member 12 1 202891100-202928636 Predicted intracellular proteins Evidence at protein level HPA071324 Supported Vesicles
Microtubule organizing center Expressed in all Expressed in all testis: 81.6 KLHL2 MAV ENSG00000109466 Kelch-like family member 2 4 165207618-165323156 Predicted intracellular proteins Evidence at protein level HPA051637 Uncertain Nucleoplasm
Vesicles Renal cancer:3.77e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 77.5 thyroid gland: 21.5 KLHL38 C8ORFK36 ENSG00000175946 Kelch-like family member 38 8 123645527-123652950 Predicted intracellular proteins Evidence at protein level HPA024770, HPA027115 Uncertain Uncertain Nucleoplasm
Vesicles Tissue enhanced Group enriched 15 heart muscle: 39.2;skeletal muscle: 91.2 smooth muscle: 4.2 KRT222 KA21, KRT222P, MGC45562 ENSG00000213424 Keratin 222, type II 17 40654665-40665181 Predicted intracellular proteins Evidence at protein level HPA043708, HPA054586, HPA069774 Uncertain Approved Vesicles
Lipid droplets Mixed Tissue enhanced cerebral cortex: 10.0;epididymis: 3.1 gallbladder: 2.7 KRT34 Ha-4, KRTHA4 ENSG00000131737 Keratin 34, type I 17 41377650-41382403 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA055194, HPA072208 Supported Approved Nucleus
Vesicles Tissue enhanced Tissue enriched 8 cervix, uterine: 4.2 testis: 0.5 L3MBTL4 FLJ35936, HsT1031 ENSG00000154655 L(3)mbt-like 4 (Drosophila) 18 5954706-6415237 Predicted intracellular proteins Evidence at protein level HPA064194, HPA069042 Approved Approved Nucleoplasm
Vesicles Mixed Mixed testis: 24.8 LAMA5 ENSG00000130702 Laminin, alpha 5 20 62307955-62367312 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054609, CAB078157 Supported Supported Nucleoplasm
Vesicles Expressed in all Tissue enhanced skin: 42.2 placenta: 28.8 LAMB2 LAMS ENSG00000172037 Laminin, beta 2 (laminin S) 3 49121114-49133118 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000053, HPA001895, HPA050033, CAB078160 Supported Approved Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 203.5 LAMP3 CD208, DC-LAMP, DCLAMP, LAMP, TSC403 ENSG00000078081 Lysosomal-associated membrane protein 3 3 183122213-183163839 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025133, HPA051467 Supported Supported Nucleus
Vesicles Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable) Mixed Tissue enriched 7 lung: 320.1 appendix: 46.2 LAMTOR2 ENDAP, MAPBPIP, MAPKSP1AP, p14, Ragulator2, ROBLD3 ENSG00000116586 Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 1 156054752-156058510 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA004126 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.10e-6 (unfavourable) Expressed in all Expressed in all epididymis: 83.7 LATS1 WARTS ENSG00000131023 Large tumor suppressor kinase 1 6 149658153-149718256 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031804 Approved Uncertain Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 23.2 LCMT2 KIAA0547, MGC9534, PPM2, TYW4 ENSG00000168806 Leucine carboxyl methyltransferase 2 15 43323649-43330605 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039401, HPA048176 Approved Approved Nucleoplasm
Vesicles Renal cancer:5.69e-9 (favourable) Expressed in all Mixed parathyroid gland: 12.9 LDHA ENSG00000134333 Lactate dehydrogenase A 11 18394388-18408425 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB015336 Approved Supported Vesicles
Cytosol Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 499.8 LDLRAD4 C18orf1 ENSG00000168675 Low density lipoprotein receptor class A domain containing 4 18 13217498-13652755 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047633, HPA054556, HPA065246 Approved Supported Nucleoplasm
Vesicles Renal cancer:4.58e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 27.6 LGSN GLULD1, LGS ENSG00000146166 Lengsin, lens protein with glutamine synthetase domain 6 63275951-63319977 Predicted intracellular proteins Evidence at protein level HPA030957, HPA039983 Supported Approved Nucleoplasm
Vesicles Tissue enhanced Tissue enhanced kidney: 2.8;liver: 2.4;placenta: 1.8 testis: 0.7 LHFPL2 KIAA0206 ENSG00000145685 Lipoma HMGIC fusion partner-like 2 5 78485215-78770021 Predicted membrane proteins Evidence at protein level HPA042402 Uncertain Approved Vesicles
Actin filaments Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable) Expressed in all Mixed gallbladder: 36.4 LIPT2 ENSG00000175536 Lipoyl(octanoyl) transferase 2 (putative) 11 74491712-74493733 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040249 Approved Approved Vesicles
Centrosome Ovarian cancer:1.63e-4 (favourable) Expressed in all Mixed testis: 14.4 LLGL2 HGL, Hugl-2 ENSG00000073350 Lethal giant larvae homolog 2 (Drosophila) 17 75525080-75575208 Predicted intracellular proteins Evidence at protein level HPA022913 Uncertain Supported Vesicles
Cytosol Renal cancer:6.14e-9 (favourable), Pancreatic cancer:6.00e-5 (favourable), Head and neck cancer:9.25e-4 (favourable) Expressed in all Mixed stomach: 64.0 LNX2 MGC46315, PDZRN1 ENSG00000139517 Ligand of numb-protein X 2 13 27545911-27620404 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040698 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-13 (favourable) Expressed in all Expressed in all testis: 23.2 LPAR6 P2RY5, P2Y5 ENSG00000139679 Lysophosphatidic acid receptor 6 13 48389567-48444704 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA028934, HPA076273 Approved Supported Vesicles
Plasma membrane Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable) Expressed in all Expressed in all placenta: 100.1 LRP2 DBS, gp330 ENSG00000081479 Low density lipoprotein receptor-related protein 2 2 169127109-169362685 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005980, HPA064792 Supported Approved Vesicles
Mitochondria Renal cancer:3.43e-5 (favourable) Group enriched Group enriched 6 kidney: 49.4;parathyroid gland: 153.0;thyroid gland: 36.8 breast: 14.1 LRRC15 LIB ENSG00000172061 Leucine rich repeat containing 15 3 194355247-194369743 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035503 Uncertain Approved Vesicles
Plasma membrane Tissue enhanced Mixed cervix, uterine,tonsil: 4.7 LRRC43 MGC35140 ENSG00000158113 Leucine rich repeat containing 43 12 122167738-122203471 Predicted intracellular proteins Evidence at transcript level HPA039425, HPA047606 Uncertain Approved Golgi apparatus
Vesicles Mixed Group enriched 5 fallopian tube: 29.9;testis: 8.5 parathyroid gland: 3.5 LRRK2 DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2 ENSG00000188906 Leucine-rich repeat kinase 2 12 40196744-40369285 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA014293, CAB037160 Approved Approved Nucleus
Vesicles Renal cancer:3.02e-6 (favourable) Group enriched Tissue enhanced lung: 78.2 parathyroid gland: 22.9 LSM1 CASM, YJL124C ENSG00000175324 LSM1 homolog, mRNA degradation associated 8 38163321-38176730 Predicted intracellular proteins Evidence at protein level HPA024601 Supported Vesicles
Cytosol Expressed in all Expressed in all placenta: 35.5 LSM14B bA11M20.3, C20orf40, FAM61B, FLJ25473, FT005, LSM13, RAP55B ENSG00000149657 LSM family member 14B 20 62122461-62135378 Predicted intracellular proteins Evidence at protein level HPA041274, HPA061189 Approved Supported Nucleoli fibrillar center
Vesicles Liver cancer:3.61e-5 (unfavourable) Expressed in all Expressed in all testis: 78.8 LSM8 YJR022W ENSG00000128534 LSM8 homolog, U6 small nuclear RNA associated 7 118184032-118192824 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020116 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:7.46e-6 (unfavourable), Endometrial cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all lymph node: 53.1 LYPD3 C4.4A ENSG00000124466 LY6/PLAUR domain containing 3 19 43460787-43465660 Predicted membrane proteins Evidence at protein level HPA041529, HPA041797, HPA077859 Supported Approved Endoplasmic reticulum
Vesicles Lung cancer:7.86e-5 (unfavourable) Tissue enhanced Group enriched 5 esophagus: 676.5;skin: 594.5 tonsil: 118.9 MAK16 MAK16L, RBM13 ENSG00000198042 MAK16 homolog 8 33484750-33501260 Predicted intracellular proteins Evidence at protein level HPA044417, HPA050574 Uncertain Supported Nucleoli
Vesicles Liver cancer:1.00e-4 (unfavourable), Renal cancer:3.66e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 12.6 MAN1C1 HMIC ENSG00000117643 Mannosidase, alpha, class 1C, member 1 1 25617468-25786207 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048352 Uncertain Uncertain Nucleus
Vesicles Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable) Expressed in all Mixed thyroid gland: 40.6 MAN2B1 LAMAN, MANB ENSG00000104774 Mannosidase, alpha, class 2B, member 1 19 12646511-12666742 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA041530, HPA053404 Supported Approved Nucleoplasm
Vesicles Renal cancer:1.94e-5 (unfavourable) Expressed in all Expressed in all spleen: 96.8 MANSC1 FLJ10298, LOH12CR3 ENSG00000111261 MANSC domain containing 1 12 12326056-12350541 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007955, HPA007956 Approved Approved Golgi apparatus
Vesicles Renal cancer:3.30e-5 (favourable) Expressed in all Mixed parathyroid gland: 24.2 MARCO SCARA2 ENSG00000019169 Macrophage receptor with collagenous structure 2 118942166-118994660 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063793 Supported Approved Golgi apparatus
Vesicles Mixed Tissue enhanced appendix: 125.3;lung: 288.5 adipose tissue: 77.1 MARVELD3 MRVLDC3 ENSG00000140832 MARVEL domain containing 3 16 71626161-71642114 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043514, HPA045471 Approved Vesicles
Intermediate filaments Renal cancer:6.80e-10 (favourable) Mixed Tissue enhanced small intestine: 37.8 duodenum: 32.4 MBNL3 CHCR, FLJ11316, MBLX39, MBXL ENSG00000076770 Muscleblind-like splicing regulator 3 X 132369317-132489968 Predicted intracellular proteins Evidence at protein level HPA001584 Supported Approved Golgi apparatus
Vesicles Endometrial cancer:1.57e-4 (unfavourable) Expressed in all Group enriched 5 placenta: 240.2;testis: 81.1 liver: 30.5 MED23 CRSP130, CRSP3, DRIP130, Sur2 ENSG00000112282 Mediator complex subunit 23 6 131573966-131628229 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070341 Approved Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 31.6 MEF2C ENSG00000081189 Myocyte enhancer factor 2C 5 88717117-88904257 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005533, CAB068196, CAB068197 Supported Supported Nucleoplasm
Vesicles Renal cancer:1.01e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 221.1 METTL7B ALDI, MGC17301 ENSG00000170439 Methyltransferase like 7B 12 55681546-55684611 Predicted secreted proteins Evidence at protein level HPA038644 Supported Supported Vesicles
Microtubules Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable) Mixed Tissue enhanced epididymis: 134.9;liver: 121.9 duodenum: 53.4 MFSD8 CLN7, MGC33302 ENSG00000164073 Major facilitator superfamily domain containing 8 4 127917805-127965995 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044802 Approved Supported Nucleoplasm
Vesicles Urothelial cancer:2.21e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 12.2 MGAM2 ENSG00000257743 Maltase-glucoamylase 2 (putative) 7 142111749-142222324 Enzymes, Predicted membrane proteins Evidence at protein level HPA055697 Supported Approved Vesicles
Cytosol Group enriched Group enriched 5 duodenum: 12.2;small intestine: 10.6 salivary gland: 2.1 MICB PERB11.2 ENSG00000204516 MHC class I polypeptide-related sequence B 6 31494881-31511124 Disease related genes, Predicted membrane proteins Evidence at protein level HPA064618 Approved Golgi apparatus
Vesicles Renal cancer:4.94e-9 (unfavourable), Liver cancer:7.04e-5 (unfavourable) Mixed Tissue enhanced lymph node: 3.3 spleen: 2.8 MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 (membrane-inserted) 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 MMP19 MMP18, RASI-1 ENSG00000123342 Matrix metallopeptidase 19 12 55835433-55842966 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA070804 Approved Endoplasmic reticulum
Vesicles Renal cancer:8.56e-9 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 63.1;gallbladder: 97.5 placenta: 27.9 MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles
Cytosol Expressed in all Tissue enhanced gallbladder: 1688.5 urinary bladder: 944.6 MMP7 MPSL1, PUMP-1 ENSG00000137673 Matrix metallopeptidase 7 11 102520508-102530753 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025869, HPA051358 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 824.4 breast: 201.5 MOSPD1 dJ473B4 ENSG00000101928 Motile sperm domain containing 1 X 134887626-134915267 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031158 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all fallopian tube: 41.8 MPO ENSG00000005381 Myeloperoxidase 17 58269856-58280935 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000059, HPA021147, HPA061464 Supported Supported Nucleus
Vesicles Tissue enhanced Tissue enriched 81 bone marrow: 2504.1 salivary gland: 30.8 MPZL1 FLJ21047, PZR ENSG00000197965 Myelin protein zero-like 1 1 167721192-167791919 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026966, HPA063538 Approved Supported Vesicles
Plasma membrane Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable) Expressed in all Expressed in all breast: 111.3 MSH2 COCA1, HNPCC, HNPCC1 ENSG00000095002 MutS homolog 2 2 47402969-47562311 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009572, CAB070867 Supported Approved Nucleoplasm
Vesicles Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable) Expressed in all Expressed in all testis: 32.6 MSH5 ENSG00000204410 MutS homolog 5 6 31739948-31762834 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA062688 Approved Endoplasmic reticulum
Vesicles Mixed Mixed skin: 1.8 MSLN CAK1, MPF ENSG00000102854 Mesothelin 16 643262-768865 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002216, HPA017172 Supported Approved Nucleoplasm
Vesicles Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable) Tissue enhanced Group enriched 9 fallopian tube: 440.6;lung: 105.4 epididymis: 29.2 MSMP PC-3, PSMP ENSG00000215183 Microseminoprotein, prostate associated 9 35752990-35756613 Predicted intracellular proteins Evidence at protein level HPA055174 Uncertain Supported Vesicles
Cytosol Not detected Tissue enhanced placenta: 1.8 appendix,breast: 0.3 MSS51 FLJ39565, ZMYND17 ENSG00000166343 MSS51 mitochondrial translational activator 10 73423579-73433561 Predicted intracellular proteins Evidence at protein level HPA038564, HPA038566 Uncertain Uncertain Vesicles
Cytosol Mixed Group enriched 18 parathyroid gland: 159.7;skeletal muscle: 81.4 heart muscle: 6.7 MTA3 KIAA1266 ENSG00000057935 Metastasis associated 1 family, member 3 2 42494569-42756947 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA039433 Approved Supported Nucleus
Vesicles Endometrial cancer:2.30e-4 (unfavourable), Liver cancer:4.69e-4 (unfavourable) Expressed in all Expressed in all testis: 52.2 MTHFSD FLJ12998 ENSG00000103248 Methenyltetrahydrofolate synthetase domain containing 16 86530176-86555235 Predicted intracellular proteins Evidence at protein level HPA041333 Uncertain Approved Nucleus
Vesicles Colorectal cancer:9.88e-5 (unfavourable) Expressed in all Expressed in all testis: 33.1 MTOR FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 ENSG00000198793 Mechanistic target of rapamycin (serine/threonine kinase) 1 11106535-11262507 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB069425, HPA071227 Approved Approved Vesicles
Cytosol Renal cancer:1.49e-5 (favourable) Expressed in all Expressed in all testis: 62.0 MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM ENSG00000185499 Mucin 1, cell surface associated 1 155185824-155192916 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000036, CAB001986, HPA004179, HPA007235, HPA008855 Supported Validated Vesicles
Plasma membrane Pancreatic cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced lung: 447.5;stomach: 650.2 cervix, uterine: 286.5 MVB12B C9orf28, FAM125B, FLJ00001 ENSG00000196814 Multivesicular body subunit 12B 9 126326849-126507041 Predicted intracellular proteins Evidence at protein level HPA043683, HPA049383 Uncertain Approved Golgi apparatus
Vesicles Pancreatic cancer:7.89e-4 (favourable) Expressed in all Mixed cerebral cortex: 36.6 MYBBP1A FLJ37886, P160, PAP2 ENSG00000132382 MYB binding protein (P160) 1a 17 4538897-4555631 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005466 Supported Supported Nucleoli
Vesicles Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable) Expressed in all Expressed in all skin: 21.7 MYEOV OCIM ENSG00000172927 Myeloma overexpressed 11 69294138-69367726 Predicted membrane proteins Evidence at transcript level HPA012949 Uncertain Approved Nucleus
Vesicles Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable) Mixed Group enriched 5 adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 7.0 appendix: 1.0 MYOF FER1L3, KIAA1207 ENSG00000138119 Myoferlin 10 93306429-93482317 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014245 Approved Supported Vesicles
Plasma membrane Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 100.7 NADK FLJ13052 ENSG00000008130 NAD kinase 1 1751232-1780457 Enzymes, Predicted intracellular proteins Evidence at protein level HPA048909, HPA053368 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Expressed in all spleen: 78.8 NCAN CSPG3 ENSG00000130287 Neurocan 19 19211973-19252233 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036814 Supported Uncertain Vesicles
Centrosome Tissue enriched Tissue enriched 101 cerebral cortex: 183.9 testis: 1.8 NECAP1 DKFZP566B183 ENSG00000089818 NECAP endocytosis associated 1 12 8082211-8097771 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA053980, HPA063300 Uncertain Approved Vesicles
Cytosol Expressed in all Expressed in all cerebral cortex: 115.2 NEK10 FLJ32685 ENSG00000163491 NIMA-related kinase 10 3 27110085-27369460 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038941 Uncertain Approved Nucleoplasm
Vesicles Breast cancer:4.20e-4 (favourable) Tissue enriched Tissue enhanced testis: 65.6 breast: 18.4 NET1 ARHGEF8, NET1A ENSG00000173848 Neuroepithelial cell transforming 1 10 5412551-5458463 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020068 Uncertain Approved Nucleus
Vesicles Liver cancer:3.87e-5 (unfavourable), Pancreatic cancer:8.27e-4 (unfavourable) Expressed in all Expressed in all rectum: 98.1 NEU1 NEU ENSG00000204386 Sialidase 1 (lysosomal sialidase) 6 31857659-31862906 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015634, HPA021506 Approved Supported Vesicles
Cell Junctions Expressed in all Mixed thyroid gland: 14.3 NEU3 ENSG00000162139 Sialidase 3 (membrane sialidase) 11 74988134-75018893 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038729, HPA038730, HPA070381 Uncertain Supported Nucleoplasm
Vesicles Pancreatic cancer:5.98e-4 (favourable) Expressed in all Mixed parathyroid gland: 25.0 NFE2L3 Nrf3 ENSG00000050344 Nuclear factor, erythroid 2-like 3 7 26152240-26187125 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA055889 Supported Approved Nucleoplasm
Vesicles Renal cancer:7.58e-12 (unfavourable), Pancreatic cancer:6.62e-5 (unfavourable), Stomach cancer:2.14e-4 (favourable) Expressed in all Tissue enhanced placenta: 51.1 appendix: 14.8 NIPBL DKFZp434L1319, FLJ11203, FLJ12597, FLJ13354, FLJ13648, IDN3, Scc2 ENSG00000164190 Nipped-B homolog (Drosophila) 5 36876759-37066413 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040834, HPA058239 Approved Supported Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 55.9 NKX2-1 BCH, NKX2A, TITF1, TTF-1, TTF1 ENSG00000136352 NK2 homeobox 1 14 36516392-36521149 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000078, CAB053633, HPA074316 Supported Uncertain Golgi apparatus
Vesicles Group enriched Group enriched 174 lung: 102.0;thyroid gland: 103.6 stomach: 0.5 NMRK2 ITGB1BP3, MIBP, NRK2 ENSG00000077009 Nicotinamide riboside kinase 2 19 3933103-3942416 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049909, HPA054792, HPA072450 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.19e-4 (favourable) Tissue enhanced Group enriched 50 heart muscle: 396.7;skeletal muscle: 218.5 esophagus: 6.1 NOS1AP CAPON, KIAA0464 ENSG00000198929 Nitric oxide synthase 1 (neuronal) adaptor protein 1 162069774-162370475 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018582, HPA030066, HPA055561 Approved Approved Nucleus
Vesicles Mixed Tissue enriched 6 cerebral cortex: 23.5 adrenal gland: 3.8 NPL C1orf13, DHDPS1, NPL1 ENSG00000135838 N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 1 182789293-182830384 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028345 Approved Vesicles
Plasma membrane Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable) Expressed in all Mixed placenta: 63.2 NRP2 VEGF165R2 ENSG00000118257 Neuropilin 2 2 205681990-205798133 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039980, HPA054974 Approved Supported Vesicles
Plasma membrane Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable) Expressed in all Mixed smooth muscle: 83.5 NRSN1 p24, VMP ENSG00000152954 Neurensin 1 6 24126122-24154900 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA061006 Approved Approved Nucleus
Vesicles Tissue enriched Tissue enriched 14 cerebral cortex: 96.7 adrenal gland: 6.7 NSMCE1 NSE1 ENSG00000169189 NSE1 homolog, SMC5-SMC6 complex component 16 27224991-27268794 Predicted intracellular proteins Evidence at protein level HPA041567, HPA043091 Supported Supported Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 121.1 NTRK1 MTC, TRK, TRKA ENSG00000198400 Neurotrophic tyrosine kinase, receptor, type 1 1 156815640-156881850 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004606, HPA035799, HPA076570 Approved Uncertain Vesicles
Cytosol Tissue enhanced Tissue enriched 6 adrenal gland: 9.6 testis: 1.6 NUP62 DKFZp547L134, FLJ20822, FLJ43869, IBSN, MGC841, p62, SNDI ENSG00000213024 Nucleoporin 62kDa 19 49906825-49929763 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA005435, CAB020724 Supported Supported Nuclear membrane
Vesicles Renal cancer:5.71e-12 (unfavourable), Liver cancer:2.50e-7 (unfavourable) Expressed in all Expressed in all testis: 76.8 NUP98 NUP96 ENSG00000110713 Nucleoporin 98kDa 11 3671083-3797792 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA074810 Supported Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 150.1 NUS1 C6orf68, MGC7199, NgBR, TANGO14 ENSG00000153989 NUS1 dehydrodolichyl diphosphate synthase subunit 6 117675502-117710640 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027504 Supported Approved Vesicles
Plasma membrane Cervical cancer:6.99e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 91.7 NXPE3 FAM55C, MGC15606 ENSG00000144815 Neurexophilin and PC-esterase domain family, member 3 3 101779202-101828229 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA036259 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:7.76e-6 (unfavourable) Mixed Mixed parathyroid gland: 34.2 NYAP1 C7orf51, FLJ37538, KIAA1486L ENSG00000166924 Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1 7 100483927-100494799 Predicted intracellular proteins Evidence at protein level HPA022251 Uncertain Supported Golgi apparatus
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 25.2;testis: 7.7 adrenal gland: 3.3 OAZ1 AZI, MGC138338, OAZ ENSG00000104904 Ornithine decarboxylase antizyme 1 19 2269509-2273490 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA009291 Uncertain Approved Vesicles
Microtubule organizing center Pancreatic cancer:4.10e-5 (favourable), Liver cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all lymph node: 271.9 ORM1 ENSG00000229314 Orosomucoid 1 9 114323056-114326475 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB006265, HPA046438, HPA047725, HPA057726 Approved Approved Golgi apparatus
Vesicles Renal cancer:2.35e-4 (unfavourable) Tissue enriched Tissue enriched 69 liver: 10546.0 bone marrow: 152.7 ORM2 AGP-B, AGP-B', AGP2 ENSG00000228278 Orosomucoid 2 9 114329869-114333252 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA046438, HPA047725, HPA057726 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.23e-9 (unfavourable) Tissue enriched Tissue enriched 75 liver: 3754.6 prostate: 49.7 OSBPL8 MST120, MSTP120, ORP8, OSBP10 ENSG00000091039 Oxysterol binding protein-like 8 12 76351797-76559809 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001309 Uncertain Approved Vesicles
Cytosol Pancreatic cancer:9.79e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.6 OSBPL9 ENSG00000117859 Oxysterol binding protein-like 9 1 51577179-51798427 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027378, HPA027397 Supported Supported Golgi apparatus
Vesicles Expressed in all Expressed in all parathyroid gland: 96.5 OXLD1 C17orf90, MGC104712 ENSG00000204237 Oxidoreductase-like domain containing 1 17 81665036-81666635 Predicted intracellular proteins Evidence at protein level HPA056878, HPA057019 Uncertain Approved Vesicles
Cytosol Cervical cancer:2.91e-4 (favourable) Expressed in all Mixed testis: 10.7 P3H1 GROS1, LEPRE1, LEPRECAN, MGC117314 ENSG00000117385 Prolyl 3-hydroxylase 1 1 42746335-42767084 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA012113, HPA016980 Approved Approved Nucleoli
Vesicles Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable) Expressed in all Tissue enhanced placenta: 53.1 smooth muscle: 28.0 P4HA2 C-P4Halpha(II) ENSG00000072682 Prolyl 4-hydroxylase, alpha polypeptide II 5 132191838-132295315 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA016997, HPA027824, CAB062557 Supported Validated Endoplasmic reticulum
Vesicles Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable) Expressed in all Expressed in all epididymis: 93.7 P4HTM EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4 ENSG00000178467 Prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) 3 48989886-49007154 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007199 Supported Uncertain Vesicles
Cytosol Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable) Expressed in all Expressed in all fallopian tube: 49.9 PACRGL C4orf28, MGC29898 ENSG00000163138 PARK2 co-regulated-like 4 20696282-20752907 Predicted intracellular proteins Evidence at protein level HPA054666 Approved Nucleoplasm
Vesicles Urothelial cancer:4.85e-4 (favourable) Expressed in all Expressed in all testis: 59.8 PACSIN1 SDPI ENSG00000124507 Protein kinase C and casein kinase substrate in neurons 1 6 34466061-34535231 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009929, HPA028852, HPA055491 Supported Approved Nucleus
Vesicles Mixed Tissue enriched 32 cerebral cortex: 134.1 lymph node: 4.2 PADI3 PDI3 ENSG00000142619 Peptidyl arginine deiminase, type III 1 17249098-17284233 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043739 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 3.8;seminal vesicle: 4.9;urinary bladder: 10.6 epididymis: 0.6 PAG1 CBP, PAG ENSG00000076641 Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 8 80967810-81112068 Predicted intracellular proteins Evidence at protein level HPA001632, HPA066527 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable) Expressed in all Mixed placenta: 22.8 PAGE4 CT16.7, GAGEC1, PAGE-4 ENSG00000101951 P antigen family, member 4 (prostate associated) X 49829260-49833973 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA023880 Supported Approved Golgi apparatus
Vesicles Group enriched Group enriched 6 epididymis: 1431.1;placenta: 2026.4 prostate: 279.7 PAH PH ENSG00000171759 Phenylalanine hydroxylase 12 102836885-102958410 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA028407, HPA031642 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:4.30e-4 (favourable) Tissue enriched Tissue enhanced kidney: 500.3;liver: 720.9 gallbladder: 126.2 PAK2 PAK65, PAKgamma ENSG00000180370 P21 protein (Cdc42/Rac)-activated kinase 2 3 196739857-196832647 Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB007794 Approved Supported Nucleus
Vesicles Pancreatic cancer:3.36e-4 (unfavourable), Prostate cancer:9.58e-4 (unfavourable) Expressed in all Expressed in all spleen: 61.0 PAPPA2 PAPP-A2, PAPPE, PLAC3 ENSG00000116183 Pappalysin 2 1 176463171-176845605 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018412, HPA018430 Supported Approved Endoplasmic reticulum
Vesicles Mixed Tissue enriched 8 placenta: 82.1 cervix, uterine: 10.8 PARG ENSG00000227345 Poly (ADP-ribose) glycohydrolase 10 49818279-49970203 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021819, HPA053007 Approved Validated Nucleus
Vesicles Liver cancer:5.57e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 16.6 PAXIP1 CAGF28, CAGF29, PAXIP1L, PTIP, TNRC2 ENSG00000157212 PAX interacting (with transcription-activation domain) protein 1 7 154943687-155003084 Predicted intracellular proteins Evidence at protein level HPA006694, HPA016950 Supported Approved Nucleoplasm
Vesicles Expressed in all Mixed testis: 16.3 PBXIP1 HPIP ENSG00000163346 Pre-B-cell leukemia homeobox interacting protein 1 1 154944076-154956123 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006949 Approved Approved Vesicles
Cytosol Renal cancer:9.22e-6 (favourable), Pancreatic cancer:2.64e-4 (favourable), Colorectal cancer:2.73e-4 (unfavourable), Head and neck cancer:7.19e-4 (favourable), Lung cancer:8.99e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 137.9 PCDHA11 CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11 ENSG00000249158 Protocadherin alpha 11 5 140868183-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077160 Approved Vesicles
Cell Junctions Not detected Tissue enhanced cerebral cortex: 7.6;parathyroid gland: 4.7 testis: 2.3 PCDHB10 ENSG00000120324 Protocadherin beta 10 5 141182560-141195642 Predicted membrane proteins Evidence at protein level HPA013445, HPA014668, HPA029441 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.3 endometrium: 5.1 PCDHB16 KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a ENSG00000272674 Protocadherin beta 16 5 141181399-141186399 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014668 Supported Vesicles
Plasma membrane Mixed Mixed parathyroid gland: 10.6 PCED1B FAM113B, MGC16044 ENSG00000179715 PC-esterase domain containing 1B 12 47079603-47236662 Predicted intracellular proteins Evidence at protein level HPA043901 Approved Approved Golgi apparatus
Vesicles Renal cancer:4.55e-6 (unfavourable), Urothelial cancer:5.36e-5 (favourable) Expressed in all Mixed lymph node: 42.9 PCOLCE PCPE, PCPE1 ENSG00000106333 Procollagen C-endopeptidase enhancer 7 100602177-100608175 Plasma proteins, Predicted secreted proteins Evidence at protein level CAB017623, HPA042927 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 215.7 gallbladder: 146.7 PCP2 GPSM4, MGC41903 ENSG00000174788 Purkinje cell protein 2 19 7631611-7633748 Predicted intracellular proteins Evidence at protein level HPA057428 Approved Nuclear speckles
Vesicles Urothelial cancer:2.76e-5 (favourable), Breast cancer:7.93e-4 (favourable) Mixed Tissue enriched 9 testis: 72.6 skin: 8.1 PDCD11 ALG-4, KIAA0185, RRP5 ENSG00000148843 Programmed cell death 11 10 103396648-103446292 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017924, CAB026472 Approved Supported Nucleoli
Vesicles Liver cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all testis: 27.9 PDE9A ENSG00000160191 Phosphodiesterase 9A 21 42653636-42775509 Enzymes, Predicted intracellular proteins Evidence at protein level HPA011380 Approved Approved Nucleoplasm
Vesicles Expressed in all Tissue enhanced prostate: 57.3 spleen: 25.9 PDGFA PDGF-A, PDGF1 ENSG00000197461 Platelet-derived growth factor alpha polypeptide 7 497258-520296 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005579 Uncertain Approved Vesicles
Microtubule organizing center Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable) Expressed in all Expressed in all placenta: 39.1 PDGFD IEGF, MSTP036, SCDGF-B ENSG00000170962 Platelet derived growth factor D 11 103907186-104164379 Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA046183, HPA066271 Approved Approved Golgi apparatus
Vesicles Stomach cancer:9.60e-4 (unfavourable) Expressed in all Tissue enhanced adrenal gland: 141.1 ovary: 96.4 PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet-derived growth factor receptor, beta polypeptide 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB003842, CAB018144, HPA028499 Approved Approved Vesicles
Cytosol Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable) Expressed in all Mixed gallbladder: 194.6 PDXDC1 KIAA0251 ENSG00000179889 Pyridoxal-dependent decarboxylase domain containing 1 16 14974591-15139339 Predicted intracellular proteins Evidence at protein level HPA047369, HPA049121, HPA051484 Approved Validated Golgi apparatus
Vesicles Renal cancer:3.13e-4 (favourable) Expressed in all Expressed in all testis: 105.9 PDZK1 NHERF3, PDZD1 ENSG00000174827 PDZ domain containing 1 1 145670852-145708148 Predicted intracellular proteins Evidence at protein level HPA005755, HPA006155, CAB008971 Supported Supported Endoplasmic reticulum
Vesicles Renal cancer:2.54e-7 (favourable) Group enriched Tissue enhanced kidney: 557.9;small intestine: 129.6 duodenum: 70.9 PEX6 PAF-2, PXAAA1 ENSG00000124587 Peroxisomal biogenesis factor 6 6 42963870-42979220 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA025924, HPA074179 Supported Approved Nucleoplasm
Vesicles Expressed in all Expressed in all fallopian tube: 36.4 PGLYRP4 PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67 ENSG00000163218 Peptidoglycan recognition protein 4 1 153330120-153348840 Predicted secreted proteins Evidence at protein level CAB025879 Approved Vesicles
Plasma membrane Group enriched Group enriched 5 esophagus: 5.8;skin: 18.2 tonsil: 2.2 PHB PHB1 ENSG00000167085 Prohibitin 17 49404049-49414905 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003280 Supported Supported Vesicles
Mitochondria Head and neck cancer:1.58e-4 (unfavourable), Renal cancer:3.77e-4 (favourable), Liver cancer:9.91e-4 (unfavourable) Expressed in all Expressed in all kidney: 201.1 PIGG FLJ20265, GPI7, LAS21 ENSG00000174227 Phosphatidylinositol glycan anchor biosynthesis, class G 4 499210-540196 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015997 Uncertain Uncertain Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 34.9 PIK3CD p110D ENSG00000171608 Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta 1 9651732-9729114 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB015420, HPA044953 Approved Approved Vesicles
Cytokinetic bridge Expressed in all Tissue enhanced lymph node: 57.2 spleen: 52.1 PIK3R3 p55 ENSG00000117461 Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 1 46040140-46133036 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA005751, HPA071988 Approved Approved Nucleoplasm
Vesicles Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable) Expressed in all Mixed testis: 46.2 PIK3R4 p150, VPS15 ENSG00000196455 Phosphoinositide-3-kinase, regulatory subunit 4 3 130678935-130746829 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036032, HPA036033 Approved Approved Vesicles
Microtubules Renal cancer:4.40e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 45.7 PIP5K1B MSS4, STM7 ENSG00000107242 Phosphatidylinositol-4-phosphate 5-kinase, type I, beta 9 68705414-69009176 Enzymes, Predicted intracellular proteins Evidence at protein level HPA009687 Uncertain Approved Nucleus
Vesicles Renal cancer:1.03e-9 (favourable) Mixed Mixed testis: 49.8 PITPNA PITPN, VIB1A ENSG00000174238 Phosphatidylinositol transfer protein, alpha 17 1517718-1562816 Predicted intracellular proteins Evidence at protein level HPA000528 Uncertain Approved Vesicles
Cytosol Pancreatic cancer:1.80e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Renal cancer:9.35e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.3 PITPNB VIB1B ENSG00000180957 Phosphatidylinositol transfer protein, beta 22 27851669-27920134 Predicted intracellular proteins Evidence at protein level HPA000528 Uncertain Approved Vesicles
Cytosol Head and neck cancer:5.28e-4 (unfavourable) Expressed in all Expressed in all placenta: 70.1 PLA2G15 GXVPLA2, LLPL, LYPLA3 ENSG00000103066 Phospholipase A2, group XV 16 68245304-68261062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041702, HPA041727 Supported Approved Nucleoplasm
Vesicles Expressed in all Expressed in all placenta: 37.3 PLA2G4F PLA2G4F/Z ENSG00000168907 Phospholipase A2, group IVF 15 42139034-42156636 Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA042713, HPA056752 Approved Approved Nucleus
Vesicles Endometrial cancer:2.00e-4 (unfavourable) Mixed Tissue enriched 5 skin: 92.8 lung: 18.4 PLEK2 ENSG00000100558 Pleckstrin 2 14 67386983-67412200 Predicted intracellular proteins Evidence at protein level HPA001208 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:8.26e-5 (unfavourable), Lung cancer:1.58e-4 (unfavourable) Expressed in all Mixed adrenal gland: 43.3 PLEKHM1 KIAA0356 ENSG00000225190 Pleckstrin homology domain containing, family M (with RUN domain) member 1 17 45435900-45490749 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA025018, HPA039473 Approved Supported Nucleoli
Vesicles Endometrial cancer:1.28e-6 (favourable), Liver cancer:3.25e-4 (unfavourable) Expressed in all Mixed esophagus: 11.9 PLEKHM3 DAPR, PLEKHM1L ENSG00000178385 Pleckstrin homology domain containing, family M, member 3 2 207828303-208025560 Predicted intracellular proteins Evidence at protein level HPA035046 Uncertain Approved Vesicles
Cytosol Mixed Mixed parathyroid gland: 16.5 PLOD1 LH1, LLH, PLOD ENSG00000083444 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 1 11934205-11975538 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA049137, HPA055799 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all placenta: 121.3 PLPP6 FLJ46512, FLJ90191, PDP1, PPAPDC2 ENSG00000205808 Phospholipid phosphatase 6 9 4662315-4665258 Predicted membrane proteins Evidence at protein level HPA018096 Approved Approved Nucleoplasm
Vesicles Renal cancer:3.99e-4 (favourable) Expressed in all Mixed prostate: 26.8 PLPP7 C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3 ENSG00000160539 Phospholipid phosphatase 7 (inactive) 9 131289694-131309262 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070252 Uncertain Approved Nucleus
Vesicles Mixed Group enriched 5 heart muscle: 33.8;skeletal muscle: 72.2 cerebral cortex: 10.1 PMF1 ENSG00000160783 Polyamine-modulated factor 1 1 156212993-156240042 Predicted intracellular proteins Evidence at protein level HPA034583, HPA071854 Supported Nucleoplasm
Vesicles Expressed in all Expressed in all thyroid gland: 68.4 PMF1-BGLAP ENSG00000260238 PMF1-BGLAP readthrough 1 156212982-156243332 Predicted intracellular proteins Evidence at protein level HPA034583, HPA071854 Supported Nucleoplasm
Vesicles Liver cancer:1.50e-4 (unfavourable), Renal cancer:3.22e-4 (unfavourable) Mixed Mixed fallopian tube: 8.1 PODXL2 endoglycan, PODLX2 ENSG00000114631 Podocalyxin-like 2 3 127629181-127672809 Predicted membrane proteins Evidence at protein level CAB024934, HPA042265 Approved Approved Golgi apparatus
Vesicles Expressed in all Tissue enhanced cerebral cortex: 77.3 testis: 35.9 POGK BASS2, KIAA15131, KRBOX2, LST003 ENSG00000143157 Pogo transposable element with KRAB domain 1 166839447-166856344 Predicted intracellular proteins Evidence at protein level HPA007838, HPA031630 Approved Supported Nucleoplasm
Vesicles Liver cancer:5.93e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 41.5 POP7 RPP2, RPP20 ENSG00000172336 POP7 homolog, ribonuclease P/MRP subunit 7 100706053-100707495 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021007 Uncertain Supported Nucleoli
Vesicles Liver cancer:4.99e-5 (unfavourable), Renal cancer:6.02e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 41.2 PPARG NR1C3, PPARG1, PPARG2, PPARgamma ENSG00000132170 Peroxisome proliferator-activated receptor gamma 3 12287368-12434356 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004282, HPA051239, HPA063663 Approved Validated Nucleus
Vesicles Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 172.8 placenta: 58.6 PPFIA3 KIAA0654, LPNA3, MGC126567, MGC126569 ENSG00000177380 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3 19 49119389-49151026 Predicted intracellular proteins Evidence at protein level HPA043567, HPA050340 Supported Uncertain Nucleoli fibrillar center
Vesicles Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable) Expressed in all Group enriched 5 cerebral cortex: 21.6;skin: 20.2 parathyroid gland: 3.9 PPP1R11 CFAP255, HCG-V, HCGV, TCTE5, Tctex5 ENSG00000204619 Protein phosphatase 1, regulatory (inhibitor) subunit 11 6 30066709-30070333 Predicted intracellular proteins Evidence at protein level HPA043266, HPA060174 Approved Approved Nucleus
Vesicles Expressed in all Tissue enhanced epididymis: 37.3 fallopian tube: 16.9 PPP5C PP5, PPP5 ENSG00000011485 Protein phosphatase 5, catalytic subunit 19 46346994-46392981 Enzymes, Predicted intracellular proteins Evidence at protein level CAB022641, HPA029065, HPA056933 Approved Supported Vesicles
Cytosol Liver cancer:3.45e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 44.5 PPP6R2 dJ579N16.1, KIAA0685, SAP190, SAPS2 ENSG00000100239 Protein phosphatase 6, regulatory subunit 2 22 50343304-50445090 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030656, CAB034919 Uncertain Supported Vesicles
Cytosol Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable) Expressed in all Expressed in all testis: 65.3 PRAF2 JM4 ENSG00000243279 PRA1 domain family, member 2 X 49071156-49074071 Predicted membrane proteins Evidence at protein level HPA002859, HPA005504, CAB011655 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable) Expressed in all Expressed in all epididymis: 181.8 PREX1 KIAA1415, P-REX1 ENSG00000124126 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 20 48624252-48827883 Predicted intracellular proteins Evidence at protein level HPA001927 Supported Supported Vesicles
Cytosol Head and neck cancer:8.56e-4 (favourable) Expressed in all Expressed in all spleen: 61.8 PRICKLE2 DKFZp686D143 ENSG00000163637 Prickle homolog 2 3 64093867-64445476 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035493 Approved Golgi apparatus
Vesicles Mixed Mixed endometrium: 40.5 PRKG1 PGK, PKG, PRKG1B, PRKGR1B ENSG00000185532 Protein kinase, cGMP-dependent, type I 10 50991358-52298350 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007699, CAB009629 Approved Approved Vesicles
Cytosol Mixed Mixed smooth muscle: 24.5 PRR15 ENSG00000176532 Proline rich 15 7 29563811-29567295 Predicted intracellular proteins Evidence at protein level HPA040996, HPA048121 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable) Mixed Tissue enhanced cervix, uterine: 91.8 colon,small intestine: 80.6 PRRG1 PRGP1 ENSG00000130962 Proline rich Gla (G-carboxyglutamic acid) 1 X 37349275-37457295 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056029, HPA078129 Uncertain Approved Vesicles
Plasma membrane Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PRSS2 TRY2 ENSG00000275896 Protease, serine, 2 (trypsin 2) 7 142748662-142774564 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA062452, HPA063471 Supported Approved Endoplasmic reticulum
Vesicles Breast cancer:2.32e-4 (favourable) Tissue enriched Tissue enriched 53 pancreas: 30691.5 small intestine: 579.8 PRSS3 PRSS4, TRY3, TRY4 ENSG00000010438 Protease, serine, 3 9 33750466-33799231 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA062452, HPA063471 Supported Approved Endoplasmic reticulum
Vesicles Endometrial cancer:4.30e-4 (unfavourable) Group enriched Tissue enriched 62 pancreas: 6299.8 small intestine: 101.1 PSD3 DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942 ENSG00000156011 Pleckstrin and Sec7 domain containing 3 8 18527301-19084730 Predicted intracellular proteins Evidence at protein level HPA002455 Approved Nucleus
Vesicles Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 83.5 testis: 29.5 PSMB10 beta2i, LMP10, MECL1, MGC1665 ENSG00000205220 Proteasome subunit beta 10 16 67934502-67937087 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030224, HPA030225, CAB034384 Supported Supported Vesicles
Cytosol Urothelial cancer:5.44e-4 (favourable) Expressed in all Expressed in all lymph node: 92.6 PSMB8 beta5i, D6S216E, LMP7, PSMB5i, RING10 ENSG00000204264 Proteasome subunit beta 8 6 32840717-32844703 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046995, HPA050327 Supported Approved Vesicles
Cytokinetic bridge Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable) Expressed in all Mixed lymph node: 23.3 PSMD6 KIAA0107, p44S10, Rpn7, S10 ENSG00000163636 Proteasome 26S subunit, non-ATPase 6 3 64010549-64024010 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036921, HPA036922 Uncertain Supported Golgi apparatus
Vesicles Liver cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all testis: 215.1 PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Supported Supported Golgi apparatus
Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.9 esophagus: 85.8 PTPRA HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA ENSG00000132670 Protein tyrosine phosphatase, receptor type, A 20 2864184-3039076 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029412, CAB034366, HPA069480 Approved Approved Nucleus
Vesicles Renal cancer:3.29e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 167.8 PTPRN2 IA-2beta, ICAAR, KIAA0387, phogrin ENSG00000155093 Protein tyrosine phosphatase, receptor type, N polypeptide 2 7 157539056-158587788 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006900, HPA026656 Approved Uncertain Vesicles
Plasma membrane Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 82.5 stomach: 39.0 PTRF cavin-1, CAVIN1 ENSG00000177469 Polymerase I and transcript release factor 17 42402452-42423517 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049838, HPA074213 Supported Supported Vesicles
Plasma membrane Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 342.2 QRSL1 DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA ENSG00000130348 Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 6 106629578-106668417 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029585, HPA029587 Approved Approved Vesicles
Centrosome Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable) Expressed in all Expressed in all lymph node: 18.9 QSOX1 QSCN6 ENSG00000116260 Quiescin Q6 sulfhydryl oxidase 1 1 180154834-180204030 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042127, HPA056243 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.86e-5 (unfavourable) Expressed in all Expressed in all gallbladder: 234.2 RAB11B H-YPT3 ENSG00000185236 RAB11B, member RAS oncogene family 19 8389981-8404434 Predicted intracellular proteins Evidence at protein level HPA054396 Approved Vesicles
Microtubule organizing center Pancreatic cancer:7.58e-5 (favourable), Renal cancer:2.06e-4 (favourable), Cervical cancer:2.08e-4 (favourable) Expressed in all Expressed in all thyroid gland: 152.7 RAB11FIP2 KIAA0941, nRip11, Rab11-FIP2 ENSG00000107560 RAB11 family interacting protein 2 (class I) 10 118004916-118046603 Predicted intracellular proteins Evidence at protein level HPA037726 Approved Supported Nucleoplasm
Vesicles Renal cancer:9.69e-5 (favourable) Expressed in all Expressed in all seminal vesicle: 36.2 RAB11FIP5 GAF1, KIAA0857, pp75, RIP11 ENSG00000135631 RAB11 family interacting protein 5 (class I) 2 73073382-73156721 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036406, HPA036407 Supported Validated Vesicles
Microtubule organizing center Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable) Expressed in all Tissue enhanced testis: 39.1 parathyroid gland: 22.5 RAB15 ENSG00000139998 RAB15, member RAS oncogene family 14 64945814-64972776 Predicted intracellular proteins Evidence at protein level HPA041177 Uncertain Approved Vesicles
Microtubule organizing center Liver cancer:4.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 63.0 RAB20 FLJ20429 ENSG00000139832 RAB20, member RAS oncogene family 13 110523066-110561733 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA052111, HPA068647 Uncertain Supported Golgi apparatus
Vesicles Urothelial cancer:4.48e-4 (favourable), Renal cancer:8.57e-4 (favourable) Expressed in all Mixed spleen: 42.7 RAB8B ENSG00000166128 RAB8B, member RAS oncogene family 15 63189469-63267782 Predicted intracellular proteins Evidence at protein level HPA074534 Supported Nucleoplasm
Vesicles Renal cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 50.7 RABEP2 FLJ23282, FRA ENSG00000177548 Rabaptin, RAB GTPase binding effector protein 2 16 28904421-28936526 Predicted intracellular proteins Evidence at protein level HPA047641 Approved Supported Vesicles
Cytosol Renal cancer:1.24e-6 (favourable), Head and neck cancer:5.84e-4 (favourable) Expressed in all Expressed in all lymph node: 58.0 RAD1 HRAD1, REC1 ENSG00000113456 RAD1 checkpoint DNA exonuclease 5 34905264-34918989 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006692 Approved Supported Nucleoplasm
Vesicles Liver cancer:1.06e-5 (unfavourable), Breast cancer:6.30e-4 (unfavourable) Expressed in all Mixed testis: 11.9 RANBP2 ADANE, ANE1, NUP358 ENSG00000153201 RAN binding protein 2 2 108719481-108785811 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564 Supported Validated Nuclear membrane
Vesicles Expressed in all Expressed in all parathyroid gland: 73.6 RASA4B ENSG00000170667 RAS p21 protein activator 4B 7 102482445-102517781 Predicted intracellular proteins, RAS pathway related proteins Evidence at transcript level HPA043010 Uncertain Uncertain Vesicles
Cell Junctions Not detected Tissue enhanced skeletal muscle: 39.7 cerebral cortex: 15.7 RBP5 CRBPIII ENSG00000139194 Retinol binding protein 5, cellular 12 7123684-7128942 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038723 Approved Approved Golgi apparatus
Vesicles Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable) Group enriched Tissue enhanced kidney: 453.4;liver: 204.9 spleen: 105.3 RCN3 RLP49 ENSG00000142552 Reticulocalbin 3, EF-hand calcium binding domain 19 49527618-49546962 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043134, HPA050402 Uncertain Approved Endoplasmic reticulum
Vesicles Renal cancer:5.80e-12 (unfavourable) Expressed in all Expressed in all small intestine: 46.0 RDH5 HSD17B9, RDH1, SDR9C5 ENSG00000135437 Retinol dehydrogenase 5 (11-cis/9-cis) 12 55720367-55724705 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063345 Approved Vesicles
Cytosol Mixed Tissue enhanced adipose tissue: 97.7 liver: 29.9 RFC3 MGC5276, RFC38 ENSG00000133119 Replication factor C (activator 1) 3, 38kDa 13 33818049-33966558 Predicted intracellular proteins Evidence at protein level HPA030149 Approved Supported Nucleoplasm
Vesicles Expressed in all Mixed lymph node: 27.1 RFX3 ENSG00000080298 Regulatory factor X, 3 (influences HLA class II expression) 9 3218297-3526004 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035689 Approved Approved Nucleoplasm
Vesicles Breast cancer:1.47e-4 (favourable) Mixed Tissue enhanced testis: 38.4 fallopian tube: 18.1 RGPD1 RGP1 ENSG00000187627 RANBP2-like and GRIP domain containing 1 2 86907953-87013981 Predicted intracellular proteins Evidence at transcript level HPA049497, HPA051675, HPA067564 Uncertain Approved Nuclear membrane
Vesicles Not detected Group enriched 8 cervix, uterine: 12.6;placenta: 14.2;testis: 44.0 bone marrow: 2.8 RGPD2 RANBP2L2, RGP2 ENSG00000185304 RANBP2-like and GRIP domain containing 2 2 87755955-87825952 Predicted intracellular proteins Evidence at transcript level HPA049497, HPA051675, HPA067564 Uncertain Approved Nuclear membrane
Vesicles Not detected Tissue enhanced testis: 13.1 placenta: 8.3 RGPD3 RGP3 ENSG00000153165 RANBP2-like and GRIP domain containing 3 2 106391290-106468376 Predicted intracellular proteins Evidence at transcript level HPA049497, HPA051675, HPA067564 Uncertain Approved Nuclear membrane
Vesicles Not detected Tissue enriched 13 testis: 11.7 cerebral cortex,kidney: 0.9 RGPD4 DKFZp686P0288, RGP4 ENSG00000196862 RANBP2-like and GRIP domain containing 4 2 107826937-107890841 Predicted intracellular proteins Evidence at transcript level HPA049497, HPA051675, HPA067564 Uncertain Uncertain Nuclear membrane
Vesicles Not detected Tissue enriched 58 testis: 5.7 all non-specific tissues: 0.0 RGPD5 BS-63, DKFZp686I1842, RGP5 ENSG00000015568 RANBP2-like and GRIP domain containing 5 2 109792758-109857695 Predicted intracellular proteins Evidence at protein level HPA045704, HPA049497, HPA051675, HPA067564 Uncertain Uncertain Nuclear membrane
Vesicles Not detected Tissue enhanced testis: 6.8 duodenum: 3.2 RGPD6 RGP6 ENSG00000183054 RANBP2-like and GRIP domain containing 6 2 110513812-110577185 Predicted intracellular proteins Evidence at protein level HPA045704, HPA049497, HPA051675, HPA067564 Uncertain Uncertain Nuclear membrane
Vesicles Not detected Expressed in all testis: 82.8 RGPD8 RanBP2alpha, RANBP2L1 ENSG00000169629 RANBP2-like and GRIP domain containing 8 2 112370092-112434488 Predicted intracellular proteins Evidence at protein level HPA045704, HPA049497, HPA051675, HPA067564 Uncertain Uncertain Nuclear membrane
Vesicles Not detected Tissue enriched 5 testis: 31.6 cerebral cortex: 5.8 RGS14 ENSG00000169220 Regulator of G-protein signaling 14 5 177357837-177372601 Predicted intracellular proteins Evidence at protein level HPA046847, HPA061819 Approved Validated Nucleoplasm
Vesicles Liver cancer:1.84e-6 (unfavourable), Glioma:9.11e-4 (unfavourable) Expressed in all Mixed spleen: 22.1 RGS19 GAIP, RGSGAIP ENSG00000171700 Regulator of G-protein signaling 19 20 64073181-64079988 Predicted intracellular proteins Evidence at protein level HPA070250 Approved Nucleoli
Vesicles Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 54.7 lymph node: 40.4 RHOQ ARHQ, RASL7A, TC10 ENSG00000119729 Ras homolog family member Q 2 46541806-46583121 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044938 Approved Vesicles
Cytosol Liver cancer:9.60e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 169.1 RIMBP3 KIAA1666, RIMBP3.1, RIMBP3A ENSG00000275793 RIMS binding protein 3 22 18605815-18611919 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 38 testis: 45.4 parathyroid gland: 1.2 RIMBP3B ENSG00000274600 RIMS binding protein 3B 22 21383374-21389478 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 26 testis: 12.1 appendix,parathyroid gland: 0.4 RIMBP3C ENSG00000183246 RIMS binding protein 3C 22 21545357-21551461 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 32 testis: 15.7 spleen: 0.4 RINL FLJ45909 ENSG00000187994 Ras and Rab interactor-like 19 38867834-38878279 Predicted intracellular proteins Evidence at protein level HPA042083, HPA042103 Uncertain Approved Nucleoplasm
Vesicles Cervical cancer:6.49e-5 (favourable), Head and neck cancer:1.64e-4 (favourable) Expressed in all Mixed lymph node: 14.2 RNASE1 RAC1, RNS1 ENSG00000129538 Ribonuclease, RNase A family, 1 (pancreatic) 14 20801228-20803278 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001140 Supported Approved Nucleoplasm
Vesicles Expressed in all Expressed in all pancreas: 1947.0 RNASE12 RAI1 ENSG00000258436 Ribonuclease, RNase A family, 12 (non-active) 14 20590193-20590823 Predicted secreted proteins Evidence at transcript level HPA044175 Uncertain Uncertain Vesicles
Microtubules Not detected Tissue enriched 255 epididymis: 1061.8 seminal vesicle: 4.1 RNF149 FLJ90504 ENSG00000163162 Ring finger protein 149 2 101271219-101308701 Predicted membrane proteins Evidence at protein level HPA011424 Approved Approved Vesicles
Plasma membrane Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable) Expressed in all Expressed in all appendix: 69.4 RNF157 KIAA1917 ENSG00000141576 Ring finger protein 157 17 76142453-76240373 Predicted intracellular proteins Evidence at protein level HPA021854, HPA021991, HPA023922 Uncertain Approved Golgi apparatus
Vesicles Mixed Tissue enhanced cerebral cortex: 60.8;testis: 58.1 skeletal muscle: 24.9 RP11-219A15.1 ENSG00000266302 17 16690261-16804453 Predicted intracellular proteins No evidence HPA047220, HPA047851 Uncertain Approved Nucleoplasm
Vesicles Not detected Not detected all non-specific tissues: 0.0 RPRD2 FLJ32145, HSPC099, KIAA0460 ENSG00000163125 Regulation of nuclear pre-mRNA domain containing 2 1 150363091-150476566 Predicted intracellular proteins Evidence at protein level HPA061693 Approved Nucleoplasm
Vesicles Expressed in all Expressed in all thyroid gland: 38.2 RRAGA FIP-1, RAGA ENSG00000155876 Ras-related GTP binding A 9 19049395-19050983 Predicted intracellular proteins Evidence at protein level HPA003734 Supported Approved Golgi apparatus
Vesicles Head and neck cancer:7.43e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 128.4 RRAGB ENSG00000083750 Ras-related GTP binding B X 55717739-55758774 Predicted intracellular proteins Evidence at protein level HPA003734 Approved Approved Golgi apparatus
Vesicles Lung cancer:3.64e-6 (favourable), Glioma:5.36e-5 (favourable), Colorectal cancer:7.60e-4 (unfavourable) Expressed in all Expressed in all epididymis: 41.5 RRAGC FLJ13311, GTR2 ENSG00000116954 Ras-related GTP binding C 1 38838198-38859823 Predicted intracellular proteins Evidence at protein level HPA018247, HPA055489 Supported Supported Nucleus
Vesicles Liver cancer:9.97e-9 (unfavourable) Expressed in all Expressed in all adipose tissue: 40.3 RUBCN KIAA0226, rubicon, rundataxin ENSG00000145016 RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein 3 197671393-197749727 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050908, HPA054497 Approved Supported Vesicles
Cytosol Liver cancer:9.91e-5 (unfavourable), Prostate cancer:1.62e-4 (unfavourable), Colorectal cancer:6.65e-4 (unfavourable) Expressed in all Expressed in all spleen: 24.7 RUNX1 AML1, AMLCR1, CBFA2, PEBP2A2 ENSG00000159216 Runt-related transcription factor 1 21 34787801-36004667 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004176, HPA037912 Supported Validated Nucleoplasm
Vesicles Renal cancer:3.44e-15 (unfavourable) Expressed in all Mixed breast: 33.8 S100B S100beta ENSG00000160307 S100 calcium binding protein B 21 46598962-46605208 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins Evidence at protein level CAB000073, HPA015768, CAB078196 Supported Approved Nucleus
Vesicles Group enriched Group enriched 9 adipose tissue: 208.2;cerebral cortex: 628.0 seminal vesicle: 49.1 SALL2 Hsal2, KIAA0360, ZNF795 ENSG00000165821 Spalt-like transcription factor 2 14 21521081-21537216 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004162 Approved Approved Nucleus
Vesicles Pancreatic cancer:1.23e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 66.6 cerebral cortex: 42.5 SAMD11 MGC45873 ENSG00000187634 Sterile alpha motif domain containing 11 1 924880-944581 Predicted intracellular proteins Evidence at protein level HPA030110 Approved Nucleoplasm
Vesicles Renal cancer:3.35e-5 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 37.6 fallopian tube: 29.0 SAMD9 C7orf5, FLJ20073, KIAA2004 ENSG00000205413 Sterile alpha motif domain containing 9 7 93099513-93118023 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021318, HPA021319 Approved Validated Vesicles
Cytosol Renal cancer:8.40e-7 (unfavourable), Pancreatic cancer:8.31e-5 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Endometrial cancer:3.14e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 43.4 spleen: 24.6 SAPCD1 C6orf26, NG23 ENSG00000228727 Suppressor APC domain containing 1 6 31762799-31764851 Predicted intracellular proteins Evidence at transcript level HPA071699 Approved Vesicles
Cell Junctions Mixed Tissue enhanced skin: 3.2 bone marrow: 1.0 SBF1 DENND7A, MTMR5 ENSG00000100241 SET binding factor 1 22 50445000-50475024 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA065538 Approved Endoplasmic reticulum
Vesicles Head and neck cancer:3.46e-5 (favourable) Expressed in all Expressed in all testis: 84.3 SCAMP2 ENSG00000140497 Secretory carrier membrane protein 2 15 74843730-74873365 Predicted membrane proteins Evidence at protein level HPA014699, HPA019194 Approved Supported Golgi apparatus
Vesicles Renal cancer:1.12e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 126.3 SCN8A CerIII, MED, NaCh6, Nav1.6, PN4 ENSG00000196876 Sodium channel, voltage gated, type VIII alpha subunit 12 51590266-51812864 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022169 Supported Vesicles
Cell Junctions Mixed Tissue enriched 6 cerebral cortex: 22.1 testis: 3.5 SCRN3 FLJ23142 ENSG00000144306 Secernin 3 2 174395730-174429575 Enzymes, Predicted intracellular proteins Evidence at protein level HPA034689, HPA034690 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 47.7 SDCBP2 SITAC18, ST-2 ENSG00000125775 Syndecan binding protein (syntenin) 2 20 1309909-1329239 Predicted intracellular proteins Evidence at protein level HPA054554 Approved Vesicles
Cytosol Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable) Expressed in all Tissue enhanced duodenum: 138.8;small intestine: 146.8 stomach: 96.4 SEC13 D3S1231E, npp-20, SEC13L1, SEC13R ENSG00000157020 SEC13 homolog, nuclear pore and COPII coat complex component 3 10293131-10321178 Predicted intracellular proteins, Transporters Evidence at protein level HPA035292, HPA057943 Approved Supported Nucleoplasm
Vesicles Liver cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 119.1 SEC23A ENSG00000100934 Sec23 homolog A, COPII coat complex component 14 39031919-39109646 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043806, HPA069974 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.69e-4 (unfavourable), Stomach cancer:2.94e-4 (unfavourable), Colorectal cancer:3.56e-4 (favourable), Cervical cancer:5.75e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 139.3 SEC24A ENSG00000113615 SEC24 homolog A, COPII coat complex component 5 134648789-134727823 Predicted intracellular proteins Evidence at protein level HPA038901, HPA056825 Approved Approved Nucleoli fibrillar center
Vesicles Cervical cancer:3.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.3 SEC24B ENSG00000138802 SEC24 homolog B, COPII coat complex component 4 109433772-109540896 Predicted intracellular proteins Evidence at protein level HPA038181 Approved Approved Nucleus
Vesicles Renal cancer:2.33e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 42.0 SEC31A ABP125, ABP130, KIAA0905, SEC31L1 ENSG00000138674 SEC31 homolog A, COPII coat complex component 4 82818661-82901166 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005457 Approved Supported Vesicles
Cytosol Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 279.9 SEMA3A coll-1, Hsema-I, SEMA1, SEMAD, SemD ENSG00000075213 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 7 83955777-84492724 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA029447, HPA052235 Approved Approved Nucleoplasm
Vesicles Cervical cancer:2.69e-5 (unfavourable) Mixed Mixed placenta: 14.4 SEMA3E coll-5, KIAA0331, M-SemaK, SEMAH ENSG00000170381 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E 7 83363906-83649010 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA029419, HPA063804 Uncertain Supported Approved Nucleoplasm
Vesicles Mixed Mixed prostate: 8.1 SEMA4D C9orf164, CD100, coll-4, FLJ39737, SEMAJ ENSG00000187764 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D 9 89360787-89498130 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015662, HPA023277 Approved Supported Endoplasmic reticulum
Vesicles Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable) Expressed in all Expressed in all lymph node: 73.3 SENP8 DEN1, HsT17512, NEDP1, PRSC2 ENSG00000166192 SUMO/sentrin peptidase family member, NEDD8 specific 15 72114258-72143688 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036273 Approved Approved Nucleoplasm
Vesicles Mixed Tissue enhanced testis: 27.8 thyroid gland: 8.5 SERPINF2 A2AP, AAP, ALPHA-2-PI, API, PLI ENSG00000167711 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 17 1742836-1755268 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001885, CAB024863 Approved Uncertain Nucleoplasm
Vesicles Liver cancer:2.26e-5 (favourable) Tissue enriched Tissue enhanced epididymis: 115.3;liver: 452.4 kidney: 63.1 SH3RF1 KIAA1494, POSH, RNF142, SH3MD2 ENSG00000154447 SH3 domain containing ring finger 1 4 169094256-169271105 Predicted intracellular proteins Evidence at protein level HPA074783 Uncertain Vesicles
Intermediate filaments Renal cancer:5.51e-8 (favourable) Expressed in all Expressed in all thyroid gland: 32.0 SHOX GCFX, PHOG, SHOXY, SS ENSG00000185960 Short stature homeobox X 624344-659411 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035141, HPA060931 Validated Nucleoplasm
Vesicles Not detected Mixed spleen: 1.1 SIAH2 ENSG00000181788 Siah E3 ubiquitin protein ligase 2 3 150741127-150763477 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA061293, CAB069930 Approved Supported Nucleoplasm
Vesicles Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable) Expressed in all Expressed in all adrenal gland: 95.8 SIKE1 FLJ21168, SIKE ENSG00000052723 Suppressor of IKBKE 1 1 114769479-114780685 Predicted intracellular proteins Evidence at protein level HPA024177, HPA025726 Supported Approved Vesicles
Focal adhesion sites Expressed in all Expressed in all thyroid gland: 19.3 SIRT7 ENSG00000187531 Sirtuin 7 17 81911939-81921323 Predicted intracellular proteins Evidence at protein level CAB037261, HPA053669 Supported Supported Nucleoli fibrillar center
Vesicles Renal cancer:1.69e-7 (unfavourable), Liver cancer:1.97e-5 (unfavourable) Expressed in all Mixed esophagus: 21.7 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 SLC12A6 ACCPN, KCC3 ENSG00000140199 Solute carrier family 12 (potassium/chloride transporter), member 6 15 34229996-34338060 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034563 Uncertain Approved Vesicles
Cytosol Renal cancer:3.33e-6 (favourable) Expressed in all Mixed testis: 46.2 SLC16A10 MCT10, TAT1 ENSG00000112394 Solute carrier family 16 (aromatic amino acid transporter), member 10 6 111087503-111231194 Predicted membrane proteins, Transporters Evidence at protein level HPA016860 Approved Approved Vesicles
Cell Junctions Tissue enriched Tissue enhanced placenta: 38.2 skin: 22.5 SLC23A2 KIAA0238, SLC23A1, SVCT2, YSPL2 ENSG00000089057 Solute carrier family 23 (ascorbic acid transporter), member 2 20 4852356-5010293 Predicted membrane proteins, Transporters Evidence at protein level HPA052825, HPA059314 Approved Supported Golgi apparatus
Vesicles Urothelial cancer:6.08e-5 (favourable), Pancreatic cancer:7.14e-5 (favourable), Liver cancer:3.35e-4 (favourable) Expressed in all Expressed in all adrenal gland: 98.6 SLC25A25 KIAA1896, MCSC, PCSCL ENSG00000148339 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 9 128068201-128109245 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA020381 Uncertain Supported Vesicles
Mitochondria Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable) Expressed in all Expressed in all gallbladder: 63.1 SLC25A35 FLJ40217 ENSG00000125434 Solute carrier family 25, member 35 17 8287763-8295343 Predicted membrane proteins, Transporters Evidence at protein level HPA051720 Uncertain Approved Vesicles
Mitochondria Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable) Expressed in all Mixed testis: 19.6 SLC29A3 ENT3, FLJ11160 ENSG00000198246 Solute carrier family 29 (equilibrative nucleoside transporter), member 3 10 71319258-71363385 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046085, HPA054976, HPA057905 Approved Supported Golgi apparatus
Vesicles Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable) Expressed in all Mixed placenta: 18.7 SLC30A1 ZNT1, ZRC1 ENSG00000170385 Solute carrier family 30 (zinc transporter), member 1 1 211571568-211578742 Predicted membrane proteins, Transporters Evidence at protein level HPA015275, HPA049000 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed liver: 47.3 SLC38A9 FLJ90709 ENSG00000177058 Solute carrier family 38, member 9 5 55625845-55773194 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043785 Uncertain Approved Nucleoplasm
Vesicles Endometrial cancer:7.24e-5 (unfavourable) Expressed in all Expressed in all placenta: 79.8 SLC44A2 CTL2 ENSG00000129353 Solute carrier family 44 (choline transporter), member 2 19 10602457-10644559 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003228, HPA070799 Approved Approved Vesicles
Cell Junctions Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 224.3 SLC45A3 IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein ENSG00000158715 Solute carrier family 45, member 3 1 205657851-205680459 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA019073, HPA019075 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable) Tissue enriched Tissue enriched 25 prostate: 430.6 stomach: 16.9 SLC4A11 BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1 ENSG00000088836 Solute carrier family 4, sodium borate transporter, member 11 20 3227417-3239190 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018120, HPA058377 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable) Expressed in all Tissue enhanced salivary gland: 19.3;thyroid gland: 27.6 cervix, uterine: 14.3 SLC4A1AP HLC3, kanadaptin ENSG00000163798 Solute carrier family 4 (anion exchanger), member 1, adaptor protein 2 27663471-27694976 Predicted intracellular proteins, Transporters Evidence at protein level HPA036679 Approved Supported Nucleoplasm
Vesicles Liver cancer:3.76e-7 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Urothelial cancer:1.79e-4 (unfavourable) Expressed in all Expressed in all testis: 61.8 SLC51B OSTbeta ENSG00000186198 Solute carrier family 51, beta subunit 15 65045370-65053396 Predicted membrane proteins, Transporters Evidence at protein level HPA008398, HPA008533 Supported Approved Vesicles
Mitochondria Renal cancer:8.46e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 87.8;small intestine: 120.6 cervix, uterine: 63.7 SLC5A1 D22S675, NAGT, SGLT1 ENSG00000100170 Solute carrier family 5 (sodium/glucose cotransporter), member 1 22 32043032-32113029 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015467, HPA051805, HPA055106 Supported Approved Nucleoplasm
Vesicles Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable) Mixed Group enriched 10 duodenum: 518.9;small intestine: 320.2 gallbladder: 40.3 SLC6A15 FLJ10316, hv7-3, NTT73, SBAT1, V7-3 ENSG00000072041 Solute carrier family 6 (neutral amino acid transporter), member 15 12 84859488-84913615 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008609 Uncertain Approved Nucleoli
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 23.1 placenta: 5.5 SLC6A4 5-HTT, HTT, OCD1, SERT1 ENSG00000108576 Solute carrier family 6 (neurotransmitter transporter), member 4 17 30194319-30236002 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA054723, HPA074728 Supported Supported Golgi apparatus
Vesicles Tissue enhanced Group enriched 10 duodenum: 10.7;lung: 44.2;placenta: 26.3;small intestine: 46.2 esophagus: 3.1 SLC7A6 KIAA0245, LAT-2, LAT3, y+LAT-2 ENSG00000103064 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 16 68264516-68301823 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050713 Uncertain Approved Vesicles
Plasma membrane Urothelial cancer:1.84e-4 (unfavourable) Expressed in all Mixed adipose tissue: 35.1 SLF2 C10orf6, FAM178A, FLJ10512, FLJ25012 ENSG00000119906 SMC5-SMC6 complex localization factor 2 10 100912569-100965136 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038499, HPA057568 Approved Supported Nucleus
Vesicles Expressed in all Expressed in all epididymis: 56.6 SLFN5 MGC19764 ENSG00000166750 Schlafen family member 5 17 35243036-35273655 Predicted intracellular proteins Evidence at protein level HPA017760 Approved Approved Nucleoplasm
Vesicles Expressed in all Mixed lymph node: 37.9 SMARCA1 hSNF2L, ISWI, NURF140, SNF2L, SNF2L1, SNF2LB, SWI ENSG00000102038 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 X 129446501-129523500 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003335, HPA064712 Uncertain Supported Nucleoplasm
Vesicles Pancreatic cancer:3.03e-4 (favourable), Renal cancer:5.09e-4 (favourable) Expressed in all Mixed testis: 112.7 SMARCD1 BAF60A, CRACD1, Rsc6p ENSG00000066117 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 12 50084972-50100712 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA004101 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-8 (unfavourable) Expressed in all Expressed in all parathyroid gland: 84.7 SMIM5 C17orf109 ENSG00000204323 Small integral membrane protein 5 17 75633434-75641404 Predicted membrane proteins Evidence at protein level HPA065332, HPA071268 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.12e-4 (favourable), Cervical cancer:5.52e-4 (favourable) Mixed Mixed thyroid gland: 14.7 SMUG1 FDG, HMUDG, UNG3 ENSG00000123415 Single-strand-selective monofunctional uracil-DNA glycosylase 1 12 54121277-54189008 Predicted intracellular proteins Evidence at protein level HPA051149, HPA071486 Approved Vesicles
Centrosome Ovarian cancer:1.31e-4 (favourable), Liver cancer:6.96e-4 (unfavourable) Expressed in all Expressed in all epididymis: 47.9 SMYD3 KMT3E, ZMYND1, ZNFN3A1 ENSG00000185420 SET and MYND domain containing 3 1 245749342-246507312 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB012229, HPA045821, HPA054352 Approved Approved Golgi apparatus
Vesicles Expressed in all Expressed in all thyroid gland: 26.9 SNX21 C20orf161, dJ337O18.4, SNX-L ENSG00000124104 Sorting nexin family member 21 20 45833810-45843275 Predicted intracellular proteins Evidence at protein level HPA046359 Approved Approved Vesicles
Microtubule organizing center Expressed in all Mixed skin: 25.3 SNX22 FLJ13952 ENSG00000157734 Sorting nexin 22 15 64151715-64157481 Predicted intracellular proteins Evidence at protein level HPA038470 Approved Approved Nucleoplasm
Vesicles Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 16.4;thyroid gland: 14.7 tonsil: 9.7 SOBP FLJ10159 ENSG00000112320 Sine oculis binding protein homolog 6 107489958-107660167 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA029242 Uncertain Approved Nucleoplasm
Vesicles Pancreatic cancer:1.55e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 26.5 ovary: 13.7 SOS2 ENSG00000100485 Son of sevenless homolog 2 (Drosophila) 14 50117120-50231558 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB004577, HPA047368, HPA052689 Approved Approved Nucleoplasm
Vesicles Renal cancer:8.48e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 79.3 SP2 KIAA0048 ENSG00000167182 Sp2 transcription factor 17 47896150-47928957 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003357, CAB010245 Supported Validated Nucleoplasm
Vesicles Renal cancer:1.82e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 31.3 SPANXA1 CT11.1, NAP-X, SPAN-Xa, SPAN-Xb, SPANX ENSG00000198021 Sperm protein associated with the nucleus, X-linked, family member A1 X 141583674-141698444 Predicted intracellular proteins Evidence at protein level HPA046423 Uncertain Supported Nucleoplasm
Vesicles Not detected Tissue enriched 340 testis: 34.0 all non-specific tissues: 0.0 SPANXA2 SPANX ENSG00000203926 SPANX family, member A2 X 141589435-141590772 Predicted intracellular proteins Evidence at protein level HPA046423 Uncertain Supported Nucleoplasm
Vesicles Not detected Tissue enriched 43 testis: 4.3 all non-specific tissues: 0.0 SPANXB1 CT11.2, SPANXB2, SPANXF1, SPANXF2 ENSG00000227234 SPANX family, member B1 X 141002591-141003706 Predicted intracellular proteins Evidence at transcript level HPA046423 Uncertain Approved Nucleoplasm
Vesicles Mixed Tissue enriched 369 testis: 42.3 kidney: 0.1 SPANXC CT11.3, CTp11 ENSG00000198573 SPANX family, member C X 141241463-141242496 Predicted intracellular proteins Evidence at protein level HPA046423 Uncertain Supported Nucleoplasm
Vesicles Tissue enhanced Tissue enriched 151 testis: 15.0 all non-specific tissues: 0.0 SPANXD CT11.4, SPANXE ENSG00000196406 SPANX family, member D X 141697411-141698739 Predicted intracellular proteins Evidence at protein level HPA046423 Uncertain Approved Nucleoplasm
Vesicles Not detected Tissue enriched 188 testis: 18.7 all non-specific tissues: 0.0 SPATA21 spergen-2, spergen2 ENSG00000187144 Spermatogenesis associated 21 1 16387117-16437424 Predicted intracellular proteins Evidence at transcript level HPA032080 Approved Vesicles
Cytosol Not detected Tissue enriched 14 testis: 8.3 skin: 0.6 SPATA33 C16orf55, FLJ31606 ENSG00000167523 Spermatogenesis associated 33 16 89657802-89671272 Predicted intracellular proteins Evidence at protein level HPA045648, HPA073096 Approved Approved Nucleoplasm
Vesicles Cervical cancer:1.06e-4 (favourable) Expressed in all Tissue enhanced testis: 77.1 fallopian tube: 25.5 SPCS1 HSPC033, SPC1, SPC12, YJR010C-A ENSG00000114902 Signal peptidase complex subunit 1 3 52704955-52711146 Predicted membrane proteins Evidence at protein level HPA046091, HPA055273 Supported Approved Golgi apparatus
Vesicles Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable) Expressed in all Expressed in all testis: 215.4 SPG21 ACP33, BM-019, GL010, MAST ENSG00000090487 Spastic paraplegia 21 (autosomal recessive, Mast syndrome) 15 64963021-64990310 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040407, HPA040436 Approved Supported Vesicles
Cytosol Expressed in all Expressed in all epididymis: 179.9 SPPL3 DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4 ENSG00000157837 Signal peptide peptidase like 3 12 120762510-120904371 Enzymes, Predicted membrane proteins Evidence at protein level HPA004194, HPA059958 Uncertain Supported Vesicles
Plasma membrane Liver cancer:1.29e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 SPTAN1 ENSG00000197694 Spectrin, alpha, non-erythrocytic 1 9 128552558-128633662 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004581, HPA007927 Supported Approved Vesicles
Microtubules Renal cancer:1.84e-12 (favourable) Expressed in all Expressed in all cerebral cortex: 202.6 SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.2 SQSTM1 A170, OSIL, p60, p62, p62B, PDB3 ENSG00000161011 Sequestosome 1 5 179806398-179838078 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB004587, HPA064165 Approved Validated Vesicles
Cytosol Liver cancer:2.31e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 376.5 ST14 HAI, MT-SP1, PRSS14, SNC19, TMPRSS14 ENSG00000149418 Suppression of tumorigenicity 14 (colon carcinoma) 11 130159562-130210376 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA047014 Approved Nucleoplasm
Vesicles Renal cancer:5.03e-11 (favourable) Expressed in all Mixed small intestine: 152.0 STAC2 24b2 ENSG00000141750 SH3 and cysteine rich domain 2 17 39210536-39225872 Predicted intracellular proteins Evidence at protein level HPA017288 Approved Nucleoplasm
Vesicles Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable) Group enriched Group enriched 6 breast: 31.7;cerebral cortex: 30.2;epididymis: 14.8;seminal vesicle: 35.5 skin: 4.5 STAP1 BRDG1, STAP-1 ENSG00000035720 Signal transducing adaptor family member 1 4 67558728-67607337 Predicted intracellular proteins Evidence at protein level HPA038529 Supported Uncertain Nucleoplasm
Vesicles Tissue enriched Group enriched 6 appendix: 24.7;kidney: 13.1;lymph node: 60.3;spleen: 27.0;tonsil: 58.9 testis: 6.1 STMN2 SCG10, SCGN10 ENSG00000104435 Stathmin 2 8 79610814-79666175 Predicted intracellular proteins Evidence at protein level HPA026922 Supported Approved Endoplasmic reticulum
Vesicles Group enriched Tissue enriched 6 cerebral cortex: 490.7 adrenal gland: 88.6 STMN4 RB3 ENSG00000015592 Stathmin-like 4 8 27235323-27258420 Predicted intracellular proteins Evidence at protein level HPA027765 Uncertain Golgi apparatus
Vesicles Tissue enriched Tissue enriched 25 cerebral cortex: 339.4 adrenal gland: 13.4 SULT2B1 HSST2 ENSG00000088002 Sulfotransferase family, cytosolic, 2B, member 1 19 48552075-48599425 Enzymes, Predicted intracellular proteins Evidence at protein level CAB033013, HPA041724, HPA043539 Approved Supported Vesicles
Cytosol Mixed Tissue enhanced esophagus: 152.8;skin: 152.7 cervix, uterine: 45.7 SUMF2 DKFZp566I1024 ENSG00000129103 Sulfatase modifying factor 2 7 56064002-56080670 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024040, CAB025743, HPA074892 Supported Uncertain Vesicles
Plasma membrane Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 159.3 SUSD5 KIAA0527 ENSG00000173705 Sushi domain containing 5 3 33150042-33219215 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052788 Uncertain Uncertain Golgi apparatus
Vesicles Tissue enhanced Mixed cerebral cortex: 11.0 SV2C ENSG00000122012 Synaptic vesicle glycoprotein 2C 5 76083172-76353939 Predicted membrane proteins Evidence at protein level HPA040722, HPA040770 Supported Approved Nucleoplasm
Vesicles Not detected Tissue enhanced adrenal gland: 1.7;cerebral cortex: 3.4 fallopian tube,ovary: 0.6 SYT10 ENSG00000110975 Synaptotagmin X 12 33374238-33439819 Predicted membrane proteins Evidence at transcript level HPA055426 Uncertain Approved Nucleoplasm
Vesicles Tissue enriched Tissue enhanced fallopian tube: 3.5 seminal vesicle: 1.1 SYT4 HsT1192, KIAA1342 ENSG00000132872 Synaptotagmin IV 18 43267878-43277650 Predicted intracellular proteins Evidence at protein level HPA010574 Approved Supported Vesicles
Plasma membrane Tissue enhanced Tissue enhanced adrenal gland: 20.5;cerebral cortex: 82.7 seminal vesicle: 11.1 SYTL3 exophilin-6, SLP3 ENSG00000164674 Synaptotagmin-like 3 6 158650014-158764876 Predicted intracellular proteins Evidence at protein level HPA030584, HPA030585, HPA030586 Approved Approved Nucleoli fibrillar center
Vesicles Cervical cancer:8.84e-5 (favourable) Mixed Tissue enhanced thyroid gland: 44.4 fallopian tube: 22.6 TBC1D5 KIAA0210 ENSG00000131374 TBC1 domain family, member 5 3 17157162-18444817 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035125, HPA035126 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.75e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 55.9 TCEA3 TFIIS.H ENSG00000204219 Transcription elongation factor A (SII), 3 1 23381061-23424740 Predicted intracellular proteins Evidence at protein level HPA044960, HPA055811 Approved Approved Nucleoplasm
Vesicles Head and neck cancer:2.56e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 157.4 ovary: 62.6 TCEANC2 C1orf83, FLJ32112 ENSG00000116205 Transcription elongation factor A (SII) N-terminal and central domain containing 2 1 54053587-54112519 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046918 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Mixed testis: 12.8 TCTN2 C12orf38, FLJ12975, MKS8, TECT2 ENSG00000168778 Tectonic family member 2 12 123671113-123708403 Disease related genes, Predicted membrane proteins Evidence at protein level HPA039900 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed fallopian tube: 46.1 TDRP C8orf42, INM01, TDRP1, TDRP2 ENSG00000180190 Testis development related protein 8 489792-545781 Predicted intracellular proteins Evidence at protein level HPA008462 Approved Supported Vesicles
Cytosol Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:9.37e-4 (favourable) Expressed in all Mixed placenta: 46.5 TEP1 p240, TLP1, TP1, TROVE1, VAULT2 ENSG00000129566 Telomerase-associated protein 1 14 20365667-20413429 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029206 Supported Nucleoplasm
Vesicles Endometrial cancer:9.58e-4 (favourable) Expressed in all Mixed parathyroid gland: 46.0 TFDP2 Dp-2 ENSG00000114126 Transcription factor Dp-2 (E2F dimerization partner 2) 3 141944428-142149544 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB018396 Supported Supported Nucleus
Vesicles Cervical cancer:6.32e-4 (favourable), Renal cancer:9.84e-4 (favourable) Expressed in all Expressed in all testis: 127.0 TFG FLJ36137, SPG57, TF6 ENSG00000114354 TRK-fused gene 3 100709331-100748966 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019473, HPA052206 Approved Approved Vesicles
Cytosol Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 161.6 TGFBR1 ACVRLK4, ALK-5, ESS1, MSSE ENSG00000106799 Transforming growth factor, beta receptor 1 9 99104038-99154192 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002441, CAB031481, HPA056473 Uncertain Supported Vesicles
Plasma membrane Expressed in all Expressed in all placenta: 69.3 THAP7 MGC10963 ENSG00000184436 THAP domain containing 7 22 20999104-21002196 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003083 Approved Approved Nucleus
Vesicles Expressed in all Expressed in all testis: 20.4 TIAL1 TIAR ENSG00000151923 TIA1 cytotoxic granule-associated RNA binding protein-like 1 10 119571802-119597029 Predicted intracellular proteins Evidence at protein level HPA060962 Approved Nucleus
Vesicles Liver cancer:7.81e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 84.9 TIPIN FLJ20516 ENSG00000075131 TIMELESS interacting protein 15 66336206-66386746 Predicted intracellular proteins Evidence at protein level HPA039704, HPA058799 Supported Supported Nucleus
Vesicles Liver cancer:2.47e-4 (unfavourable), Cervical cancer:4.15e-4 (favourable), Prostate cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced testis: 36.7 parathyroid gland: 12.3 TIPRL dJ69E11.3, MGC3794, TIP41 ENSG00000143155 TOR signaling pathway regulator 1 168178933-168202114 Predicted intracellular proteins Evidence at protein level HPA027995, HPA054282 Approved Supported Vesicles
Cytosol Renal cancer:1.45e-8 (unfavourable), Liver cancer:1.60e-4 (unfavourable) Expressed in all Expressed in all endometrium: 38.5 TLCD2 ENSG00000185561 TLC domain containing 2 17 1702790-1710438 Predicted membrane proteins Evidence at transcript level HPA046063 Uncertain Approved Nucleoli
Vesicles Renal cancer:4.36e-5 (unfavourable) Expressed in all Mixed adipose tissue: 6.1 TM4SF18 L6D ENSG00000163762 Transmembrane 4 L six family member 18 3 149318498-149334414 Predicted membrane proteins Evidence at transcript level HPA053639, HPA069378 Approved Uncertain Nucleoli
Vesicles Liver cancer:8.63e-4 (favourable) Expressed in all Mixed spleen: 47.6 TM7SF2 ANG1, DHCR14A, NET47 ENSG00000149809 Transmembrane 7 superfamily member 2 11 65111845-65116384 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030691, HPA072704 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:8.49e-8 (favourable) Expressed in all Expressed in all adrenal gland: 161.3 TM9SF3 SMBP ENSG00000077147 Transmembrane 9 superfamily member 3 10 96518109-96587452 Predicted membrane proteins Evidence at protein level HPA039609 Approved Approved Golgi apparatus
Vesicles Expressed in all Expressed in all stomach: 182.0 TMEM131 CC28, KIAA0257, PRO1048, RW1, YR-23 ENSG00000075568 Transmembrane protein 131 2 97756333-97995891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017678, HPA017682 Approved Uncertain Vesicles
Intermediate filaments Expressed in all Expressed in all parathyroid gland: 46.7 TMEM136 MGC17839 ENSG00000181264 Transmembrane protein 136 11 120325129-120333682 Predicted membrane proteins Evidence at transcript level HPA074432 Approved Vesicles
Cytosol Endometrial cancer:6.65e-4 (unfavourable) Expressed in all Mixed adrenal gland: 12.7 TMEM150A FLJ90024, TM6P1, TMEM150 ENSG00000168890 Transmembrane protein 150A 2 85598548-85603196 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019015 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Mixed placenta: 33.3 TMEM164 FLJ22679, RP13-360B22.2 ENSG00000157600 Transmembrane protein 164 X 110002631-110182734 Predicted membrane proteins Evidence at protein level HPA038784 Approved Approved Vesicles
Cell Junctions Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable) Expressed in all Expressed in all lung: 26.7 TMEM165 GDT1, TMPT27, TPARL ENSG00000134851 Transmembrane protein 165 4 55395957-55453397 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038299 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable) Expressed in all Expressed in all placenta: 86.4 TMEM178A MGC33926, TMEM178 ENSG00000152154 Transmembrane protein 178A 2 39664982-39717963 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA052128, HPA058560 Uncertain Approved Nucleus
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 55.6 kidney: 19.1 TMEM178B DKFZp547G036 ENSG00000261115 Transmembrane protein 178B 7 141074232-141480380 Predicted membrane proteins Evidence at protein level HPA048771 Uncertain Uncertain Nucleoli
Vesicles Renal cancer:4.10e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 19.4;parathyroid gland: 28.5;thyroid gland: 14.3 heart muscle: 7.4 TMEM181 GPR178, KIAA1423 ENSG00000146433 Transmembrane protein 181 6 158536436-158635428 Predicted membrane proteins Evidence at protein level HPA040189 Approved Approved Golgi apparatus
Vesicles Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 41.5 TMEM182 FLJ30294 ENSG00000170417 Transmembrane protein 182 2 102736908-102843893 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045861 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Group enriched 10 heart muscle: 60.3;skeletal muscle: 44.1 prostate: 5.0 TMEM184C FLJ10846, TMEM34 ENSG00000164168 Transmembrane protein 184C 4 147617383-147672044 Predicted membrane proteins Evidence at protein level HPA054013 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable) Expressed in all Group enriched 5 parathyroid gland: 253.7;thyroid gland: 54.5 placenta: 28.5 TMEM2 ENSG00000135048 Transmembrane protein 2 9 71683366-71816690 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044889 Approved Approved Vesicles
Cytosol Renal cancer:1.31e-4 (unfavourable) Expressed in all Expressed in all placenta: 93.9 TMEM241 C18orf45, FLJ44259, MGC11386 ENSG00000134490 Transmembrane protein 241 18 23197144-23437961 Predicted membrane proteins Evidence at protein level HPA029489, HPA059922 Uncertain Approved Golgi apparatus
Vesicles Urothelial cancer:5.80e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 4.3 TMEM25 FLJ14399 ENSG00000149582 Transmembrane protein 25 11 118531041-118547280 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012163, HPA051562 Approved Approved Golgi apparatus
Vesicles Renal cancer:0.00e+0 (favourable) Expressed in all Expressed in all duodenum: 48.3 TMEM27 NX17 ENSG00000147003 Transmembrane protein 27 X 15627318-15665031 Predicted membrane proteins, Transporters Evidence at protein level HPA048543 Approved Approved Endoplasmic reticulum
Vesicles Renal cancer:6.78e-9 (favourable), Ovarian cancer:5.65e-4 (favourable) Tissue enriched Tissue enriched 16 kidney: 418.5 parathyroid gland: 26.1 TMEM39A FLJ10902 ENSG00000176142 Transmembrane protein 39A 3 119429500-119468830 Predicted membrane proteins Evidence at protein level HPA039140 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 32.9 TMEM63A KIAA0792 ENSG00000196187 Transmembrane protein 63A 1 225845536-225882369 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066504, HPA066936, HPA068918 Validated Vesicles
Microtubule organizing center Endometrial cancer:8.79e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 77.4 TMEM87B FLJ14681 ENSG00000153214 Transmembrane protein 87B 2 112055223-112119318 Predicted membrane proteins Evidence at protein level HPA035183 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.52e-7 (unfavourable), Cervical cancer:3.78e-4 (unfavourable), Head and neck cancer:4.28e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable) Expressed in all Mixed prostate: 43.2 TMIE DFNB6 ENSG00000181585 Transmembrane inner ear 3 46701333-46710886 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038298 Uncertain Uncertain Vesicles
Cytosol Tissue enriched Tissue enhanced adrenal gland: 7.5;cerebral cortex: 5.3 testis: 1.7 TMUB2 MGC3123 ENSG00000168591 Transmembrane and ubiquitin-like domain containing 2 17 44186970-44191731 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043137 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 48.5 TNFSF4 CD252, gp34, OX-40L, TXGP1 ENSG00000117586 Tumor necrosis factor (ligand) superfamily, member 4 1 173183734-173207313 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059579 Approved Approved Nucleus
Vesicles Expressed in all Tissue enhanced testis: 7.5 appendix: 3.2 TNNC2 ENSG00000101470 Troponin C type 2 (fast) 20 45823214-45833745 Predicted intracellular proteins Evidence at protein level HPA043174, HPA058481 Supported Approved Nucleoplasm
Vesicles Mixed Tissue enriched 78 skeletal muscle: 9900.8 esophagus: 127.0 TNNI3 CMD2A, CMH7, TNNC1 ENSG00000129991 Troponin I type 3 (cardiac) 19 55151767-55157773 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009349, HPA046428 Supported Approved Vesicles
Cytosol Mixed Tissue enriched 158 heart muscle: 3237.3 breast: 20.4 TOB1 TOB, TROB, TROB1 ENSG00000141232 Transducer of ERBB2, 1 17 50862223-50867978 Predicted intracellular proteins Evidence at protein level HPA047839 Approved Approved Nucleoplasm
Vesicles Pancreatic cancer:5.04e-5 (unfavourable), Prostate cancer:3.37e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 280.3 TOR1A DQ2, DYT1 ENSG00000136827 Torsin family 1, member A (torsin A) 9 129812944-129824134 Disease related genes, Predicted secreted proteins Evidence at protein level CAB012473, HPA051195 Approved Supported Nuclear membrane
Vesicles Lung cancer:5.45e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 39.8 TPD52L2 D54, hD54 ENSG00000101150 Tumor protein D52-like 2 20 63865228-63891545 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047489 Approved Approved Vesicles
Cytosol Renal cancer:1.74e-8 (unfavourable), Liver cancer:1.39e-5 (unfavourable) Expressed in all Expressed in all smooth muscle: 103.8 TPRG1L FAM79A, FLJ21811, RP11-46F15.3 ENSG00000158109 Tumor protein p63 regulated 1-like 1 3625002-3630127 Predicted intracellular proteins Evidence at protein level HPA063163 Approved Vesicles
Cytosol Renal cancer:1.76e-9 (favourable) Expressed in all Expressed in all cerebral cortex: 102.5 TRA2A AWMS1, htra-2-alpha, tra2a ENSG00000164548 Transformer 2 alpha homolog (Drosophila) 7 23504780-23532041 Predicted intracellular proteins Evidence at protein level HPA054018 Uncertain Supported Nucleoli
Vesicles Renal cancer:1.79e-6 (unfavourable), Liver cancer:2.07e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 65.5 TRAF3IP2 ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CIKS, DKFZP586G0522 ENSG00000056972 TRAF3 interacting protein 2 6 111556454-111606278 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036352 Approved Approved Golgi apparatus
Vesicles Endometrial cancer:4.73e-5 (favourable), Renal cancer:5.16e-5 (unfavourable), Cervical cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 49.4 TRAF7 DKFZp586I021, MGC7807, RFWD1, RNF119 ENSG00000131653 TNF receptor-associated factor 7, E3 ubiquitin protein ligase 16 2155698-2178129 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041229 Approved Supported Vesicles
Plasma membrane Expressed in all Expressed in all duodenum: 41.1 TRAPPC2L HSPC176 ENSG00000167515 Trafficking protein particle complex 2-like 16 88856220-88862686 Predicted intracellular proteins Evidence at protein level HPA041714 Approved Supported Vesicles
Cytosol Endometrial cancer:3.75e-4 (favourable) Expressed in all Expressed in all adrenal gland: 91.9 TRIM33 FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA ENSG00000197323 Tripartite motif containing 33 1 114392777-114511160 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA004345 Supported Approved Nucleoplasm
Vesicles Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable) Expressed in all Expressed in all testis: 46.0 TRIM44 DIPB, MC7 ENSG00000166326 Tripartite motif containing 44 11 35662805-35818007 Predicted intracellular proteins Evidence at protein level HPA049053, HPA057633 Approved Approved Vesicles
Plasma membrane Liver cancer:5.24e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 30.8 TRIM62 DEAR1, FLJ10759 ENSG00000116525 Tripartite motif containing 62 1 33145402-33182059 Predicted intracellular proteins Evidence at protein level HPA050061 Approved Vesicles
Focal adhesion sites Renal cancer:7.08e-5 (unfavourable) Expressed in all Mixed skin: 11.6 TRIO ARHGEF23 ENSG00000038382 Trio Rho guanine nucleotide exchange factor 5 14143702-14532128 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008157, HPA064664 Supported Approved Vesicles
Cytosol Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all breast: 30.8 TRIP10 CIP4, HSTP, STOT, STP ENSG00000125733 Thyroid hormone receptor interactor 10 19 6737925-6751526 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041934 Supported Nucleoplasm
Vesicles Head and neck cancer:1.76e-4 (favourable), Colorectal cancer:3.61e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 129.1 TRUB1 PUS4 ENSG00000165832 TruB pseudouridine (psi) synthase family member 1 10 114938193-114977676 Predicted intracellular proteins Evidence at protein level HPA037914, HPA057552 Approved Supported Vesicles
Actin filaments Expressed in all Expressed in all adrenal gland: 38.7 TSPAN1 NET-1, TSPAN-1 ENSG00000117472 Tetraspanin 1 1 46175073-46185958 Predicted membrane proteins Evidence at protein level HPA011909 Approved Approved Nucleoplasm
Vesicles Renal cancer:9.28e-6 (favourable) Expressed in all Tissue enhanced colon: 534.2;rectum: 660.3 prostate: 315.2 TSPAN12 NET-2, TM4SF12 ENSG00000106025 Tetraspanin 12 7 120787320-120858402 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051570, HPA058244 Uncertain Approved Vesicles
Microtubules Expressed in all Mixed kidney: 90.9 TTI1 KIAA0406, smg-10 ENSG00000101407 TELO2 interacting protein 1 20 37983007-38033468 Predicted intracellular proteins Evidence at protein level CAB034230, HPA068338 Uncertain Approved Nucleoplasm
Vesicles Liver cancer:2.40e-7 (unfavourable), Endometrial cancer:3.30e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 20.6 TTL MGC46235 ENSG00000114999 Tubulin tyrosine ligase 2 112482154-112541739 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA066819 Approved Nucleoplasm
Vesicles Liver cancer:5.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 4.5 TTLL6 FLJ35808 ENSG00000170703 Tubulin tyrosine ligase-like family member 6 17 48762235-48817214 Predicted intracellular proteins Evidence at protein level HPA052397 Supported Approved Vesicles
Microtubules Mixed Tissue enhanced testis: 25.9 fallopian tube: 5.8 TUSC1 TSG-9 ENSG00000198680 Tumor suppressor candidate 1 9 25676389-25678440 Predicted intracellular proteins Evidence at protein level HPA051426 Approved Approved Nucleus
Vesicles Expressed in all Expressed in all testis: 16.5 TUSC2 C3orf11, FUS1, PAP, PDAP2 ENSG00000114383 Tumor suppressor candidate 2 3 50320027-50328251 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA030116 Approved Vesicles
Cytosol Renal cancer:8.70e-7 (favourable), Liver cancer:2.84e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 42.2 UBA5 FLJ23251, UBE1DC1 ENSG00000081307 Ubiquitin-like modifier activating enzyme 5 3 132654446-132678097 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017235 Uncertain Validated Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 63.1 UBR1 ENSG00000159459 Ubiquitin protein ligase E3 component n-recognin 1 15 42942897-43106113 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038838 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 26.9 UGT3A1 FLJ34658 ENSG00000145626 UDP glycosyltransferase 3 family, polypeptide A1 5 35951010-36001028 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047697, HPA056290 Uncertain Approved Vesicles
Cytosol Group enriched Tissue enhanced kidney: 52.9;liver: 29.1 duodenum: 9.7 ULBP2 RAET1H ENSG00000131015 UL16 binding protein 2 6 149942000-149949235 Predicted membrane proteins Evidence at protein level CAB018974 Approved Supported Vesicles
Plasma membrane Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable) Expressed in all Mixed cerebral cortex,esophagus: 3.0 ULBP3 RAET1N ENSG00000131019 UL16 binding protein 3 6 150063150-150069095 Predicted secreted proteins Evidence at protein level HPA056541, HPA063007 Uncertain Uncertain Vesicles
Microtubule organizing center Mixed Tissue enhanced testis: 11.9;thyroid gland: 8.8 fallopian tube: 3.9 URM1 C9orf74, MGC2668 ENSG00000167118 Ubiquitin related modifier 1 9 128371319-128392016 Predicted intracellular proteins Evidence at protein level HPA053645, HPA065160 Approved Approved Nucleoplasm
Vesicles Renal cancer:7.43e-6 (favourable), Liver cancer:6.91e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 24.9 USF2 bHLHb12, FIP ENSG00000105698 Upstream transcription factor 2, c-fos interacting 19 35268978-35279821 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029764, HPA046567 Supported Nucleoplasm
Vesicles Pancreatic cancer:5.12e-5 (favourable), Urothelial cancer:3.28e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 216.0 VAC14 ArPIKfyve, FLJ10305, TAX1BP2 ENSG00000103043 Vac14 homolog (S. cerevisiae) 16 70687439-70801161 Predicted intracellular proteins Evidence at protein level HPA027766 Approved Approved Vesicles
Cytosol Renal cancer:1.56e-6 (favourable), Cervical cancer:8.33e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 31.0 VBP1 PFD3, PFDN3 ENSG00000155959 Von Hippel-Lindau binding protein 1 X 155197007-155239817 Predicted intracellular proteins Evidence at protein level CAB006260, HPA023230 Approved Supported Vesicles
Cytosol Expressed in all Expressed in all cerebral cortex: 85.5 VN1R1 V1RL1, VNR19I1, ZVNH1, ZVNR1 ENSG00000178201 Vomeronasal 1 receptor 1 19 57454790-57457142 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA062209 Uncertain Nucleus
Vesicles Mixed Mixed epididymis: 2.8 VPS29 DC15, DC7, PEP11 ENSG00000111237 VPS29 retromer complex component 12 110491097-110502117 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039748 Uncertain Supported Vesicles
Cytosol Liver cancer:2.79e-5 (unfavourable), Ovarian cancer:7.70e-4 (favourable) Expressed in all Expressed in all epididymis: 107.2 VPS37C FLJ20847 ENSG00000167987 Vacuolar protein sorting 37 homolog C (S. cerevisiae) 11 61130256-61161617 Predicted intracellular proteins Evidence at protein level HPA043348 Approved Approved Nucleus
Vesicles Renal cancer:2.37e-7 (favourable), Liver cancer:5.85e-5 (unfavourable) Expressed in all Expressed in all skin: 25.2 VPS4B SKD1, SKD1B, VPS4-2 ENSG00000119541 Vacuolar protein sorting 4 homolog B (S. cerevisiae) 18 63389190-63422483 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040393, CAB046445, HPA057649 Approved Approved Vesicles
Intermediate filaments Renal cancer:1.23e-4 (favourable) Expressed in all Expressed in all esophagus: 83.0 VRK3 ENSG00000105053 Vaccinia related kinase 3 19 49976467-50025946 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA056489 Approved Supported Nucleus
Vesicles Renal cancer:1.83e-4 (favourable), Urothelial cancer:5.66e-4 (favourable) Expressed in all Expressed in all testis: 168.2 VSIG1 MGC44287 ENSG00000101842 V-set and immunoglobulin domain containing 1 X 108044970-108079184 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001445, HPA036310, HPA036311 Supported Approved Vesicles
Cytosol Group enriched Group enriched 10 stomach: 187.2;testis: 90.9 gallbladder: 14.3 VSTM4 C10orf72, FLJ31737 ENSG00000165633 V-set and transmembrane domain containing 4 10 49014245-49115509 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA017279 Uncertain Approved Nucleus
Vesicles Urothelial cancer:4.25e-4 (unfavourable) Tissue enriched Mixed adrenal gland: 55.1 VTI1A MVti1, Vti1-rp2, Vti1a ENSG00000151532 Vesicle transport through interaction with t-SNAREs 1A 10 112446998-112818744 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054108 Supported Supported Golgi apparatus
Vesicles Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable) Expressed in all Mixed parathyroid gland: 12.1 VTI1B VTI2 ENSG00000100568 Vesicle transport through interaction with t-SNAREs 1B 14 67647075-67674831 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044121, HPA048150, HPA060118 Approved Validated Golgi apparatus
Vesicles Renal cancer:3.53e-12 (favourable) Expressed in all Expressed in all epididymis: 62.3 VTN VN ENSG00000109072 Vitronectin 17 28367276-28373091 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016695, CAB016765, HPA060933 Supported Supported Endoplasmic reticulum
Vesicles Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable) Tissue enriched Tissue enriched 28 liver: 2540.4 gallbladder: 91.6 VWA8 KIAA0564 ENSG00000102763 Von Willebrand factor A domain containing 8 13 41566837-41961120 Predicted intracellular proteins Evidence at protein level HPA039075, HPA045478 Uncertain Approved Vesicles
Lipid droplets Renal cancer:6.38e-14 (favourable), Liver cancer:8.56e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 21.3 WDR54 FLJ12953 ENSG00000005448 WD repeat domain 54 2 74421678-74425755 Predicted intracellular proteins Evidence at protein level HPA043257, HPA053558 Supported Approved Vesicles
Cytosol Expressed in all Tissue enhanced fallopian tube: 111.9 testis: 47.8 WDTC1 ADP, DCAF9, KIAA1037 ENSG00000142784 WD and tetratricopeptide repeats 1 1 27234516-27308633 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028177, HPA028180, HPA028182 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:8.84e-8 (favourable), Cervical cancer:4.51e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 72.3 WDYHV1 C8orf32, FLJ10204 ENSG00000156795 WDYHV motif containing 1 8 123416725-123467230 Predicted intracellular proteins Evidence at protein level HPA024823, HPA053680 Approved Supported Nucleoplasm
Vesicles Endometrial cancer:4.93e-5 (unfavourable), Liver cancer:3.47e-4 (unfavourable) Expressed in all Expressed in all testis: 18.4 XAB2 HCNP, HCRN, NTC90, SYF1 ENSG00000076924 XPA binding protein 2 19 7619525-7629565 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048751 Approved Nucleus
Vesicles Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable) Expressed in all Expressed in all testis: 39.3 XAGE5 CT12.5, GAGED5, XAGE-5 ENSG00000171405 X antigen family, member 5 X 52812204-52818301 Predicted intracellular proteins Evidence at transcript level HPA052507, HPA055941, HPA059045 Uncertain Approved Nucleoplasm
Vesicles Tissue enhanced Tissue enriched 10 testis: 2.0 skin: 0.2 XRCC2 ENSG00000196584 X-ray repair complementing defective repair in Chinese hamster cells 2 7 152644779-152676165 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA065153 Approved Nucleoplasm
Vesicles Mixed Mixed testis: 3.8 YBX1 BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1 ENSG00000065978 Y box binding protein 1 1 42682427-42702349 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB005875, HPA040304, HPA057159 Supported Validated Vesicles
Cytosol Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable) Expressed in all Expressed in all testis: 1538.1 YIF1B FinGER8 ENSG00000167645 Yip1 interacting factor homolog B (S. cerevisiae) 19 38305104-38317273 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039328, HPA055257, HPA062675 Approved Approved Golgi apparatus
Vesicles Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 49.6 ZBED6CL C7orf29 ENSG00000188707 ZBED6 C-terminal like 7 150329789-150332721 Predicted intracellular proteins Evidence at transcript level HPA019724, HPA055805 Approved Approved Nuclear membrane
Vesicles Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable) Expressed in all Tissue enhanced adrenal gland: 31.9;parathyroid gland: 30.0 lymph node: 10.0 ZC4H2 HCA127, KIAA1166, WWS ENSG00000126970 Zinc finger, C4H2 domain containing X 64915802-65034713 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049584 Approved Approved Vesicles
Microtubules Thyroid cancer:3.51e-5 (unfavourable) Mixed Mixed parathyroid gland: 17.2 ZDHHC24 ENSG00000174165 Zinc finger, DHHC-type containing 24 11 66520637-66546238 Enzymes, Predicted membrane proteins Evidence at protein level HPA016619 Approved Approved Vesicles
Cytosol Glioma:2.39e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 10.9 ZFAND3 FLJ13222, TEX27 ENSG00000156639 Zinc finger, AN1-type domain 3 6 37819499-38154624 Predicted intracellular proteins Evidence at protein level HPA016755 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all testis: 184.1 ZFP37 ZNF906 ENSG00000136866 ZFP37 zinc finger protein 9 113038380-113056759 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049112 Uncertain Approved Nucleus
Vesicles Glioma:9.22e-5 (favourable) Mixed Mixed ovary: 8.8 ZFYVE16 KIAA0305, PPP1R69 ENSG00000039319 Zinc finger, FYVE domain containing 16 5 80408013-80479350 Predicted intracellular proteins Evidence at protein level HPA035935, HPA035936 Supported Validated Vesicles
Cytosol Expressed in all Mixed cervix, uterine: 25.1 ZFYVE9 MADHIP, PPP1R173, SARA, SMADIP ENSG00000157077 Zinc finger, FYVE domain containing 9 1 52142094-52346686 Predicted intracellular proteins Evidence at protein level CAB017702, HPA065852, HPA065862 Approved Validated Vesicles
Cytosol Expressed in all Mixed parathyroid gland: 44.4 ZG16B HRPE773, JCLN2, PRO1567 ENSG00000162078 Zymogen granule protein 16B 16 2830169-2839585 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041125, HPA053549 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:3.48e-6 (favourable) Tissue enhanced Tissue enriched 210 salivary gland: 19669.3 prostate: 93.6 ZGLP1 GATAD3, GLP-1, GLP1 ENSG00000220201 Zinc finger, GATA-like protein 1 19 10304803-10309880 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049855 Uncertain Approved Nucleus
Vesicles Mixed Mixed testis: 3.1 ZIC5 ENSG00000139800 Zic family member 5 13 99962964-99971909 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA074045 Uncertain Nucleoplasm
Vesicles Mixed Group enriched 45 cerebral cortex: 2.3;testis: 6.6 all non-specific tissues: 0.0 ZMIZ1 FLJ13541, hZIMP10, KIAA1224, MIZ, RAI17, RP11-519K18.1, Zimp10 ENSG00000108175 Zinc finger, MIZ-type containing 1 10 79069035-79316528 Predicted intracellular proteins Evidence at protein level HPA045144 Approved Approved Nucleoplasm
Vesicles Renal cancer:3.64e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 65.5 ZMYND19 MIZIP ENSG00000165724 Zinc finger, MYND-type containing 19 9 137582079-137590490 Predicted intracellular proteins Evidence at protein level HPA020642, HPA050761 Supported Approved Golgi apparatus
Vesicles Liver cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all testis: 46.2 ZNF132 pHZ-12 ENSG00000131849 Zinc finger protein 132 19 58432814-58440222 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA008726 Uncertain Approved Vesicles
Intermediate filaments Renal cancer:7.26e-13 (favourable), Pancreatic cancer:1.92e-4 (favourable) Mixed Mixed parathyroid gland: 10.6 ZNF133 pHZ-13, pHZ-66, ZNF150 ENSG00000125846 Zinc finger protein 133 20 18288283-18316996 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001493 Supported Approved Nucleus
Vesicles Liver cancer:4.46e-6 (unfavourable), Renal cancer:2.20e-5 (unfavourable) Expressed in all Expressed in all epididymis: 19.7 ZNF215 ZKSCAN11, ZSCAN43 ENSG00000149054 Zinc finger protein 215 11 6926404-6984632 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047243, HPA051010 Approved Approved Nucleoplasm
Vesicles Mixed Mixed lymph node: 4.8 ZNF229 ENSG00000278318 Zinc finger protein 229 19 44417519-44448578 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA001494 Uncertain Approved Vesicles
Plasma membrane Renal cancer:8.43e-5 (favourable) Mixed Tissue enhanced parathyroid gland: 6.5 fallopian tube,thyroid gland: 3.1 ZNF302 ZNF135L, ZNF140L, ZNF327 ENSG00000089335 Zinc finger protein 302 19 34677639-34686397 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059503 Approved Vesicles
Cytokinetic bridge Endometrial cancer:2.03e-5 (unfavourable), Urothelial cancer:9.85e-5 (favourable), Renal cancer:5.41e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 41.4 ZNF341 dJ553F4.3 ENSG00000131061 Zinc finger protein 341 20 33731657-33792269 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023240, HPA024607, HPA067108 Uncertain Approved Nucleoplasm
Vesicles Liver cancer:1.87e-4 (unfavourable), Head and neck cancer:3.93e-4 (favourable) Expressed in all Mixed testis: 2.3 ZNF365 KIAA0844, UAN ENSG00000138311 Zinc finger protein 365 10 62374192-62672011 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA052446 Approved Supported Vesicles
Microtubule organizing center Mixed Tissue enriched 5 cerebral cortex: 54.6 parathyroid gland: 10.7 ZNF442 FLJ14356 ENSG00000198342 Zinc finger protein 442 19 12345949-12365905 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA045738, HPA053407 Uncertain Approved Nuclear membrane
Vesicles Mixed Mixed ovary: 6.0 ZNF550 MGC41917 ENSG00000251369 Zinc finger protein 550 19 57535257-57559863 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003251 Uncertain Approved Vesicles
Microtubules Prostate cancer:2.21e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 13.5 ZNF586 FLJ20070 ENSG00000083828 Zinc finger protein 586 19 57769655-57819939 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030306, HPA060782 Approved Approved Nucleoli fibrillar center
Vesicles Breast cancer:9.83e-5 (favourable), Urothelial cancer:5.36e-4 (favourable) Expressed in all Expressed in all bone marrow: 16.3 ZNF605 ENSG00000196458 Zinc finger protein 605 12 132918308-132956306 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA061970, HPA062655 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Mixed parathyroid gland,thyroid gland: 11.1 ZNF613 FLJ13590 ENSG00000176024 Zinc finger protein 613 19 51879872-51948759 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA026833 Uncertain Approved Nucleoplasm
Vesicles Urothelial cancer:1.92e-6 (favourable) Expressed in all Tissue enhanced prostate: 25.7 parathyroid gland: 8.5 ZNF638 MGC26130, NP220, ZFML, Zfp638 ENSG00000075292 Zinc finger protein 638 2 71276561-71435069 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036784, HPA057395 Supported Validated Nucleoplasm
Vesicles Urothelial cancer:8.73e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 57.8 ZNF768 FLJ23436 ENSG00000169957 Zinc finger protein 768 16 30524001-30526821 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA024630, HPA066512 Supported Approved Nucleus
Vesicles Renal cancer:9.30e-6 (favourable), Urothelial cancer:6.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 55.0 ZNHIT6 BCD1, C1orf181, FLJ20729, NY-BR-75 ENSG00000117174 Zinc finger, HIT-type containing 6 1 85649423-85708433 Predicted intracellular proteins Evidence at protein level HPA018132 Uncertain Approved Nuclear speckles
Vesicles Liver cancer:6.08e-6 (unfavourable) Expressed in all Expressed in all cervix, uterine: 21.1 ZXDC FLJ13861, MGC11349 ENSG00000070476 ZXD family zinc finger C 3 126437601-126475919 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049593 Supported Nucleoli
Vesicles Liver cancer:2.27e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 25.5